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Part 1 : Methodological aspects of medication errors and adverse 
drug events 
World-wide many patients suffer from drug related problems of which a large part 
is preventable. Already in 1969 Hurwitz et al. published the article 'Intensive Hospi­
tal Monitoring to Adverse Reactions to Drugs· in the British Medical Journal. 1 She 
showed that l O % of the hospitalised patients in the UK suffered from harm due 
to medication. Her findings were comparable to the results of earlier studies in 
the sixties.2-4 These research findings led to an increased awareness in the UK con­
cerning medication related harm. Thirty years later the US report 'To Err is Human' 
showed that many people died each year in hospitals partially due to medica­
tion related harm often caused by medication errors.5 Again awareness and anxi­
ety increased and since then improving medication safety has been high on the 
agenda of health care providers in the United States as well as in European coun­
tries (e.g. the Netherlands). This has resulted in a number of studies looking into the 
frequency and preventability of drug related problems in hospitalised patients. In 
their literature review Krahlenbuhl-Melcher et a/.6 concluded that overall in about 
6% of the hospitalised patients medication related harm occurs of which about 
half is preventable and can be considered the result of medication errors. The 
same percentages are mentioned for the frequency and preventability of hospital 
admissions due to medication in for example the UK7 (6.5 % medication related 
admissions of which 72% avoidable) and the Netherlands8· 9 (approximately 5% 
medication related admissions of which around 40% potentially avoidable). These 
findings indicate the scope of drug related problems in hospitals. 
For a further exploration of these problems and their causes a good understanding 
of the terminology is needed. Drug related problems are defined as circumstances 
involving a patients· drug treatment. that actually or potentially interfere with the 
achievement of an optimal outcome.10· 11 These problems include medication 
errors. adverse drug reactions and adverse drug events. The definitions of these 
terms and their relationship are presented in Table l and graphically displayed in 
Figure 1. 
Adverse drug events are injuries related to the use of a drug, although the causality 
of this relationship may not be proven. 12 Adverse drug events include adverse drug 
reactions which are not preventable, but also injuries which are related to medi­
cation errors and thus are preventable - preventable adverse drug events. So, in 
terms of improving medication safety interventions should focus on drug related 
problems that are preventable, i.e. medication errors and preventable adverse 
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drug events. A substantial number of studies have performed into the nature and 
rates of medication errors in the hospital setting.6 1 1. 13·15 However. from a clinical 
point of view preventable adverse drug events are more relevant as outcome 
measures because not all medication errors do cause patient harm. 
Table l : definitions of drug related problems 
Any error in the process of prescribing, 
Medication error dispensing or administering of a drug whether there are adverse 
consequences or not. 12 
An injury related to the use of a 
Adverse drug event drug. although the causality of this 
relationship may not be proven.12 
A response to a drug which is noxious 
and unintended, and which occurs 
Adverse drug reaction at doses normally used in man for the prophylaxis, diagnosis. or therapy 
of disease, or for the modification of 
physiological function29 
Preventable adverse drug event Injury that is the result of an error in any stage in the medication use17 
Studies use different methods for identifying adverse drug events (non-preventable 
as well as preventable); spontaneous reporting by patients or health care profes­
sionals16. interviewing patlents17, studying electronical databases 18, using computer­
ised trigger tools19 and chart review.20 This variety of methods - and the sometimes 
different definitions used - leads to a high variability in the rates of adverse drug 
events found in medication safety studles.6 All these methodologies have strengths 
and limitations. A limitation of spontaneous reporting is underreporting of adverse 
drug events. on the one hand due to lack of willingness to report an adverse drug 
event and on the other hand due to lack of awareness of an adverse drug event.21 
In contrast. a limitation of interviewing patients is the low positive predictive value 
for detecting true adverse drug events because of bias .. i.e. patients come up with 
many disease related events.22 Screening electronic databases is helpful because 
of the availability of clear and structured data. However a disadvantage is the 
restriction to data that can only be entered in the strict format of the database. 
Applying computerised trigger tools on patient data may play an important role 
in future because It may be time-saving. However. these tools should be further 
developed to decrease the false positive signals they generate. The main benefit 
of chart review in comparison to the other methods is that it usually gives a large 
amount of rather objective and detailed data. Furthermore. Jha et a/.23 showed 
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that chart review detected more adverse drug events in comparison to computer 
monitoring or spontaneous reporting and it was more effective in detecting pre­
ventable adverse drug events. Therefore, chart review can be considered as the 
best approach so far in methodologies for identifying adverse drug events. 











Figure 1: relationship between different drug related problems 
limitations. First, it is labour intensive and therefore costly. Secondly, physicians and 
nurses notice many patients' symptoms and clinical events but do not link them 
to drugs or when they suspect a link they usually do not note this presumption. 
Therefore researchers need to assess the association between drugs, medication 
errors and adverse drug events by themselves. For the assessment of (non-prevent­
able) adverse drug reactions, i.e. the assessment of the link between a drug and 
an adverse drug event, the agreement is often not very high between individual 
assessors.24-26 In an attempt to increase agreement, various instruments (e.g. sets of 
questions and algorithms) have been developed to assess the causality between 
an adverse event and medication use in a systematic way, such as the method of 
Naranjo27 or the algorithm of Kramer26 • These instruments focus on the assessment 
of adverse drug reactions, however not on preventable adverse drug events. For 
identifying preventable adverse drug events actually two assessments should be 
performed; one for the relation between a drug and a medication error and sec­
ond for the relation between a medication error and an adverse drug event. This 
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combined systematic approach has not been used previously in studies looking 
into preventable adverse drug events. In chapter 2 of this thesis this approach was 
tested in panels of pharmacists and physicians. 
In general, there are two types of medication safety studies. One type of stud­
ies focuses on the characteristics of medication errors and adverse drug events, 
such as the classification of errors/adverse drug events, determinants of errors/ 
adverse drug events and the relation between medication errors and adverse 
drug events. The other type of studies are intervention studies that focus on inter­
ventions and strategies to reduce the incidences of medication errors and/or 
adverse drug events, e.g. that study the effect of computerised prescribing or the 
effect of education for physicians or pharmacists. In order to develop interventions 
that will improve medication safety, the characteristics of medication errors and 
adverse drug events should be explored first. Knowledge on the most clinically 
relevant medication errors at which interventions should be directed, is important. 
Studies of characteristics of medication safety problems offer the opportunity to 
specify types of medication errors associated with adverse drug events enabling 
future studies and interventions to focus more on these types of errors. For the same 
reason it is important to explore whether determinants of errors are the same as 
determinants of adverse drug events. Interventions can then focus on those deter­
minants. This information Is relevant because methods for identifying medication 
errors and adverse drug events are very labour intensive. In chapter 3 and chapter 
4 we explored the clinical relevance of errors and determinants further. Chapter 
3 focused on which types of medication error are mostly associated with adverse 
drug events and are therefore most clinlcally relevant. Chapter 4 investigated 
whether the determinants of medication errors that do not cause any patient 
harm are the same as determinants of medication errors that do cause patient 
harm. 
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Part 2: Computerised Physician Order Entry system with Clinical 
Decision Support (CPOE/CDSS) in relation to medication safety 
Until recently the medication distribution process in Dutch hospitals was based on 
hand-written information where medication orders were written on paper charts 
by physicians and thereafter transcribed to drug administration charts by nurses. 
In some hospitals the pharmacy took care of central order entry, but not in all. 
Hospitals without central order entry also lacked systematic medication review of 
medication orders by pharmacists. In general, no immediate clinical decision sup­
port was present (e.g. warnings on drug - drug interactions and drug overdoses) 
for the physicians during prescribing. Even in central order entry hospitals this was 
lacking. Omission of these last two aspects combined with the fact that the system 
was based on hand-writing, was a potential source for the occurrence of medica­
tion errors and preventable adverse drug events. 
Since the publication of 'To Err is Human' many strategies to make health care safer 
have been created and meanwhile implemented. One of these strategies is the 
Computerised Physician Order Entry (CPOE) system. Before the first introduction of this 
system in the United States in the nineties, expectations about CPOE systems reduc­
ing medication errors and preventable adverse drug events were high. These com­
puterised systems would standardise the medication ordering process. Legible and 
complete orders would be ensured.30 Furthermore, Clinical Decision Support systems 
(CDSS) would be incorporated in these CPOE systems which could assist the physi­
cians by triggering alerts in case of drug-drug interactions and inappropriate dosing. 
Pharmacists could check alerts that were neglected by the physicians. Because of 
Clinical Decision Support Systems and the production of legible standardised orders, 
CPOE/CDSS systems promised to reduce medication errors (especially regarding 
prescribing and transcribing) and preventable adverse drug events. Meanwhile, 
a number of studies (predominantly from the US) have shown that CPOES/CDSS 
systems may be a successful strategy in reducing medication errors31 .J3 as well as 
preventable adverse drug events.34·35 other studies showed negative effects in the 
sense that new medication errors were being introduced by CPOE/CDSS 36 or that 
mortality increased after implementation of CPOE/CDSS in a children's hospital.37 A 
problem with most studies is that the findings of these studies cannot be considered 
robust because of a weak study design. Moreover the majority of these studies were 
from the United States where CPOE/CDSS was first introduced. Europe differs from 
the United States and here other types of CPOE/CDSS are used. It is important to 
know what the effect of CPOE/CDSS is on medication safety in the European setting. 
In chapter 5 of this thesis we evaluated the effect of CPOE/CDSS on the incidence 
of medication errors and preventable adverse drug events in two Dutch hospitals. 
5 
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CPOE/CDSS is a first step in the computerization of the prescribing process. It offers 
the possibility of extensive support systems at the point of care that facilitate better 
and safer medication use. Currently COSS in CPOE systems is relatively basic38, i.e. it 
provides only support on dosages, drug-drug interactions, duplicate therapy and 
allergies. More advanced decision support such as support on dosages for patients 
with renal or liver failure, support on drug choice for specific patients or support on 
therapy for patients with specific risk factors may further help to reduce medication 
errors and preventable adverse drug events. At present some hospitals in the Neth­
erlands are developing more advanced decision support. Clinical rules are defined 
that are basically computerised algorithms that look for specific medication orders, 
patient characteristics and/or laboratory values that could lead to patient harm.39 
These clinical rules will select hospitalised patients who are at risk for suffering from 
an adverse drug event. Based on this selection, health care professionals can inter­
vene before actual patient harm will occur. The development of these clinical rules 
is still in progress and several aspects should be explored further before implementa­
tion in clinical practice can take place. For example: who will be the receivers of 
the Information that clinical rules will generate, pharmacists or physicians? What is 
the best way of developing a validated clinical rule that is supported by all health 
care professionals? What is the sensitivity of the clinical rules to prevent adverse drug 
events, I.e. do these rules select all patients that are at risk? And what is the efficiency 
of the clinical rules to prevent adverse drug events, i.e. do they not generate too 
many alerts that need no clinical action? In chapter 6 of this thesis we address the 
efficiency of a small set of clinical rules to prevent medication errors and thus finally 
adverse drug events. 
The development and validation of computer technology Is one thing, however 
It has to be implemented effectively in clinical practice before it can have any 
effect. The introduction of CPOE/CDSS on the workftoor will affect clinical prac­
tice in the sense that the workftow of health care professionals will change as well 
as the communication between them.40-42 Therefore for a successful implementa­
tion, it is important to know the expectations and experiences of (future) users, I.e. 
physicians and nurses. Knowing the views of users towards this system may lead 
to Improvements of the system and help to fit in clinical practice. In chapter 7 
of this thesis we explored the expectations and experiences with CPOE/CDSS of 
physicians and nurses in a survey study. Besides the effectiveness of CPOE/CDSS for 
preventing medication errors and preventable adverse drug events, the aspect 
of costs is an important issue. Organisations contemplating the implementation 
of CPOE/CDSS benefit from information on the cost-effectiveness of these tech­
nologies in comparison to the traditional methods used before. Introduction and 
maintenance of CPOE/CDSS is costly43 and it is important to know whether the 
ratio between costs and prevented medication errors or adverse drug events is 
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acceptable. At present, limited information is available on the cost-effectiveness 
of these systems. The few available studies generally show high cost-effectiveness 
ratios. 43• 44 However, differences in study design, measures of effect, setting and 
health care system, limit the generalisability of these results. For the Dutch situation 
no previous studies have been performed. In chapter 8 of this thesis we performed 
an economic evaluation into the cost-effectiveness of CPOE/CDSS in comparison 
to the paper-based system of medication ordering. 
In this thesis we studied the implementation of CPOE/CDSS in two hospitals in the 
Netherlands, taking into account methodological issues, effectiveness in prevent­
ing medication errors and adverse drug events as well as the cost-effectiveness of 
CPOE/CDSS in comparison to the traditional paper based system. 
Outline of this thesis 
In chapter l of this thesis we introduced the main objectives of this thesis. 
This thesis covers two parts: 
PART l of this thesis focuses on the methodological aspects of medication errors 
and adverse drug events: 
• In chapter 2 the focus is on the assessment of the relation between medication 
errors and adverse drug events. In this chapter we evaluate the agreement on 
assessing preventable adverse drug events between different professionals, i.e. 
physicians and pharmacists. 
• In chapter 3 the relation between different subtypes of medication errors and 
patient harm is assessed in depth. We address which type of medication errors 
is mostly related to adverse drug events and is therefore most relevant from a 
clinical perspective. 
• In chapter 4 we assess whether the determinants of medication errors not related 
to any patient harm are the same as medication errors related to patient harm. 
PART 2 focuses on CPOE/CDSS in relation to medication safety: 
• Chapter 5 discusses the effect of the introduction of CPOE/CDSS on the inci­
dence medication errors and preventable adverse drug events in two Dutch 
hospitals. We distinguish the effect on different types of medication errors and 
preventable adverse drug events. 
• In chapter 6 we focuses on the different forms of decision support during elec­
tronic prescribing. We compare two computerised systems (a basic CDSS within 
a CPOE and a set of clinical rules) with medication review to answer the ques­
tion to what extent patients at risk for medication related harm as identified by 
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the two computerised systems actually have a medication error as identified 
by medication review. 
• Because the effectiveness of the CPOE/CDSS system in reducing medication 
errors depends also on the use of CPOE/CDSS by health care professionals, we 
surveyed the expectations and experiences with the system of physicians and 
nurses. These results are shown in chapter 7. 
• Currently, in most Dutch hospitals CPOE/CDSS is already used or will be imple­
mented in the coming future . It is important to know what should be extra 
invested to increase medication safety by using CPOE/CDSS. Chapter 8 aims to 
evaluate the balance between the effects and costs of CPOE/CDSS compared 
to the paper-based system. 
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To determine the reliability of the assessment of preventable adverse drug events 
(ADEs) in daily practice and to explore the impact of the assessors' professional 
background and the case characteristics on reliability. 
Methods 
We used a combination of the simplified Yale algorithm and the NCC MERP 
scheme to assess on the one hand the causal relationship between medication 
errors (MEs) and adverse events in hospitalised patients and on the other hand the 
severity of the clinical consequence of MEs. Five pharmacists and five physicians 
applied this algorithm to 30 potential MEs. After individual assessment. the phar­
macists reached consensus and so did the physicians. Outcome was both MEs' 
severity (ordinal scale, NCC MERP categories A-1) and the occurrence of prevent­
able harm (binary outcome. NCC MERP categories A-D vs E-1). Kappa-statistics was 
used to assess agreement. 
Results 
The overall agreement on MEs' severity was fair for the pharmacists (kappa=0.34) 
as well as for the physicians (kappa=0.25). Overall agreement for the ten raters was 
fair (kappa=0.25) as well as the agreement between both consensus outcomes 
(kappa=0.30). 
Agreement on the occurrence of preventable harm was higher, ranging from 
kappa=0.36 for the physicians through kappa=0.49 for the pharmacists . Overall 
agreement for the ten raters was fair (kappa=0.36). The agreement between both 
consensus outcomes was moderate (kappa=0.47) . None of the Included case 
characteristics had a significant impact on agreement. 
Conclusions 
Individual assessment of preventable ADEs in real patients is difficult, possibly 
because of the difficult assessment of contextual information . Best approach 
seems to be a consensus method, including both pharmacists and physicians. 
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Introduction 
Drugs have undoubtedly contributed to a better disease control. However, besides 
their obvious benefits they have untoward harmful effects, i.e. adverse drug events 
(ADEs). These events can occur as either adverse drug reactions (non-preventable) 
or as harm due to medication errors (MEs) (preventable). 1 Historically, the focus has 
been on ' idiosyncratic' adverse drug reactions (ADRs) especially since the thalido­
mide disaster in the 1 960s. Lately, the focus has been shifting towards preventable 
ADEs.2 Minimising this type of events makes health care safer, for which various risk 
reduction strategies (e.g. computerised physician order entry) have been devel­
oped. However, to critically assess the strategies' impact on patient safety, reliable 
instruments are needed to identify preventable ADEs. These instruments should not 
only be applicable for scientific purposes but also in daily clinical practice. 
Various instruments have been developed and are being used to assess in a sys­
tematic way the causality between a drug and an adverse event.3-7 The structure of 
these instruments varies from sets of questions to complex algorithms. Their focus usu­
ally is the assessment of ADRs (non-preventable) and not specifically the assessment 
of preventable ADEs. Specific instruments for assessing the drug causality of prevent­
able ADEs are to our knowledge not available. Nevertheless, the underlying principle 
of assessing ADRs and preventable ADEs is the same. Therefore the aforementioned 
instruments can in our view be applied to preventable ADEs as well. 
If there is a causal relationship, the severity of the consequence of the error can 
be classified. For classification of the severity of an error the National Coordinating 
Council for Medication Error Reporting and Prevention (NCC MERP) index 8 is widely 
used. This index was recently found to be reliable based on the substantial agree­
ment between the assessors.9 In this study the assessment was based on centrally 
extracted data pertaining to the occurrence of a specific event and presented in 
a standardised format to experienced assessors who were mainly pharmacists. This 
leaves open the question about the reliability and the generalisability to everyday 
practice, in which MEs and related ADEs are not assessed by specialised pharma­
cists on extracted data, but have to be made based on data from medical charts 
with a variety of clinical information and by professionals, who are not specifically 
trained as assessors. Nevertheless, it is important to know this reliability. Only if both 
physicians and pharmacists agree on the presence or absence of preventable 
ADEs, useful strategies for reduction of these events in daily practice can be devel­
oped and implemented in a successful way. And only on this condition, a positive 
effect of these strategies can be expected. 
The aim of this study is to determine the reliability of the assessment of preventable 
ADEs in daily practice (i.e. assessment by practicing physicians and pharmacists 
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using complete clinical information), and to explore the impact of the assessors' 
professional background and the case characteristics on reliability. 
Methods 
Setting 
This study was part of a larger study on the effect of a computerised Physician 
Order Entry system on Medication Safety and costs (the POEMS study), which col­
lected data in three internal medicine wards (two general internal medicine wards 
and one gastroenterology /rheumatology ward) of the 1 300 bed University Medi­
cal Center Gronlngen and in two internal medicine wards (one geriatric and one 
general internal medicine ward) of the 600 bed teaching hospital 'TweeSteden' in 
Tilburg, the Netherlands. 
A waiver of the Medical Ethical Committee was obtained for this study, as the study 
fell within the boundaries of normal hospital routine of quality improvement and 
assurance. However, to protect patient privacy, patients were informed of the study 
and could object to inclusion of the study. 
Study population & data collection 
In the POEMS study, patients admitted to the study wards were included from July 
2005 through November 2005. Patients received a letter with information about the 
study and they could object to inclusion. During daily ward visits, data on patients' 
characteristics, diseases, medication, laboratory values and adverse events 
were prospectively extracted by chart review. Two research pharmacists initially 
reviewed the medication and identified potential prescribing and transcribing 
errors according to the classification scheme for medication errors of the Neth­
erlands Association of Hospital Pharmacists. 10 Prescribing errors were defined as 
errors in the process of prescribing drugs and were subdivided Into administrative 
(e.g. errors on readability, drug name or route of administration), dosing (e.g. errors 
on dosage, frequency or length of therapy) and therapeutic errors (e.g. inter­
actions, contra-indications or duplicate therapy). Transcribing errors were defined 
as errors in the process of interpreting, verifying and transcribing of medication 
orders (MOs). For the current study, 30 patients were randomly selected, for whom 
in the initial medication review at least one potential medication error (ME) was 
detected by one of the two research pharmacists. 
Assessment tool 
To standardise the assessment procedure for POEMS, we combined the National 
Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) 
scheme with the simplified Yale algorithm3 (Figure l ). The NCC MERP scheme cat-
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egorises MEs into nine categories (A through I) based on severity of related patient 
outcomes; our first primary outcome (Table 1 ). Categories A through D are asso­
ciated with the absence of a preventable ADE, and Categories E through I are 
associated with the presence of a preventable ADE. These collapsed categories, 
A-D and E-1, form our secondary outcome. The Yale algorithm assesses the causal­
ity of the association between a drug and an adverse event.3 We adopted the first 
three items of the Yale algorithm (knowledge about the relation between this drug 
and the event, influence of other clinical conditions and the time relation between 
drug and event). The causal relationship could be assessed as unlikely (score < 0), 
possible (score 2: 0 and s 3) and probable (score = 4). Combining these algorithms, 
an event was defined as a preventable adverse drug event when it was possible 
or probable related to an ME. 
Table 1: NCC MERP Categories 
Category Content 
A Circumstances or events that have the capacity to cause error 
B An error occurred but the error did not reach the patient 
C An error occurred that reached the patient but did not cause 
patient harm 
D An error occurred that reached the patient and required 
monitoring to confirm that it resulted in no harm to the patient 
and/or required intervention to preclude harm 
E An error occurred that may have contributed to or resulted in 
temporary harm to the patient and required intervention 
F An error occurred that may have contributed to or resulted in 
temporary harm to the patient and required initial or prolonged 
hospitalisation 
G An error occurred that may have contributed to or resulted in 
permanent patient harm 
H An error occurred that required intervention necessary to sustain 
life 
I An error occurred that may have contributed to or resulted in the 
patient's death 
Figure l (on the next page): Comblnaton of the NCC MERP scheme and the simplified 
version of the Yale algorithm. 
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Assessment procedure 
The reliability of the assessment tool (combination of the NCC MERP scheme and 
the simplified Yale algorithm) was tested using the following procedure. All patients' 
clinical information, including the identified potential MEs in the initial medication 
review by one of the two research pharmacists, was given to two panels. The first 
panel consisted of five pharmacists of whom two were specialised as hospital 
pharmacists. Two of them were connected to the TweeSteden hospital, the others 
to the University Medical Center Groningen. Three pharmacists had experience in 
clinical practice for more than 5 years. The other two were involved in the POEMS 
study as members of the research team. The second panel consisted of five physi­
cians who were all specialised in internal medicine. Three of them were geriatri­
cians and four of them were registered as clinical pharmacologists. One of the 
physicians was connected to the TweeSteden hospital, two to the University Medi­
cal Center Groningen and two to other Dutch hospitals (in Utrecht and Helmond). 
All physicians had experience in clinical practice for more than 5 years. 
Before assessing the thirty cases, the raters were individually instructed how to use 
the assessment tool by one of the two researchers. 
These panels performed a detailed medication review. The clinical information 
available to these assessors consisted of patients' characteristics, diseases, all 
medication used (home- and hospital-initiated), adverse events, laboratory data 
and discharge letters. The panel members assessed individually the same poten­
tial MEs. After individual assessment of all 30 cases, the five pharmacists (panel l )  
reached consensus on all cases in one plenary meeting and so did the five physi­
cians (panel 2) in their own plenary meeting after individual assessment. 
Outcome variable 
Two outcome variables were defined; (a) the severity of an ME (NCC MERP cat­
egories A through I) and (b) a dichotomised version of this severity score, namely 
presence (NCC MERP categories E through I) or absence (NCC MERP categories 
A through D) of a preventable ADE as assessed by the panel. 
Determinants 
The assessors' professional background (pharmacist versus physician) was studied 
as determinant for agreement. The case characteristics included as determinants 
were patients' age (.!: 75 years versus < 75 years), patients' length of hospital stay on 
the study ward (.!: 20 days versus < 20 days), number of medication orders per case 
(.!: 1 5  medication orders versus < 1 5  medication orders), the medical ward's spe­
cialism to which patients were admitted (geriatrics versus internal medicine includ­
ing gastroenterology/rheumatology and general internal medicine patients), and 
the type of ME (dosing errors versus therapeutic errors). Cut-off points were based 
on the mean observed results. 
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We chose as determinants those characteristics of which we thought that they 
could have an influence on agreement. 
Data analysis 
Agreement was calculated by using kappa statistics. For this calculation, the soft­
ware program, AGREE® version 7 (ProGAMMA™, the Netherlands) was used. 
Kappa values less than 0.20 were considered as poor agreement, between 0.21  
and 0.40 as fair agreement, between 0.4 l and 0.60 as moderate agreement, 
between 0.6 l and 0.80 as good agreement and between 0.8 1 and 1 .00 as very 
good agreement. 1 1  
Agreement was calculated for both outcomes; the severity of medication errors 
(expressed as an ordinal scale from NCC MERP index categories A - 1) as well as the 
presence/absence of a preventable ADE expressed as a binary outcome (absence; 
NCC MERP index categories A through D, versus presence; categories E - 1). 
The impact of assessors' professional background on agreement was assessed by 
calculating the overall agreement for all 30 cases within the total group of asses­
sors, within the group of pharmacists and within the group of physicians. To deter­
mine the impact of reaching consensus within both expert panels on reliability, 
agreement between both consensus outcomes (pharmacists vs. physicians) was 
calculated. 
To explore the impact of case characteristics on agreement, the cases were 
divided into groups with specific case characteristics. Agreement within the total 
group of assessors was calculated for these groups. 
The significance of the differences between kappa values was determined, using 
AGREE®, version 7. A p-value of less than 0.05 was considered statistically significant. 
The selected 30 cases had a power of 80% to detect a kappa difference of 0.25 




The mean age of the study population was 77 ± 1 5  years. They received 1 7  ± 9 
medication orders during their hospital stays on the study wards, which lasted on 
average 20 ± 9 days. Nineteen patients were admitted to the geriatric ward, seven 
patients to the general internal medicine ward and four patients to the gastroen­
terology /rheumatology ward. (Table 2) 
Potential MEs included fourteen dosing errors, eleven therapeutic errors, five tran­
scribing errors and no administrative errors. 
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Table 2: Patient characteristics of study population (n = 30) 
Female (n, %) 
Age (years) 
Length of stay on ward (days) 
Medication orders per patient 
(mean ± SD) 
Geriatric patients (n = 1 9) 
Primary discharge diagnoses 
General internal medicine (n = 7) 
Primary discharge diagnoses 
Gastroenterology /rheumatology 
ward (n = 4) 
Primary discharge diagnoses 
1 3  (43%) 
77 ± 1 5  
20 ± 9  
1 7  ± 9 
Delirium (4), mobility problems (4), mental disorders 
(3), cancer (2), pneumonia (2), hyponatremia 
based on medication use•, myocardial infarction, 
urinary tract infection, pulmonary embolism 
Cancer (2), sepsis, deregulated diabetes mellitus, 
gastroenteritis, cellulites, ileus 
Cancer (2), cholangltis, cholestasis 
• This adverse drug event was the reason for admission and did not occur during admission 
Agreement between assessors 
The agreement between the 1 0  raters was fair for both outcomes: the severity of 
MEs (K = 0.25) as well as the presence/absence of a preventable ADE (K = 0.36). 
The agreement on the severity of MEs was fair within the group of pharmacists 
(K = 0.34) and within the group of physicians (K = 0.25) (Table 3). The agreement 
between the consensus outcomes was also fair (K = 0.30). 
The agreement on the presence/absence of a preventable ADE was slightly higher; 
moderate for the pharmacists (K = 0.49) and fair for the physicians (K = 0.36) (Table 
3). The agreement between both consensus outcomes was moderate (K = 0.47). 
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Table 3: Agreement between assessors 
Raters 
Agreement for individual 
assessment 
Severity of MEs 
Kappa (95% Cl) 
within total group of assessors n= 1 0) 0.25 (0. 1 8  - 0.32)' 
within group of pharmacists (n=5) 0.34 (0.21 - 0.47)* 
within group of physicians (n::5) 0.25 (0. 1 4 - 0.35)* 
Consensus 
Between pharm. and phys.(n = 2) 0.30 (0.09 - 0.50)§ 
No significant difference between: 
Presence/absence of a 
preventable ADE 
Kappa (95% Cl) 
0.36 (0.23 - 0.49)' 
0.49 (0.29 - 0.68)1 
0.36 (0.23 - 0.49)1 
0.47 (0. 1 5  - 0. 78)i 
• the severity of MEs and the presence/absence of a preventable ADE: p = 0.73 
* pharmacists and physicians: p = 0.28 
t pharmacists and physicians: p = 0.30 
§ the severity of MEs and the presence/absence of a preventable ADE: p = 0.74 
For pharmacists, the agreement on both the severity of MEs and presence/ 
absence of a preventable ADE seemed to be higher than for the physicians. How­
ever these differences were not significant. In the consensus procedure, the physi­
cians assessed nine potential MEs as no error while the pharmacists considered 
all cases as an error (Figure 2). Pharmacists as well as physicians did not assess 
medication errors more severe than classification F; i.e. errors leading to prolonged 
hospitalisation. Medication errors in these 30 cases were not assessed to be asso­
ciated with permanent patient harm, needing interventions to sustain life, or with 
patient's death. 
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Figure 2: Outcomes of the ten assessors 
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Pharm = pharmacist 
Phys = physician 
Assessors 
Impact of case characteristics on agreement 
No error 
Of the different types of medication errors, only dosing errors and therapeutic 
errors were included as determinant because of the small number of transcribing 
errors (n=5). None of the included case characteristics had a significant impact on 
agreement (data not shown). 
Cases 
The cases are described in more detail in the APPENDIX, both for cases with agree­
ment (table 4) and for cases with disagreement (table 5). 
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Discussion 
Only in two cases the level of agreement between raters was higher than fair, 
i.e. the agreement on the presence of a preventable ADE within the pharma­
cists panel, and between the two consensus assessments. As is already known from 
studies into the assessment of ADRs (non-preventable), it is difficult to reach good 
agreement between raters whether there is a standardised procedure or not. 12· 
14 Our findings underline it is the same for assessing preventable ADEs and their 
severity from medical charts In everyday practice. This is in line with the recently 
published study of Haynes et a/. 15 but surprisingly is in contrast with high inter rater 
agreement found by Farrey et a/.9 and Snyder et a/.16 So, why do some studies find 
such poor agreement while others do not? 
First, the level of detail of case information given to the assessors differs. Instead of 
extracted information associated with an adverse drug event or medication error 
only 9· 16, we used an overview of all available clinical information during hospital 
admission. Yet, this overview reflects the reality of clinical situations, in which indi­
vidual patients have various diseases, use many different medications and experi­
ence several symptoms that can be adverse drug events or are caused by the 
normal disease process. 
Secondly, in our study we made use of professionals, not specialised in assessing 
ADEs. This is not in line with most other studies, where Judgements were made by 
specialised assessors. For example, in the study of Forrey et a/.9 the health care 
professionals were regular MEDMARX users and the researchers could not exclude 
that they were more experienced in assessing medication errors. However, when 
implementing strategies to Improve medication safety in everyday practice, spe­
cialised assessors are not always available in sufficient numbers In individual hospi­
tals. Moreover even such specialised assessors have been shown to disagree sig­
nificantly possibly because of variations in subjective weighing of causality argu­
ments.13· 14 This affects mainly arguments that are not factual (i.e. other risk factors or 
comorbidities which could have been the actual reason for the event). 
Thirdly, a learning curve could explain higher levels of agreement. In the study by 
Snyder et a/. 16 each case was assessed, then classified after discussion by the indi­
vidual raters before moving to the next case. This is in contrast to both the study 
of Haynes et al . 15 (in which raters individually classified only without discussion) 
and our study, in which only after all cases were classified individually, consensus 
was reached in a subsequent meeting. We chose for this method, because our 
goal was to determine agreement between individual assessors prior to consen­
sus building in order to evaluate the 'average' healthcare professional opinion on 
preventable ADEs . In our study, discussion could not have influenced the individual 
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ratings in contrast to the approach by Snyder et al. 16 that could have resulted in a 
learning curve and finally higher agreement. 
A potential barrier for implementing strategies to increase medication safety is the 
rather low agreement between pharmacists and physicians when assessing pre­
ventable ADEs. The physicians in our study considered nearly a third of all potential 
MEs not to be a real error. In contrast, the pharmacists rated all potential MEs as real 
errors. We can not exclude that the difference in clinical experience between the 
physicians and the pharmacists had an impact on this result. Besides, physicians 
will probably assess medication safety issues from another perspective than phar­
macists do, because of differences in education, specialisation and experiences. 
Furthermore, it could be hypothesised that physicians look at the patient and his 
disease first and will then consider the relevance of an error, while pharmacists 
in their daily routine are focused on the medication process (how this could be 
improved) and on pharmacological aspects from a more drug related view. This 
may have influenced the group process and outcome of the classification. Still, 
the different professional groups were in moderate agreement on the presence/ 
absence of a preventable ADE after the consensus procedure. However, agree­
ment within the group of physicians remained fair only. Overall we may conclude 
that the impact of profession is not unambiguously clear neither in our study nor 
in that of Dean and Barber 17, who also found that reliability was not affected by 
profession (comparing pharmacists, physicians and nurses). 
A remarkable finding is that in the consensus ratings of the pharmacists there were 
no 'no error' ratings while each pharmacist individually had rated some MEs as 
'no error'. A possible explanation could be that one of the raters was leading in 
the consensus meeting. Therefore, we determined the agreement between the 
individual raters and the consensus outcomes for both pharmacists and physicians 
(data not shown). Based on these results, we draw the conclusion that none of the 
pharmacists was particularly dominant. The same applies to the physicians. Unfor­
tunately, we are not able to further explain the reason for the difference between 
individual and consensus ratings than that this may have been a chance occur­
rence. 
Our findings did not indicate an effect of the studied case characteristics, but can 
also not completely rule out they did not. Decision making by the individual asses­
sors does not seem to be influenced by the case characteristics investigated. The 
results may however not extend to other specialities than internal medicine as only 
patients from these departments were included in this study. Specific population 
characteristics, e.g. children, may have a different effect on agreement. However, 
internal medicine patients use in general relatively many drugs and are therefore a 
relevant population for evaluating the reliability of assessing medication safety. 
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This study shows that there is only fair agreement on the assessment of an adverse 
event being actually preventable harm. Our conclusion is the same as Haynes' et 
a/.15; it Is still a challenge to assess ADEs in a reliable way. As long as the reliability 
is low, It will be difficult to determine the absolute number of preventable ADEs. 
This problem has to be addressed when developing useful strategies to improve 
medication safety in everyday practice. Although consensus methods have their 
limitations, the best practical solution seems to be the consensus method including 
both pharmacists and physicians because it will increase the acceptability in the 
field which is necessary when implementing change. 
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Table 4: Cases with agreement 







of a preventable 
ADE (n= l 0) 
Agreement on 
the occurrence 




Hypotension ➔ Overdose of Perindopril 
Rash ➔ A prescription of Flucloxacillin for a patient 
with a known allergy for this drug 
Type of ME 
Dosing 
Therapeutic 
Unrest ➔ Stop of administration of Strumazol® Transcribing 
(antithyroid drug) because of a transcribing error 
Agitation ➔ Prescription of high dose of oxycontin® Dosing 
(opioid) at once instead of increasing gradually 
Hypoglycemia ➔ Gliclazide administered on wrong Transcribing 
moment because of a transcribing error 
Bleeding nose ➔ Continuation of Clopidogrel Therapeutic 
instead of stopping 
Edema ➔ Interaction between Clarithromycin and Therapeutic 
Nifedipine 
Dizziness ➔ Overdose of lpratropium Dosing 
Hyperkalemia ➔ Duplicate therapy of Perindopril Therapeutic 
and lrbesartan 
Decrease of INR ➔ Stop of administration of Transcribing 
Acenocoumarol because of a transcribing error 
Pravastatin 20 mg ➔ Prescribed to administer It in the 
morning instead of in the evening 
Albumin 100 cc ➔ No indication for this drug 
lsosorbide mononitrate 50 mg ➔ Prescribed twice 
a day instead of once a day (nitrate free interval is 
required because of nitrate tolerance) 
Nitrofurantoin l 00 mg➔ wrong scheme of 
administration: l 00 mg twice a day instead of 50 
mg four times a day (mistaken for the capsule with 
extended release) 
Nitrofurantoin 100 mg ➔ Prophylaxis: prescribed to 
administer in the morning instead of in the evening 
Rifampicin 600 mg ➔ Interacts with midazolam 
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Table 5: Cases with disagreement 







of an ME, 
disagreement on 
the occurrence 
of a preventable 
ADE (n = 5) 
Disagreement on 
the occurrence 
of an ME (n=9) 
Type of ME 
Preventable harm, only according to pharmacists: 
Clostridium difficile infection ➔ Overdose of 
ceftazidime 
Dosing 
Decrease of INR ➔ Stop of administration of 
Acenocoumarol because of a transcribing error 
Transcribing 
Preventable harm, only according to physicians: 
Haematuria, diarrhea, vomiting ➔ Overdose of Dosing 
cotrimoxazole prescribed for a patient with renal 
impairment 
Rectal prolapse ➔ No administration of microlax6, Transcribing 
an enema ( a laxative), because of an omission of the 
nurses to transcribe this drug on the administration 
chart. 
Increase of alkaline phosphatase ➔ Overdose of Dosing 
acetaminophen 
MEs only according to pharmacists: 
Ferrous fumarate 200 mg once a day: an underdose. Dosing 
Prescriptions of both aspirin and dexamethasone. No Therapeutic 
prescription of a proton pump inhibitor. 
Acenocoumarol prescribed to a patient with a Therapeutic 
history of duodenal ulcer. No prescription of a proton 
pump inhibitor. 
Duplicate therapy of lactulose and magnesium Therapeutic 
hydroxide (both laxatives). 
Hydroxocobalamin 1 mg / 3months: underdose Dosing 
Nitrofurantoin prescribed to a patient with a Therapeutic 
creatlnine clearance probably of 50 ml/minute. 
Patient's weight was not known. 
Various switches of antibiotics: indication not clear. Therapeutic 
Domperidone 60 mg 3 times a day (suppository): an Dosing 
overdose. 
Allopurinol 300 mg once a day prescribed to a Dosing 
patient with a creatinine clearance lower than 60 
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Medication errors (MEs) affect patient safety to a significant extent. Because these 
errors can lead to preventable adverse drug events (pADEs), it is important to 
know what type of MEs is the most prevalent cause of these pADEs. This study 
determined the impact of the various types of prescribing (administrative, dosing 
and therapeutic) and transcribing errors on pADEs In hospitalised patients. 
Methods 
During a 5-month period, data of patients admitted to a total of five internal medi­
cine wards of one university and one teaching hospital in the Netherlands were 
prospectively collected by chart review. In each hospital. MEs were detected and 
classified by the same pharmacist, using the classification scheme for MEs devel­
oped by the Netherlands Association of Hospital Pharmacists. The primary outcome 
measure was the prevalence of pADEs during hospital stay. In consensus meetings, 
five pharmacists assessed the causal relationship between MEs and pADEs. The 
association between type of ME and pADEs was determined by a multivariate 
regression analysis taking into account potential confounders. 
Results 
The study included 592 hospital admissions with 7286 medication orders (MOs), 
of which 60% contained at least one prescribing or transcribing error. 1 .4% of all 
MOs led to pADEs, concerning 14.8% of all admitted patients. The total number of 
pADEs was 1 03 of which 92 consisted of temporary harm, eight of prolongation of 
hospital admission, two were life-threatening and one was fatal. Therapeutic errors 
were most strongly associated with pADEs (odds ratio (OR), 1 .98; 95% confidence 
interval (Cl), 1 .53 - 2.56). 
Conclusions 
Although many prescribing and transcribing errors occur In the process of medica­
tion use of hospitalised patients, a minority lead to pADEs. In particular, therapeutic 
errors are the cause of these pADEs and are therefore clinically relevant. Interven­
tion and prevention programmes should primarily focus on this type of medication 
error. 
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Introduction 
Improving patient safety is high on the agenda in health care since in 1 999 the 
Institute of Medicine published its report "To Err is Human", which highlighted the 
magnitude of the problem of patients being harmed during medical care. 1 It 
showed that as many as 98,000 people die each year from medical errors in hos­
pitals. A large proportion of these errors concern medication errors at different 
stages of the medication use process, including prescribing, transcribing, dispens­
ing and administering of drugs,2 with prescribing errors being the most common.3-5 
The frequency of the different types of errors varies across settings, but the differ­
ences may also be explained by the differences in definitions of medication errors 
and differences in the methodology of determining medication errors. 
Next to defining the prevalence of these different types of medication errors, some 
studies have determined the potential harm these medication errors could cause 
without determining whether that harm actually occurred.5 6  Therefore only an 
estimation of the clinical impact of medication errors can be made as occurrence 
of real harm related to medication errors is only inferred. Increasingly, prospec­
tive cohort and observational studies screen for injuries caused by medication, 
i.e. adverse drug events (ADEs).3.4.7-1 1  These studies have also assessed whether an 
ADE that occurred was associated with a medication error and therefore was con­
sidered to be preventable. About 26% to 42% of the ADEs were preventable and 
these preventable adverse drug events (pADEs) seemed to be mainly caused by 
prescribing and transcribing errors.3•4·8· 1 1  
To minimise pADEs, i t  i s  important to know the relation between the subtypes of 
prescribing and transcribing errors and the risk of pADEs. Unfortunately, little is 
known about this relation. Yet, such information would provide important clues as 
to which type of errors cause most harm and should therefore be the primary focus 
for intervention and prevention programmes. Therefore, we performed a study to 
investigate the impact of the various types of prescribing and transcribing errors on 
pADEs in hospitalised patients. 
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Methods 
Setting, design and patients 
This study is conducted in the framework of a study on the effect of a compu­
terised Physician Order Entry system on Medication Safety and associated costs 
(POEMS study). The study was performed in three medical wards of the 1 300 bed 
University Medical Center in Groningen (two general internal medicine wards and 
one gastroenterology/rheumatology ward) and in two medical wards (one geri­
atric and one general internal medicine ward) of the 600 bed teaching hospital 
'TweeSteden' in Tilburg and Waalwijk, the Netherlands. In these medical wards, the 
process of medication ordering and administration consisted of a hand-written 
system: physicians prescribe medication orders on charts and nurses transcribe 
these medication orders on administration charts. 
The occurrence of prescribing and transcribing errors and related harm was deter­
mined in patients hospitalised on these five medical wards using a prospective 
cohort design. 
During a 5-month period, from July 2005 through November 2005, all patients admit­
ted for more than 24 hours to the study wards were Included. Patients received a 
letter with information about the study, and they could object to inclusion. 
Data collection 
During daily ward visits, the investigators collected data on patients' characteris­
tics (sex, age, length and weight), diseases (reasons for admission and diagnoses), 
medication (medication orders during hospital stay) and adverse events (any 
untoward medical occurrences during stay) which consisted of newly upcoming 
symptoms or increasing of consisted symptoms. These data were prospectively 
extracted from the medical records, the medication order and administration 
charts. When the investigators noticed a potentially life threatening error related 
to a medication order during the process of data collection, they intervened in 
the prescribing process for ethical reasons. Such errors were not excluded from this 
study. 
Classification of prescribing and transcribing errors 
Medication errors were categorised according to the classlficatlon scheme for 
medication errors developed by the Netherlands Association of Hospital Pharma­
cists. 12 In this scheme a distinction is made between prescribing, transcribing, dis­
pensing, administering and 'across setting' errors. In this study, only prescribing and 
transcribing errors were recorded. Prescribing errors are subdivided Into adminis­
trative errors (errors on readability, patient data, ward and prescriber data, drug 
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name. dosage form and route of administration), dosing errors (errors on strength, 
frequency, dosage, length of therapy and directions for use) and therapeutic 
errors (interactions, contra-indications, incorrect monotherapy, duplicate therapy 
and errors on therapeutic drug monitoring or laboratory monitoring). Transcribing 
errors were classified as errors in the process of interpreting, verifying and transcrib­
ing of medication orders. 
Inappropriate drug choices were not actively assessed and were only taken into 
account when these were obvious. 
Classification of severity of errors 
All medication errors were classified according to severity of the consequence of 
the error using the scheme of the National Coordinating Council for Medication 
Error Reporting and Prevention (NCC MERP). 13 The severity of the consequence of 
the medication errors could range from a medication error that did not reach the 
patient (B) up to a medication error that reached the patient and led to the death 
(I). In the NCC MERP classification, category A is meant for situations that can lead 
to a medication error. In this study this category is not used. This classification is 
illustrated in table l . 
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Table 1 : Frequency of errors per severity category 
No pADEs pADEs 
NCCMERP B C D E F G H category* 
Prescribing 
Administrative 2516  6 
(n=2522) (99.8%) (0.2%) 
Dosing 1 396 220 8 30 1 2 1 
(n=1 658) (84.2%) (1 3.3%) (0.5%) ( 1 .8%) (0. 1 %) (0. 1 %) (0. 1 %) 
Therapeutic 25 255 4 50 6 
(n=340) (7 .4%) (75%) (1 .2%) (1 4.7%) (1 .8%) 
Transcribing 1020 167 5 1 2  1 
(n=1 205) (84.6%) (1 3 .9%) (0.4%) ( 1 .0%) (0. 1 %) 
Total 4957 648 1 7  92 8 2 1 
(n=5725) (86.6%) (1 1 .3%) (0.3%) (1 .6%) (0. 1 %) (0.0%) (0.0%) 
*NCC MERP Index for categorising medication errors: 
B = An error occurred but the error did not reach the patient 
C = An error occurred that reached the patient but did not cause patient harm 
D = An error occurred that reached the patient and required monitoring to confirm that it 
resulted in no harm to the patient and/or required intervention to preclude harm 
E = An error occurred that may have contributed to or resulted in temporary harm to the 
patient and required intervention 
F = An error occurred that may have contributed to or resulted in temporary harm to the 
patient and required initial or prolonged hospitalisation 
G = An error occurred that may have contributed to or resulted in permanent patient harm 
H = An error occurred that required intervention necessary to sustain life 
I = An error occurred that may have contributed to or resulted in the patient's death 
Causality assessment 
For all medication errors made while a patient was admitted, all adverse events 
that were extracted from the charts were assessed for a causal relationship. The 
relationship between a medication error and an adverse event only was assessed. 
In other words, we did not assess the relationship between drugs and adverse 
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events (including non preventable ADEs). This causality assessment was carried out 
by five pharmacists. In aid of that assessment an algorithm was developed, based 
on both the NCC MERP scheme and the Yale algorithm, an algorithm for the cau­
sality assessment between a drug and an event. 14 The first three items of the Yale 
algorithm were used; determination whether the event has been widely known 
to occur as a consequence of the drug's administration, whether there might be 
underlying clinical conditions which are responsible for the event, and whether the 
timing of the event is as expected in case of an ADE. 
After individual assessment by the pharmacists, four meetings took place, where 
consensus was reached for all cases on both causality and severity. Because we 
expected a priori that the reliability between the individual pharmacists would 
be low 15• 16, we made use of this consensus method. Other studies into medication 
safety applied a consensus procedure as well.6·17• 1 8 Although this method has its 
limitations too, such as dominant raters having an unproportionally large influence 
on outcome assessments, it seems to be the best practical solution. 
Outcome 
The measure of outcome was the prevalence of preventable adverse drug events 
(pADEs). A pADE was defined as an ADE that occurred due to a medication error 
and where the causality assessment procedure indicated that there was at least 
a possible relationship between ADE and medication error. In this paper, the term 
pADE is similar to preventable harm. 
Determinants 
The different types of prescribing and transcribing errors as determinants for pADEs 
were studied. Administrative errors were not taken into account in the analysis 
because there were no pADEs related to this type of error. Patients' age, patients' 
sex, number of errors related to one patient, number of medication orders related to 
one patient and drug groups, associated with high risk on preventable harm were 
considered as potential confounders. Relevant drug groups were selected from 
both the literature, 19 and the associations with pADEs in our own data (percentage 
of pADEs per prescribed drug group). These were antidiabetics, anticoagulants, 
drugs for anaemia, corticosteroids, antibiotics for systemic use, anti-inflammatory 
drugs, analgesics, antiepileptics, psycholeptics and drugs for gout. 
Data analysis 
All data were processed with MS Access 2003. SPSS version 1 2  and the SAS statisti­
cal package version 9.1 were used for analysis. The association between type of 
medication error and pADEs was determined by logistic regression analysis with 
the patient as unit of analysis. Patients were included only when a medication 
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error had occurred . Potential confounders were taken into account in a univariate 
analysis. Potential confounders from the univariate analysis (p<0.05) were included 
Into a multivariate logistic regression model. 
Results 
During the 5-month period of data collection, 558 patients with 592 hospital admis­
sions were included in this study (28 patients were re-admitted once and three 
patients were re-admitted twice). Four patients did not provide consent and 
were excluded from the study. Table 2 summarises the characteristics of all study 
patients. 
Table 2: Characteristics of all study patients 
Characteristic 
Female (n, %) 
Age (years) 
Length of hospital stay on study wards (days) 
Medication orders per hospital stay (mean ± SD) 
Patients admitted to: 
gastroenterology /rheumatology (n, %) 
internal medicine (n,%) 
geriatrics (n, %) 
Admissions 
(n = 592) 
324 (55%) 
65.5 ± 1 9.2 
1 4.6 ± 1 2.5 
1 2.3 ± 7,8 
1 88 (31 .8%) 
251 (42.4%) 
1 53 (25.8%) 
A total of 7286 medication orders were written, of which 4369 (60%) contained at 
least one prescribing or transcribing error. A total number of 5725 prescribing or 
transcribing errors were identified, of which l 03 ( 1 .8%) resulted in preventable harm 
(Figure l ). In nine cases, the study investigators intervened to preclude unaccept­
able patient harm: four dosing errors and five transcribing errors. These errors were 
classified as D; errors that required an Intervention to preclude harm. 
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Figure l :  frequency of patients, medication orders and medication errors 
558 patients 
592 admissions 
7,286 medication orders (MOs) 
2,91 7 (40%) MOs without 
errors 
2,522 (44%) 1,658 (29%) 
4,369 (60%) MOs with at least 
one prescribing or transcribing 
error 
5,725 prescribing or transcribing 
errors 
340 (6%) 1 ,205 (21 %) 
administrative errors dosing errors therapeutic errors administrative errors -
0 errors with 34 errors with 56 errors with 1 3  errors with 
preventable harm preventable harm preventable harm preventable harm 
i i i 
•percentage of total number of medication errors 
1 , 8  % of medication errors led to 
preventable harm 
1 ,4% of medication orders with preven­
table harm 




Table l shows the frequency of each type of error classified within a severity cat­
egory. The most commonly identified type of medication error was an administra­
tive error, but this type caused no pADEs. (Figure l and Table l )  In contrast, 56 ( 1 6%) 
of a total of 340 therapeutic errors led to a pADEs. Examples of prescribing and 
transcribing errors related to pADEs are given in table 3. 








The dosage of Oxycontin® 
( an opioid) was increased to 
a high dose at once instead 
of incrementally as required. 
The patient suffered from 
agitation. 
A high dosage of Diamicron® 
(an oral antidiabetic agent) 
was prescribed to a patient 
with renal failure. This resulted 
In hypoglycemia. 
On the administration 
chart, the frequency of 
a medication order for 
Selokeen® (beta blocker) 
was twice a day instead of 
once a day (prescribed). 
The patient suffered from 
hypotension. 
F 
An overdose of Fortum® 
(cephalosporin) led to a 
C/ostridium difficile infection. 
Oxybutynin (Drldase®) and 
tolterodine (Detrusitoll>), both 
drugs for urge incontinence, 
were prescribed to one 
patient. The patient 
suffered from sedation and 
obstlpatlon . 
The nurse transcribed 
a medication order 
for amoxlcillin on the 
administration chart three 
days later than prescribed. 
The duration of the urinary 
tract infection was longer 
than it should be. 
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Most prescribing and transcribing errors did not reach patients (severity category 
8). Still a substantial number of the prescribing and transcribing errors reached 
patients but did not lead to an adverse drug event during their hospital stay (665 
errors). The majority of errors that caused pADEs concerned temporary harm (cat­
egory E) - for example constipation. 
Preventable harm was caused by l .8% of all medication errors or 1 .4% of all medi­
cation orders. A total of 1 4.8% patients suffered from preventable harm related to 
medication errors in the prescribing or transcribing process. (Figure l )  
After adjusting for confounding factors in a multivariate analysis, therapeutic errors 
were more strongly associated with pADEs (odds ratio (OR)= l .98; 95% Cl 1 .53 to 
2.56) than transcribing errors (OR= 1 . 1 2; 95% Cl 1 .01 to 1 .25). (Table 4) In the multivari­
ate analysis, dosing errors were not significantly associated with pADEs. 
H 
In the therapy to eradicate Helicobacter 
Pylori, the dose of Amoxicillin was too 
low en the duration of the proton pump 
inhibitor was too short. Thereafter the 
patient was re-admitted because of a 
bleeding ulcer. 
An overdose of Fragmin® (low molecular 
weight heparin) was prescribed to a 
91 year old woman. Thereafter she 




Table 4: Determinants of pADEs 
Predictor 
No. of dosing errors 
No. of therapeutic errors 
No. of transcription errors 
Age: 
Lowest to 34 
35 to 49 
50 to 64 
65 to 79 
80 to highest 
Gender (male is reference) 
No. of medication errors 
No. of medication orders 
Therapeutic area (ATC code): 
Al 0 ( antidiabetics) 
801 (anticoagulants) 
803 (drugs for anaemia) 
H02 (corticosteroids 
J0l (antibiotics for systemic use) 




M04 (drugs for gout) 
OR unadjusted 
1 . 16**  
2.22 
















1. 1 1  
2. 1 6  
2.21 
95% CI 
1 .09-1 .23 
1 .77-2.78 
1 . 1 2-1 .26 
0.06-1. 1 4  
0.21-1 .23 
0 .27-1 .11 
0.75-2. 1 0  
1 .22-3.25 
0.54- 1 .42 
l .05-1. 10 
l .04-1 .09 
1 .23-4.08 









QRad)usted * 95% CI 
1 .05 0.92 - 1 .21 
1 .98 1.53 - 2.56 
1 . 1 2  1 .01 - 1 .25 
1.63 0.92 - 2.90 
0.98 0.90 - 1.05 
1 .00 0.96 - 1.05 
1 .50 0.73 - 3.09 
1 .79 0.86 - 3.71 
1 .48 0.82 - 2.68 
1.30 0.72 - 2.32 
1 .44 0.80 - 2.58 
* Adjusted for the confounding factors, which contributed significantly to the model, 
** significant values are shown in bold 
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Discussion 
Our study shows that approximately 2% of the medication errors related to the pre­
scribing and transcribing process lead to pADEs. Of these errors, therapeutic errors 
are more strongly associated with pADEs than transcribing errors. Although we 
expected a relation between dosing errors and pADEs, a significant association 
could not be demonstrated. Dosing errors were errors like dosing too high or too 
low, but also errors like unclear or incomplete dosages. This last category of errors 
was usually corrected before reaching the patient and did not lead to preventa­
ble harm. This could explain the absence of a significant association between dos­
ing errors and preventable harm. Though administrative errors are the most common 
errors made, no related harm could be detected. Most administrative errors did not 
reach patients, probably because they were intercepted by nurses or pharmacy 
staff through the various checking procedures in the prescribing process. 
Earlier studies have already shown that prescribing errors are the most responsible 
for preventable harm. 3·9•20·21 Our study shows that this is particularly the result of thera­
peutic errors . By calculating odds ratios, this study provides an estimate of the mag­
nitude of the risk, which builds on the previously conducted descriptive studies. 
No other determinants of pADEs were found after adjustment for type of error, sug­
gesting that the impact of the other included factors, such as high age (;;,, 80) is 
'mediated' through type of error. 
In our study, the frequency of errors is extremely high; more than half of the medi­
cation orders contained one or more errors. Although high frequencies have been 
mentioned in literature, 22.23 the number of medication errors in our study is higher. 
Differences in definitions and methodology are possible explanations for these find­
ings. In our opinion the very high error rates are primarily caused by the detailed 
classification scheme for medication errors. All kinds of administrative aspects (no 
administration route, missing of start date, etc .) were taken into account as errors .  
We defined these items as errors, while other studies did not. This clarifies to a large 
extent the high error rates. Our conclusion is, however, that these administrative errors 
do not (often) lead to patients being harmed. Nevertheless, removing these errors is 
still important for patient safety. Correction of administrative errors during the medi­
cation process can consume a substantial amount of time and effort and patient 
safety may be compromised indirectly because less time remains for identifying and 
correcting those types of errors that do result in patient harm. Furthermore, the cor­
rection procedures are at risk from human failures or weaknesses in the system.24 
This study has several potential limitations. A weak point of this study is that the cau­
sality assessment was made by pharmacists only. No other healthcare professionals 
were involved in the assessment procedure (eg, physicians).Although the pharma-
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cists in our study had broad clinical experience, a different clinical view from physi­
cians could be expected. Nevertheless contrary to this expectation, Dean and 
Barber25 showed that the reliability of the assessment of medication errors' severity 
was not affected by a rater's professional background, when enough assessors 
were included In the procedure (three or more). However, a group of raters includ­
ing different professions might increase the acceptance of our findings by the dif­
ferent healthcare professionals , 
Another limitation of our study Is the lack of data on reliability between the inves­
tigators who collected data (eg, kappa values). However, we think that this issue 
may have had a limited effect on our study findings as we used the classification 
scheme for medication errors developed by the Netherlands Association of Hos­
pital Pharmacists12  that precisely defines specific types and subtypes of medica­
tion errors. The investigators Individually assessed the medication of the same l 0 
patients and then discussed differences in classification. Furthermore, during the 
whole study period, the observers discussed on a regular basis how to collect and 
interpret data, and any extraordinary cases were classified in mutual agreement. 
This approach should have limited variability between the different investigators, 
but we have no objective means to tell if this assumption holds true. 
In our study the number of pADEs may be over-rated because all adverse events 
with a possible relationship to a medication error have been taken Into account. 
However, the results may also underestimate the extent of medication errors, 
because only adverse events occurring during the hospital stay were retrieved 
and not those occurring after a patient was discharged, Medication errors which 
reached patients during the hospital stay and did not immediately lead to patient 
harm could have the potential to do so in the future. For example, no gastric pro­
tection during the use of a combination of a NSAID and prednisolone usually does 
not lead immediately to a gastrointestinal bleeding, but could do so in the future. 
Furthermore, only internal medicine, gastroenterology, rheumatology and geriatric 
medical units in two hospitals were studied, so the results may not apply to other 
medical specialities or to other hospitals. 
Finally, this study considered medication errors in the process of prescribing and 
transcribing only. To provide a full overview of the extent to which medication errors 
can lead to harm, administration errors should be studied as well. Although studies 
have been conducted into the incidence and the potential severity of administra­
tion errors, 26•27 more research is needed to explore the association of administration 
errors with the occurrence of pADEs, specifically in comparison to the other types 
of medication errors, 
One of the main strengths of this study is that it provides information not only on 
error frequencies, as many other studies do, but also on the associated frequency 
of actual patient harm. Another strength of this study is the prospective nature 
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and the use of an epidemiological design to determine potential associations 
between error type and ADEs. 
To conclude, the findings indicate that a substantial percentage of the hospital­
ised patients suffer from pADEs due to prescribing and transcribing errors; in par­
ticular therapeutic errors (interactions, contra-indications, incorrect mono-therapy, 
duplicate therapy and errors on monitoring) are clinically relevant. Intervention 
and prevention programmes should focus on these medication errors. A Compu­
terised Physician Order Entry System especially with a clinical decision support sys­
tem could be a possible solution to reduce these types of medication errors.28·30 
Future research is needed to determine the impact of such interventions on the 
reduction in therapeutic errors and preventable patient harm as well as the cost­
effectiveness of these interventions. 
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To compare determinants for medication errors leading to patient harm with 
determinants for medication errors without patient harm. 
Methods 
A two-way case-control design was used to identify determinants for medication 
errors without harm (substudy l )  and determinants for medication errors caus­
ing harm (substudy 2). Data of patients admitted to five internal medicine wards 
of two Dutch hospitals during five months were collected prospectively by chart 
review. Medication errors were detected and classified by two pharmacists. Con­
sensus between five pharmacists was reached on the causal relationship between 
medication errors and patient harm. Data analysis was performed by multivariate 
logistic regression. 
Results 
We included 7286 medication orders, of which 3315  without errors (controls), and 
5622 medication errors without harm ( cases substudy l) and l 02 medication errors 
causing harm (cases substudy 2) were identified. 
Hospital, ward and the therapeutic class anti-infectives were associated with both 
medication errors without harm (hospital odds ratio (OR) l .40; 95% confidence 
interval (Cl) 1 .2 1 - 1 .63), TweeSteden hospital (TSh) geriatrics OR 2.03; 95% Cl 1 .73-
2.38, TSh general internal medicine OR 1 .44; 95% Cl l .23-1 .69 and anti-infectives OR 
1 .28; 95% Cl 1 .06-1 .56) and medication errors with harm (hospital OR 4.9 1 ;  95% Cl 
3.02-7.79, TSh geriatrics OR 5.76; 95% Cl 2.52- 13 . 1 5, TSh general internal medicine 
OR 1 .44; 95% Cl 2.82-1 5.02 and anti-infectives OR 4.20; 95% Cl 2.24-7.90). 
Conclusions 
This study shows that organisational determinants (hospital, ward) are comparable 
for medication errors with and without harm. For conclusions on patient- and medi­
cation related determinants studies with larger sample sizes are needed. 
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Introduction 
The prevalence of medication errors in hospitals is about 6% of all medication 
orders and approximately 1 0% of all medication errors is estimated to result in 
patient harm. 1 Whether or not a medication error results in patient harm depends 
on whether the error reaches the patient and when it does, on the intrinsic toxicity 
of the drug and the susceptibility of the patient to adverse events. Also, certain 
types of medication errors are more likely to cause patient harm than others, e.g. 
therapeutic prescribing errors result in harm more often than administrative pre­
scribing errors do.2-5 
Despite the fact that not all medication errors lead to patient harm, the impact 
of the problem of adverse drug events (ADEs) induced by such errors is rather 
large. The report "To err is human" showed that in the United States 2% of all admit­
ted patients is harmed as a result of a medication error and that 7000 patients 
die from medication errors annually.6 This report has led to a renewed interest of 
health care professionals in improving medication safety. Such improvements can 
be achieved by effective interventions targeted at identified risk factors that con­
tribute to unsafe practices and potential patient harm. 
Whereas preventing actual patient harm is the ultimate goal of such medication 
safety initiatives, medication errors are often used as a surrogate outcome meas­
ure, because these occur more frequently and are easier to detect. However, the 
validity of this surrogate end point has not been established and it is unknown 
whether the risk factors associated with medication errors causing patient harm 
are the same as the risk factors associated with medication errors that do not 
cause harm. Therefore, we performed a study to compare the determinants for 
medication errors resulting in patient harm and the determinants for medication 




Design and setting 
The design of the current study is a two-way case-control study. In a first substudy 
( 1 '1 way) medication orders with errors not leading to patient harm (cases) were 
compared to medication orders without errors (controls). This first substudy aimed 
to identify determinants for medication errors not leading to patient harm. In the 
second substudy (2nd way) medication orders with errors leading to patient harm 
(cases) were again compared to the same medication orders without errors (con­
trols) to identify determinants for medication errors leading to patient harm. Subse­
quently, determinants that were identified in the first substudy were compared with 
determinants identified in the second substudy. 
This study is part of the POEMS study on the effect of a Computerised Physician 
Order Entry (CPOE) system on Medication Safety and associated costs.5· 7 The 
POEMS study is a prospective intervention study, performed in two medical wards 
(one geriatric and one general internal medicine ward) of the 600 bed teach­
Ing hospital "TweeSteden" (TSh) in Tilburg and Waalwijk and three medical wards 
(two general internal medicine wards and one gastroenterology /rheumatology 
ward) of the 1300 bed University Medical Center in Groningen (UMCG), the Neth­
erlands. The current study uses data of the period before the introduction of the 
CPOE-system. The process of medication ordering and administration consisted 
of a hand-written system: physicians prescribed medication orders on charts and 
nurses transcribed these medication orders on administration charts. 
Patients 
From July through November 2005 all patients admitted to the study wards for more 
than 24 hours were included. Patients received written information about the study 
after which they could object to Inclusion. A waiver of the Medical Ethical Com­
mittee was obtained for this study, as the study fell within the boundaries of normal 
hospital care and routine of quality improvement and assurance. 
Data collection 
During ward visits the investigators prospectively extracted patients' characteristics 
(age, sex, weight and length) and data on diseases (medical history, reasons for 
admission and diagnoses) and adverse events (I.e. untoward medical occurrences 
which do not have to have a causal relationship with the treatmenfll) from medi­
cal records. Medication orders during hospitalisation were collected by reviewing 
medication order charts and administration charts. Medication errors were identi-
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tied by two pharmacists. For ethical reasons, the physician was informed in case of 
potentially life threatening errors that were discovered during the process of data 
collection. These errors were not excluded from the study. 
Classification of prescribing and transcribing errors 
Medication errors were categorised by two pharmacists according to the clas­
sification scheme for medication errors developed by the Dutch Association of 
Hospital Pharmacists.9 This classification distinguishes prescribing, transcribing, dis­
pensing, administering and "across settings" errors. In this study only prescribing and 
transcribing errors were recorded. Prescribing errors are subdivided into adminis­
trative errors (errors on readability, patient data, ward and prescriber data, drug 
name, dosage form and route of administration), dosing errors (errors on strength, 
frequency, dosage, length of therapy and directions for use) and therapeutic 
errors (interactions, contra-indications, incorrect mono-therapy, duplicate therapy 
and errors on therapeutic drug monitoring or laboratory monitoring). Inappropri­
ate drug choices were not actively assessed and were only taken into account 
when they were obvious. Transcribing errors are defined as errors in the process of 
interpreting, verifying and transcribing of medication errors. The severity of all medi­
cation errors was assessed according to the index of the National Coordinating 
Council for Medication Error Reporting and Preventing (NCC MERP). 10 
In this study, medication errors were divided into errors that did not lead to patient 
harm (NCC MERP category B up to D) and errors that did lead to harm (NCC MERP 
category E up to I). 
Patient harm 
Patient harm was defined as a preventable adverse drug event (pADE) which is 
an adverse drug event that occurred due to a medication error with a possible 
or probable causal relationship with the medication error. To assess this relation­
ship an algorithm was developed, based on the NCC MERP index and the Yale 
algorithm.7 10, 11 The first three items of the Yale algorithm were used: knowledge 
about the relation between the drug and the event, the presence of underlying 
clinical conditions which could be responsible for the event and the timing of the 
event. The causal relations between all medication errors made and the adverse 
events extracted from the medical records were assessed by five pharmacists. 
After individual assessment consensus was reached for all cases on both causality 
and severity. The causal relationship could be defined as unlikely (score < 0), pos­
sible (score 2: 0 and s 3) or probable (score = 4). An event was defined as patient 





Potential determinants of medication errors with and without patient harm that 
were studied included organisational characteristics (hospital. ward, transfer from 
another hospital ward or care institution, length of stay and readmission to study 
ward during study period), patient characteristics (gender, age, renal impairment 
(defined as creatinine clearance s 50 ml/min during hospitalisation) and the 
number of medication orders per patient during hospital stay), characteristics of 
the medication order (weekday of prescription, dosage frequency less than once 
daily and route of administration) and the therapeutic area of the medication 
(identified by Anatomical-Chemical-Therapeutic (ATC) code). 
Data analysis 
All data were processed with MS Access 2003 and analysed with SPSS version 
1 6.0. 
Determinants for medication errors that did not lead to patient harm were iden­
tified by comparing medication orders containing these errors with medication 
orders without errors (substudy l ). Determinants for medication errors that resulted 
in patient harm were identified by comparing medication orders containing these 
errors with medication orders without errors (substudy 2). Univariate logistic regres­
sion analysis was performed with the medication order as unit of analysis. Multi­
ple errors could have been made in one medication order and analysis was per­
formed for each medication error separately. 
For determinants that were statistically significantly associated (p<0.05) with errors 
in the univariate analysis, a multivariable logistic regression analysis was performed 
using a stepwise forward logistic regression model. Determinants were included in 
the model when they changed the beta coefficient with at least l 0%. Crude and 
adjusted odds ratios with 95% confidence intervals were calculated. Determinants 
that were significantly associated with medication errors without harm in substudy 
l were compared to determinants for medication errors leading to patient harm 
identified in substudy 2. 
Results 
During data collection 558 patients were included and 4 patients were excluded 
from the study due to objection to inclusion. Since 28 patients were re-admitted 
once and three patients were re-admitted twice, 592 admissions were included 
In the study. During these admissions 7286 medication orders were prescribed of 
which 331 5  contained no error (controls). In the other 397 1 medication orders a 
total of 5724 medication errors were identified of which 5622 did not cause patient 
harm (cases substudy l )  and 1 02 resulted in patient harm (cases substudy 2) 
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Age (mean ± SD): 65.5 ± 19.2 years 
Length of stay on study wards (mean ± SD): 1 4.6 ± 12.5 days 
� 










Cases (substudy 1 )  Cases (substudy 2) 
Medication errors without harm Medication errors with harm 
n=5622 n=1 02 
Figure 1 :  Patient characteristics, medication orders and medication errors 
(Figure 1 ). Nine medication errors were considered serious enough to require an 
intervention by the investigators to preclude harm. These errors were classified as 
errors that did not result in patient harm, but which required interventions to pre­
clude harm (NCC MERP category D). 
Details of the univariate and multivariate analysis of organisational characteristics, 
patient characteristics, characteristics of the medication order and the therapeu­
tic area are presented in tables 1 to 4. 
After multivariate analysis the following determinants were significantly associated 
with medication errors without patient harm: hospital, ward, transfer of patient, 
length of hospital stay, number of medication orders per patient during hospital 
stay, weekday of the prescription, route of administration and the therapeutic 
classes cardiovascular tract genitourinary system and hormonal system, hormo­




Of these determinants the following were also statistically significantly associated 
with medication errors with harm: hospital, ward and therapeutic class anti-infec­
tives. 
All other determinants that were statistically significantly associated with medica­
tion errors without harm (transfer of patient, length of hospital stay, number of medi­
cation orders per patient, day of prescription, route of administration and the other 
therapeutic classes) showed no association with medication errors with harm in 
the univariate analysis already, had insufficient cases per category to analyse 
the association or showed a different trend in the odds ratio. No determinants for 
medication errors leading to harm were identified that had not been identified as 
determinant for medication errors without harm. 
Table l: Organisational characteristics associated with medication errors with and without 
patient harm after univariate logistic regression (odds ratios) and multivariate logistic 
regression (adjusted odds ratios) 
Medication errors without harm (substuc 
Potential determinant Cases n (%) Controls n (%) OR 95% CI Oil 
Hospital 
TSh (UMCG is reference) 3468 (61 .7) 1 459 (44.0) 2.05 1 .88-2.24 1 .� 
Ward 
UMCG General Internal 
medicine 904 (1 6. 1 )  732 (22. 1 )  ref re 
UMCG Gastroenteroiogy/ 
rheumatology 1 250 (22.2) 1 1 24 (33.9) 0.90 0.79-1 .02 O.<; 
TSh Geriatrics 
2250 (40.0) 796 (24.0) 2.29 2.02-2.60 u 
TSh General internal medicine 
1 21 8 (21 .7) 663 (20.0) 1 .49 1 .30-1.70 u 
Transfer from: 
(n:8255/ n:3056) 
Home (ref) 3 1 75 (60. 1 )  1566 (52.7) ref rE 
Another hospital ward 446 (8.4) 254 (8.5) 0.87 0.73-1 .02 0.1!! 
Care institution 1663 (31 .5) 1 1 51 (38.7) 0.71 0.65-0.79 o.e 
Length of stay (days, mean ± SD)* 22.2 ± 1 7 .0 1 9.2 ± 1 5.5 1 .01 1 .01-1 .02 1.Cl 
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Figures In bold are statistically significant 
Abbreviations: OR, odds ratio; 95 %Cl, 95% confidence Interval; ORadj , adjusted odds ratio; TSh, 
TweeSteden hospital; UMCG, University Medical Centre Gronlngen; ref, reference 
1 :  Adjusted for ward, transfer and day of prescription 
2: No confounding factors were Identified 
3: Adjusted for transfer, length of stay, age group, renal Impairment, number of medication orders, day 
of prescription, hospital Initiated drug and pharmacotherapeutlc area 
4: Adjusted for age and pharmacotherapeutlc area 
5: Adjusted for hospital, ward and length of stay 
6: Adjusted for number of medication orders 
• Analysed as a continuous variable 
Medication errors with harm (substudy 2) 
Cases n (o/o) Controls n (o/o) OR 95% Cl ORac11 
81 (79.4) 1 459 (44.0) 4.91 3.02-7.97 4.9l 2 
7 (6.9) 732 (22. l )  ref ref 
1 4 (1 3.7) 1 1 24 (33.9) 1 .30 0.52-3.24 1 .73• 
2.90-
49 (48.0) 796 (24.0) 6.44 1 4.30 5.76• 
2.21-
32 (31 .4) 663 (20.0) 5.05 1 1 .51 6.51•  
56 (59.6) 1 566 (52.7) ref 
9 (9.6) 254 (8.5) 0.99 0.48-2.02 
29 (30.9) 1 1 51 (38.7) 0.71 0.45-1 . 1 1 
20.4 ± 1 1 .7 1 9.2 ± 1 5.5 1 .00 0.99-1 .02 










Table 2: Patient characteristics associated with medication errors with and without patient 
harm after univariate logistic regression (odds ratios) and multivariate logistic regression 
(adjusted odds ratios) 
Medication errors without harm (substuc 
Potential determinant Cases n (%) Controls n (%) OR 
Female gender (male is reference) 2990 (53.2) 1 780 (53.7) 0.98 
Age (years, mean ± SD)* 70.8 ± 16.8 67. l  ± 17.8 1 .01 
<50 years 778 (1 3.8) 605 (1 8.3) ref 
50 t/m 64 years 882 (1 5.7) 668 (20.2) 1 .03 
65 t/m 79 years 1 859 (33. l )  1 053 (31 .8) 1 .38 
.e 80 years 2 103 (37.4) 989 (29.8) 1 .65 
Renal impairment 31 76 (56.5) 1700 (51 .3) 1 .23 
Number of medication orders 
(mean :!: SD)* 19.2 ± 1 7.0 18.2 ± 1 0.7 1 .01 
Polyfarmacy (>4) 5534 (98.4) 3253 (98. l )  1 .20 
Figures in bold are statistically significant 
Abbreviations: OR. odds ratio; 95 %Cl, 95% confidence interval; OR
0
., , adjusted odds ratio 
1 :  Adjusted for hospital, ward, length of stay and pharmacotherapeutlc area 
2: Adjusted for hospital 
95% CI 
0.90-1 .07 
1 .01-1 .02 
0.89-1 . 1 9  
1 .21-1 .56 
1 .45-1 .88 
1 .1 3-1 .34 
1 .00-1 .01 
0.86-1 .66 
3: Adjusted for hospital, ward, transfer, length of stay, renal impairment, number of medication orders, 
day of prescription, route of administration and pharmacotherapeutlc area 
4: Adjusted for hospital, ward and pharmacotherapeutlc area 
5: Adjusted for hospital, ward, transfer, length of stay, age, number of medication orders, day of 
prescription. route of administration and pharmacotherapeutlc area 
6: Adjusted for hospital, ward, transfer, length of stay, day of prescription. route of administration and 
pharmacotherapeutlc area 
• Analysed as a continuous variable 
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Medication errors with harm (substudy 2) 
•5% CI Cases n (%) Controls n (%) OR 95% Cl ORadJ 95% Cl 
47 (46 . l )  1 780 (53.7) 0.74 0.50-1 . 1 0  
00-1 .0l 74. l ± 1 4.8 67. l ± 1 7.8 1 .03 1 .01-1 .04 l .0l 2 l .00-1 .03 
9 (8.8) 605 (1 8.3) ref ref 
85-1 . 1 8  1 2  ( l  l .8) 668 (20.2) l .2 1  0.51 -2.89 l .354 0.56-3.26 
84-1 . l 7 38 (37.3) 1 053 (31 .8) 2.43 1 . 1 7-5.05 l . 774 0.81 -3.90 
85-1 .23 43 (42.2) 989 (29.8) 2.92 1 .42-6.04 1 . 744 0.76-4.02 
92-1 . 1 6  6 1  (59.8) 1 700 (51 .3) 1 .41  0.95-2. 1 1  
�-1 .00 1 8.3 ± 9 . 1  1 8.2 ± 1 0.7 l .00 0.98-1 .02 
103 (99.0)§ 3254 (98. l )  § l .99 0.27-1 4.52 
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Table 3: Characteristics of the medication order associated with medication errors with 
and without patient harm after univariate logistic regression (odds ratios) and multivariate 
logistic regression (adjusted odds ratios) 
Medication errors without harm (substu 
Potential determinant Cases n (%) Controls n (%) OR 95% CI 
Day of prescription (n:8899/3398) 
Monday 959 (1 7. 1 )  631 (1 9. 1 )  ref 
Tuesday 871 (1 5.5) 559 (1 7.0) 1 .03 0.89-1 . 1 9  
Wednesday 971 (1 7.3) 557 (1 6.9) 1 . 1 5  0.99-1 .33 
Thursday 951 (1 7.0) 530 (1 6.1) 1 . 1 8  1 .02-1 .37 
Friday 1 1 20 (20.0) 587 (1 7.8) 1 .26 1 .09-1 .45 
Saturday 352 (6.3) 203 (6.2) 1 . 14 0.93-1 .40 
Sunday 378 (6.7) 230 (7.0) 1 .08 0.89-1 .31 
Weekend (weekdays are 
reference) 730 (1 3.0) 433 (1 3 . 1 )  0.99 0.87- 1 . 1 3  
Dosage frequency < once daily 1 63 (2.9) 83 (2.5) 1 . 1 6  0.89- 1 .52 
Route of administration 
Oral 3701 (65.8) 2346 (70.8) ref 
Topical 94 (1 .7) 35 (1 . 1 )  1 .70 1 . 1 5-2.52 
Inhalation 209 (3,7) 66 (2.0) 2.01 1 .52-2.66 
Dermal 1 23 (2.2) 1 9  (0.6) 4.1 0  2.52-6.67 
Parenteral 1 1 21 ( 1 9.9) 758 (22.9) 0.94 0.84-1 .04 
Rectal 280 (5.0) 62 (1 .9) 2.86 2.1 6-3.79 
Transdermal 55 (1 .0) 29 (0.9) 1 .20 0.76-1 .89 
Sublingual 39 (0.7) 0 (0.0) t 
Figures In bold are statistically significant 
Abbreviations: OR, odds ratio; 95 %Cl, 95% confidence Interval ;  OR°"1 , adjusted odds ratio rel, reference 
1 :  Adjusted for hospital. ward, length of stay, route of administration and pharmacotherapeutlc area 
4: Adjusted for hospital, ward, transfer, length of stay, number of medication orders, day of prescription 
and pharmacotherapeutlc area 
t Statistical analysis not possible due to Insufficient data 
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Medication errors with harm (substudy 2) 
95% CI Cases n (%) Controls n (%) OR 95% CI ORadJ 95% CI 
1 8  (1 7 .8) 631 ( 19 . 1 )  ref 
0.88-1 .20 1 5 (1 4.9) 559 (1 7.0) 0.94 0.47-1 .88 
0.94-1 .27 21  (20.8) 557 (1 6.9) 1 .32 0.70-2.51 
0.93-1 .26 20 (19.8) 530 (1 6. 1 )  1 .32 0.70-2.53 
1 .05-1 .41 1 8  (1 7.8) 587 (1 7.8) 1 .08 0.55-2.09 
l .0�1 .57 7 (6.9) 203 (6.02) 1 .2 1  0.50-2.94 
0.96- 1 .43 2 (2.0) 230 (7.0) 0.31 0.07-1 .32 
9 (8.9) 433 (1 3 . 1 )  0.65 0.32-1 .29 
1 (1 .0) § 84 (2.5) § 0.37 0.05-2.7 1 
72 (70.6) 2346 (70.8) ref 
J.99-4.62 1 (1 .0) 35 (1 . 1 )  0.93 0. 1 3-6.89 
J.7 1 - 1 .92 4 (3.9) 66 (2.0) 1 .98 0.70-5.57 
.31-8.41 0 (0) 19  (0.6) t 
).91 - 1 . 1 8  23 (22.5) 758 (22.9) 0.99 0.61 -1 .59 
:.33-4.37 2 (2.0) 62 (1 .9) 1 .05 0.25-4.38 
l.52- 1 .57 0 (0) 29 (0.9) t 
0 (0) 0 (0) t 
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Table 4: Therapeutic areas associated with medication errors with and without patient 
harm after univariate logistic regression (odds ratios) and multivariate logistic regression 
(adjusted odds ratios) 
Medication errors without harm (substu 
Potential determinant Cases n (%) Controls n (%) OR 95% CI 
Therapeutic area (ATC-code) 
Gastrointestinal tract (A) 1 1 66 (20,7) 835 (25.2) ref 
Blood system (B) 691 (12.3) 478 (1 4.4) 1 .04 0.89-1 .20 
Cardiovascular tract (C) 831 (1 4.8) 7 1 6  (21 .6) 0.83 0.73-0.95 
Dermatologicals (D) 1 24 (2.2) 24 (0.7) 3.70 2.37-5.78 
Genitourinary system and 0.40-
sex hormones (G) 35 (0.6) 40 ( 1 .2) 0.63 0.995 
Hormonal systemic therapy 
(H) 249 (4.4) 1 26 (3.8) 1 .42 1 . 1 2-1 .79 
Anti-lnfectlves (J) 454 (8. 1 )  264 (8.0) 1 .23 1 .03-1 .47 
Cancer therapy (L) 47 (0,8) 47 (l .4) 0.72 0.47-1 .08 
Musculo-skeletal system (M) 1 72 (3. 1 )  86  (2.6) 1 .43 1 .09-1 .89 
Nervous system (N) 1 4 1 5 (25.2) 537 (1 6.2) 1 .89 1 .65-2.1 6  
Antiparasitlc products, 
Insecticides and repellents (P) 5 (0. 1 )  1 3  (0.4) 0.28 0.1 0-0.78 
Respiratory tract (R) 324 (5.8) 1 04 (3. l )  2.23 1 .76-2.83 
Sensory organs (S) 
68 (1 .2) 28 (0.8) 1 .74 1 . 1 1-2.73 
Various (V) 36 (0.6) 1 3  (0.4) 1 .98 1 .05-3.76 
Unknown 5 (0, 1 )  4 (0. l )  0.90 0.24-3.34 
Figures In bold are stallstlcally significant 
Abbreviations: OR, odds ratio; 95 %Cl, 95% confidence Interval; ORadj , adjusted odds ratio; ref, 
reference 
1 :  Adjusted for hospital, ward, transfer, length of stay, day of prescription and route of administration 
2: Adjusted for hospital, ward and age 
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Medication errors with harm (substudy 2) 
95% CI Cases n (%) Controls n (%) OR 95% CI ORadJ 95% CI 
20 (1 9.6) 835 (25.2) ref ref 
0.95-1 .33 14 ( 1 3.7) 478 (14.4) 1 .22 0.61-2.44 1 .22 0.60-2.45 
).71-0.94 1 0  (9.8) 7 1 6  (21 .6) 0.58 0.27-1 .25 0.48 0.22-1.03 
J.59-3.53 0 (0) 24 (0.7) t t 
1.36-0.96 l (1 .0) 40 (1 .2) 1 .04 0. 1 4-7.97 0.84 0. 1 1 -6.51 
1 .26-2.10 l (1 .0) 126 (3.8) 0.33 0.04-2.49 0.37 0.05-2.77 
.06-1 .56 23 (22.5) 264 (8.0) 3.64 1 .97-6.73 4.202 2.24-7.90 
).49-1 .35 0 (0) 47 (1 .4) t r 
.20-2.20 2 (2.0) 86 (2.6) 0.97 0.22-4.22 1 .08 0.25-4.75 
.60-2.14 25 (24.5) 537 (1 6.2) 1 .94 1 .07-3.53 1.622 0.89-2.98 
). 1 4-1 . 1 8  0 (0) 1 3  (0.4) t I 
.54-3.43 5 (4.9) 1 04 (3.1) 2.01 0.74-5.46 2. 1 5  0.78-5.94 
0. 19- 0. 1 9-
J.38-2.21 1 (1 .0) 28 (0.8) 1 .49 1 1.51 1 .56 1 2.50 
).51 -2.42 0 (0) 13 (0.4) t I 




This study is the first study on the comparison of determinants for medication errors 
with and without consequent patient harm. 
Hospital, ward and the therapeutic class of anti-lnfectives were shown to be deter­
minants for both types of medication errors. 
In this study relatively few medication errors causing patient harm were Identified, 
despite the collection of more than 7000 medication orders during five months 
of daily ward visits, This main limitation of our study may explain why many of the 
determinants that were identified in the multivariate analysis for medication errors 
without harm, were non-significant in the univariate analysis for medication errors 
with harm. 
The determinants hospital and ward point In the same direction, namely that errors 
(either with or without harm) probably occur more often in the TSh than in the UMCG. 
Thus, even after correction for case-mix, it remains likely that the personnel or local 
processes influence the prevalence of errors, irrespective of the outcome. Therefore, 
it may be concluded that for these organisational determinants, medication errors 
are an acceptable surrogate outcome measure for patient harm. This corresponds 
with findings of previous studies separately showing that organisational determinants 
are linked to respectively medication errors and pADEs. 2.4• 12•15 
Due to the limited power of our study for medication errors leading to harm, definite 
conclusions on determinants that are more patient- or medication related can not 
be drawn, with the possible exception of anti-infectives. Theoretically it seems likely 
that for medication errors leading to patient harm, specific determinants may be 
identified that reflect either the vulnerability of the patient to experience prevent­
able adverse drug events or the intrinsic toxicity of the medication. Again, the deter­
minants Identified in our study for medication errors without harm were identified in 
other studies, both for medication errors (identified determinants were number of 
medication orders per patient, route of administration and pharmacotherapeutic 
area'· 16• 17) and for (preventable) ADEs (identified determinants were among others 
number of medication orders per patient and therapeutic area'· 13· 15 1 1-20). However, 
none of these previous studies compared the determinants for medication errors 
without harm with the determinants for medication errors leading to patient harm. 
Besides the small sample size of medication errors leading to harm, this study has 
several other limitations. First, only five wards in two hospitals were studied, so the 
results cannot be generalised to other medical specialties, wards or hospitals. Sec­
ond, the medication ordering was done in the context of a handwritten-system. 
Implementation of a computerised physician order entry system with clinical deci­
sion support could change the risk factors for medication errors. Third, risk factors 
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for medication errors and consequent harm could differ between continuation of 
pre-admission treatment and hospital-initiated drugs. Because it wasn't necessary 
to define pre-admission treatment in the POEMS-study, this determinant could not 
be included in this study either. Finally, only prescribing and transcribing errors were 
considered in this study. To provide a full overview of the potential determinants for 
medication errors with and without harm distribution errors, administration errors 
and across setting errors should also be studied. 
The main strength of this study is the epidemiological approach to identify risk fac­
tors by calculating odds ratios, whereas many other studies used error frequencies. 
Moreover, we established the actual outcome of the medication error instead of 
the potential harm an error could cause which many other studies did and our 
study is the first comparing determinants for medication errors without and with 
patient harm. 
Future research with a larger sample size of medication errors leading to patient 
harm is recommended. These future studies should also take into account other 
types of medication errors and include more organisational determinants (such as 
the use of electronic prescribing) and patient related factors (like the reason for 
admission and comorbidities). 
Conclusion 
To conclude. medication errors resulting in harm and medication errors without 
harm have some determinants in common, which are mainly on the organisa­
tional level. Therefore, the present study gives a first direction about the validity of 
medication errors as a surrogate outcome measure when looking at these organi­
sational aspects. More determinants could possibly be identified in studies with 
larger sample sizes, which may identify specific patient- and medication related 
determinants for medication errors leading to patient harm. 
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This study will evaluate the effect of a Computerised Physician Order Entry system 
with basic Clinical Decision Support (CPOE/CDSS) on the incidence of medication 
errors (MEs) and preventable adverse drug events (pADEs). 
Design 
Interrupted time-series design 
Measurements 
The primary outcome measurements are comprised of the percentage of medi­
cation orders with one or more MEs and the percentage of patients with one or 
more pADEs. 
Results 
Pre-implementation, the mean percentage of medication orders containing at 
least one ME was 55%, whereas this became 1 7% post-implementation. The intro­
duction of CPOE/CDSS has led to a significant immediate absolute reduction of 
40.3% (95%Cl:-45. l 3%;-35.48%) in medication orders with one or more errors. 
Pre-implementation. the mean percentage of admitted patients experiencing at 
least one pADE was 1 5.5%, as opposed to 7.3% post-implementation. However, this 
decrease could not be attributed to the introduction of CPOE/CDSS: the Immedi­
ate change was not significant (-0.42%, 95% Cl:- 1 5.52%; 1 4.68%) because of the 
observed underlying negative trend during the pre-CPOE period of -4.04% (95% 
Cl : -7 .70%; -0.38%) per month. 
Conclusion 
This study has shown that CPOE/CDSS reduces the incidence of medication errors 
and thus indirectly has a positive effect on the potential risk for patient harm. How­
ever. a direct effect on actual patient harm (pADEs) could not be demonstrated. 
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Introduction 
Since the publication of the Institute of Medicine (IOM) report, "To Err is Human," 
many strategies for making health care safer have been created and imple­
mented . 1 One of these strategies is computerised prescribing through the use of 
a Computerised Physician Order Entry (CPOE) system. Before the first introduction 
of this system in the United States in the 1 990s, expectations about CPOE systems 
reducing medication errors and patient harm were high. Legibility and complete­
ness of prescriptions would be ensured2 and Clinical Decision Support Systems 
(COSS) incorporated in the CPOE systems would be able to assist physicians by 
triggering alerts in case of drug-drug interactions and inappropriate dosing. These 
were all reasons to suppose that CPOE/CDSS systems would be effective in reduc­
ing medication errors and adverse drug events, and thereby improving medica­
tion safety. 
Meanwhile, a number of studies (predominantly from the US) showed that CPOE/ 
COSS systems were indeed successful strategies for reducing medication errors, 
and there was some indication of patient harm being reduced.3 9  Other studies 
showed negative effects in the sense that new medication errors were being intro­
duced through CPOE/CDSS10 or that mortality increased after implementation of 
CPOE/CDSS in a children's hospital. 1 1 However, most of these CPOE/CDSS studies 
used a pre/post analysis to evaluate the effect. This is not a robust study design, 
because it does not take into account other factors during the introduction and 
eventual use of CPOE/CDSS that might explain the change in outcome. An inter­
rupted time-series (ITS) design with segmented linear regression analysis is more 
robust, because it evaluates the longitudinal effect of CPOE/CDSS and controls for 
trends in the outcome.12 
Moreover, studies that looked into the effect of computerised prescribing were 
predominantly performed in the USA, because it was here that CPOE/CDSS was 
first introduced into clinical practice. The findings from these studies may not apply 
to the European hospital setting due to differences in computer systems and work 
processes between the two continents. Finally, most studies were monocenter stud­
ies, which makes generalisability to other hospital settings low. 
Therefore, this study has used an ITS design with segmented linear regression analy­
sis in order to evaluate the effect that CPOE/CDSS has had on the incidence of 




Setting and study population 
This study was performed in two medical wards of the 1 300-bed University Medical 
Center Groningen (a general Internal medicine and a gastroenterology/rheuma­
tology ward) and In two medical wards (a geriatric and a general internal medi­
cine ward) of the 600-bed teaching hospital "TweeSteden" in Tilburg and Waalwijk, 
the Netherlands. All patients admitted to these wards for more than 24 hours were 
included. A waiver of the Medical Ethical Committee was obtained for this study, 
as the study fell within the boundaries of quality of care improvement. Patients 
received information about the study and they could decline to participate. 
Design 
The study was set up as an interrupted time series that Is characterised by a series 
of measurements over time interrupted by an intervention. In this study the inter­
vention was the implementa11on of a Computerised Physician Order Entry system 
in combination with a basic Clinical Decision Support System (CPOE/CDSS). Data 
collection took place during a five-month pre-implementation period (during 
which the hand-written medication order system continued to be used) and dur­
ing a five-month post-implementation period (when the CPOE/CDSS system con­
tinued to be used). The post-implementation data collection period started eight 
weeks after finishing the implementation process in order to make sure that initial 
problems were solved. Because CPOE/CDSS was not simultaneously implemented 
in all study wards, the starting date for the post-implementation period was differ­
ent for each ward. 
In both hospitals, pre-implementation data were collected from July through 
November 2005 (Figure A). In the TweeSteden hospital, the post-implementation 
data collection on the geriatric ward was from April through August 2006, and on 
the general internal medicine ward from mid-June through mid-November 2006. In 
the University Medical Center Groningen, the post-Implementation period on the 
general internal medicine ward was from August through December 2006. Post­
implementation data collection on the gastroenterology /rheumatology ward 
was planned from September 2006 through January 2007, but, due to the delay 
in implementation of CPOE/CDSS, this period was postponed to January through 
May 2008. CPOE was implemented per ward, that is, simultaneously for all hospi­
tal beds in that ward. Post-implementation data collection for each ward started 
eight weeks after CPOE was implemented and lasted for five months for all beds 
In each ward. 
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Pre-implementation 
In both hospitals, the conventional process of medication ordering during the 
baseline period was paper-based; physicians prescribed handwritten medica­
tion orders on charts and nurses transcribed these medication orders onto the 
administration charts. From these administration charts nurses read what medica­
tion should be administrated to which patients. There was no decision support for 
the physicians at the moment of prescribing. 
During the conventional process, central order entry by the pharmacy was per­
formed in the TweeSteden hospital only. As a result, it was only in the TweeSteden 
hospital that medication orders were reviewed by pharmacists during the baseline 
period. 
Intervention 
The intervention was the introduction of the CPOE/CDSS system. This is a computer­
based system by which physicians order medication electronically in a standard­
ised way. In this study, the hospitals used the CPOE/CDSS system only for ordering 
medication. In the system, medication can be selected from menus In which medi­
cation from the local ward stock or from the pharmacy drug database is shown. 
Physicians are obliged to complete fields with key prescription characteristics (such 
as frequency and administration route). Moreover, standardised prescriptions and 
medication protocols (a set of prescriptions belonging to one protocol) can be 
programmed. In this system, transcription of medication orders by both the nurses 
and the pharmacy staff was no longer necessary. The CDSS system used was basic: 
safety alerts were rather straightforward and were only generated in case of drug­
drug interactions, overdosing and allergies. 13 This medication control was based 
on a national drug database for community pharmacies (the Z-index of the Royal 
Dutch Association of Pharmacists (KNMP)). More advanced CDSS systems currently 
do exist, which perform more complex functions (e .g., adjustment for renal impair­
ment), 13 but these more advanced CDSS systems are still in an experimental stage 
in the Netherlands. 
Physicians receive safety alerts in real time when prescribing drugs that, for exam­
ple, interact with already prescribed drugs or when the dosage is too high. When 
an alert is shown, physicians can continue prescribing by accepting the order 
(while knowing there is a safety issue) or they can cancel the order.The safety alerts 
for the accepted medication orders are seen by pharmacists who can contact 
the physicians and nurses if necessary, In both hospitals, different types of CPOE/ 
CDSS systems were in use. The commercially available system used in the University 
Medical Center Groningen was Medicator® (!SOFT, Leiden, the Netherlands). In this 
system, only the process of ordering medication is computerised, the process of 
dispensing and administering the medication is still paper-based. After the medi-
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cation orders are entered into the computer, labels are printed out, which nurses 
then stick onto the administration charts. This is in contrast to the partly homegrown 
system used in the TweeSteden hospital in Tilburg, Theriak® (Theriak evf, Tilburg, the 
Netherlands), a system in which the process of patient identification and medi­
cation administration is also automated (i.e., through a closed loop system) by 
scanning barcodes on patients' wristbands and barcodes on the packaging of 
medication. As mentioned before, the CDDS system in both Medicator® and The­
riak® can be considered to be quite basic. 
Data collection 
Prospectively, the following patient data were collected by two research phar­
macists: patients' characteristics (sex, age, height, weight, duration of stay in the 
ward), medical history, diseases (reasons for admission and diagnoses during hos­
pital stay), medication (medication orders (MOs) during hospital stay), laboratory 
values and adverse events (any untoward medical occurrences during hospital 
stay, which do not necessarily need to be related to medication use). Data were 
extracted from the hospital information system, medical charts, and the medica­
tion order and administration charts, and, during the post-intervention period, from 
the CPOE/CDSS system as well. Data from periods before and after the patient's 
admission period were not included (e.g., outpatient information or data from a 
stay on a ward other than the one included in this study). 
Classification of prescribing and transcribing errors 
After collecting the data, the two research pharmacists, in parallel, individually 
reviewed the medication orders and identified medication errors according to the 
classification scheme for medication errors developed by the Netherlands Associ­
ation of Hospital Pharmacists. 14 They were not blinded as to whether they assessed 
data before or after the introduction of CPOE/CDSS. The two research pharmacists 
were thoroughly trained in the classification scheme before the data collection. 
Moreover, in the first period of the study the research pharmacists discussed their 
findings weekly so as to guarantee that they were using the scheme in the same 
way. They also individually assessed ten pilot patients and afterwards discussed 
differences in classification. In this scheme, a distinction was made between pre­
scribing, transcribing, dispensing, administering and "across setting" errors. Because 
CPOE/CDSS was expected to have the largest effect on the number of prescrib­
ing and transcribing errors, only these two types of medication errors were taken 
into account. Prescribing errors are those errors made in the process of prescribing 
medication. These errors were subdivided into administrative and procedural errors 
(errors in readability, patient data, ward and prescriber data, drug name, dosage 
form and route of administration), dosing errors (errors in strength, frequency, dos-
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age, length of therapy and directions for use) and therapeutic errors (drug-drug 
interactions, contra-indications, incorrect mono-therapy, duplicate therapy, and 
errors in therapeutic drug monitoring or laboratory monitoring; inappropriate drug 
choices were not actively assessed and were only taken into account when these 
were obvious). Transcribing errors are errors that occur in the process of the inter­
preting, verifying and transcribing of medication orders. Transcribing errors were 
not subdivided into any sub-categories. 
Classification of the severity of medication errors/incidence of pADEs 
For the assessment of the severity of the identified prescribing and transcribing 
errors (including whether a related pADE had occurred), the National Coordinat­
ing Council for Medication Error Reporting and Prevention (NCC MERP) scheme15 
and the simplified Yale algorithm16 were combined into a new assessment tool . 17 
The NCC MERP scheme categorizes MEs Into nine categories (A through I) based 
on the severity of the related patient outcomes. Category A is a category for "cir­
cumstances or events that have the potential to cause an error," for example, a 
drug-drug interaction that seems not to be relevant in a specific patient. In our 
study, we did not include this kind of circumstance as belonging to MEs. Cate­
gories B through D are associated with the absence of a preventable ADE, and 
Categories E through I are associated with the presence of a pADE (Box l ). In 
order to define whether an ME was categorised in the first group (B through D) or 
the second group (E through I), a causality assessment needed to be performed 
between the ME and an adverse event. Therefore, we adopted the first three items 
of the Yale algorithm in the new assessment tool (knowledge about the relation­
ship between this drug and the event, influence of other clinical conditions, and 
the time relationship between drug and event). The causal relationship could be 
assessed as unlikely (score < 0), possible (score "' 0 and s 3), and probable (score = 
4). When the relationship was possible or probable, the ME was categorized as E, F, 
G, H or I and was defined as a pADE. When the relationship was unlikely, the ME was 
categorised as B, C or D, and was not associated with a pADE. 
The assessment procedure (on severity of medication errors and incidence of 
pADEs) was carried out by five pharmacists. After individual assessment by the 
pharmacists, consensus meetings took place where consensus was reached for 
all cases of causality, between error and adverse event, as well as for severity of 
the error. The use of a consensus method was based on our findings in another 
study in which we showed that agreement between individual assessors was low 
(kappa in range "fair"), irrespective of their professional background (pharmacists 
and physicians). 1 7 
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Box 1 :  NCC MERP scheme 
Category Content 
A Circumstances or events that have the capacity to cause error 
B An error occurred but the error did not reach the patient 
C An error occurred that reached the patient but did not cause patient harm 
An error occurred that reached the patient and required monitoring 
to confirm that it resulted in no harm to the patient and/or required 
Intervention to preclude harm 
E An error occurred that may have contributed to or resulted in temporary harm to the patient and required Intervention 
An error occurred that may have contributed to or resulted in 
temporary harm to the patient and required Initial or prolonged 
hospitalisation 
G An error occurred that may have contributed to or resulted in permanent patient harm 
H An error occurred that required intervention necessary to sustain life 
I An error occurred that may have contributed to or resulted in the patient's death 
No error 
Error no harm (no pADE) 
Error harm (pADE) 
Outcomes 
The two primary outcome measurements were defined as: l )  percentage of medi­
cation orders (MOs) with one or more medication errors (MEs); and 2) percentage 
of admitted patients with one or more preventable adverse drug events (pADEs). 
Data analysis 
All data were processed using MS Access 2003. SPSS version 14 (SPSS Inc., Chicago, 
Illinois) was used for the analysis. For the baseline period and the post-intervention 
period, the frequencies of the different types of MEs and pADEs were calculated, as 
well as the percentage of medication orders with one or more MEs and the percent­
age of patients with one or more pADEs. Segmented linear regression analysis was 
used to assess level and trend for: l )  the percentage of medication orders with one 
or more MEs at baseline; and 2) the percentage of patients with one or more pADEs 
at baseline; and to assess to what extent the intervention changed these levels. 
Separate analyses were performed for the different types of medication errors. 
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The data points for the time-series data represent the percentage of medication 
orders with MEs aggregated per week (i.e., 20 data points before and after the 
Intervention) and the percentage of patients with one or more pADEs aggregated 
per month (i.e., 5 data points before and after the intervention). MEs were ana­
lysed using weeks as data points due to their high incidence, while pADEs were 
analysed using months as data points. The low incidence of pADEs and the limited 
number of admissions ( <30) per week that was expected would otherwise lead to 
an unstable baseline . Durbin-Watson statistics and visual inspection of the residuals 
versus time were used to check for possible autocorrelation (correlation between 
error terms of consecutive observations) . In the case of non-significant trends in 
pADEs, a more parsimonious statistical analysis of mean pADE rate pre- and post­
implementatlon with a Student t-test was also performed. 
Power analysis 
The study design met the criteria for a robust ITS, that is, 3 data points pre- and post­
intervention, each consisting of at least 30 admissions. 1 8  If trends in pADEs turned 
out to be non-significant, a more parsimonious statistical analysis of mean pADE 
rate pre- and post-intervention with a Student t-test was also performed . To detect 
an assumed 50% decrease in the primary endpoint of medication orders with one 
or more medication errors (assuming a baseline prevalence of 1 0%) with a power 
of 80% and = 5%, 474 medication orders, counted two times, would be required 
for the Student's t-test. By the same token. to detect a decrease In the number of 
pADEs per l 00 admissions from 15  to 7 .5 (rate ratio < 0.5) resulting from the Interven­
tion, a sample of 496 admissions equally distributed over pre- and post-intervention 
periods achieved 80% power at an 0 .05 significance level. 
To estimate the level and trend of the percentages of medication orders with 
one or more MEs. and of the percentages of patients with one or more pADEs 
before the implementation of CPOE/CDSS, and to estimate the changes in level 
and trend after the implementation of CPOE/CDSS, the following linear regression 
model was used 1 2 :  
Y ,  = 130 + 131 • time , +  l32 • intervention , + 133 • time after intervention , + e , 
YO = mean percentage at time is O = 130 
13 1 = baseline trend 
132 = immediate change after intervention 
l33 = change in trend 
Results 
Five-hundred and ninety-two patients during the baseline period and 603 patients 
during the post intervention period were included (Table l ). Four patients did not 
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provide consent and were excluded from the study. The mean age of the patients 
included in both periods was rather high (± 65 years), which can be explained by 
the inclusion of a geriatric ward from one hospital in this study. During both periods, 
the mean number of MOs per hospital stay was 1 2  (baseline 1 2.3 ± 7 .8, intervention 
1 1 . 7 ± 8. 7). 
The mean length of hospital stay for our total study population decreased signifi­
cantly after the introduction of CPOE/CDSS: 1 4.6 ± 1 2.5 days pre-implementation 
versus 1 2. 1  ± 1 1 .6 days post-implementation. 
During the baseline period, 55% of all MOs contained at least one error, whereas 
during the post-intervention period this was 1 7% (Figure 1 ). In the baseline period, 
1 5.5% of admitted patients experienced patient harm (pADE), as opposed to 7 .3% 
after CPOE/CDSS was implemented (post-intervention) (Figu re 1 ) .  
Table 1 :  Descriptives of the study population 
Study period Hospital 
Twee-
pre post p-value* UMCG Steden p-value* 
hospital 
Age (mean ± SD) 65.5 ± 65. l ± 0.74 58,2 ± 73.0 ± <0.001 
1 9.2 1 9. l  1 9. l  1 6.0 
Female (%) 54,7 56.6 0.53 55.7 55.6 0.96 
MOs per hospital 1 2.3 ± 1 1 .7± 0.21 1 1 . 1 ±  1 3.0 ± <0.001 
stay 7,8 8.7 8.4 8 . 1  
(mean ± SD) 
Patients (n) 0,04 NA ** 
Internal medicine 251 235 200 286 
Geriatrics 1 53 1 35 288 
Gastroenterology / 
rheumatology 1 88 233 421 
Total 592 603 62 1 574 
* Continues variables are analysed with a t-test and categorical with a Chi-square test. 
* *NA not appropriate: clearly the distribution per ward was different across the hospital as 
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Effect of CPOE/CDSS 
Figures 2 to 4 show the medication error and pADEs patterns during the study 
period. The introduction of CPOE/CDSS led to a significant immediate absolute 
reduction of 40.3% (95%Cl :-45%; -36%) of medication orders with one or more errors 
(�2), and a change in trend of -0.92% (95%CI: -l .3%; -0.5%) per week (�3) (Fig­
ure 2). The trend of + 0.63% (95% Cl: 0.35%; 0.91 %) of ME/MO per week that was 
observed at baseline was remarkable. Similar effect sizes in both trend and imme­
diate change were observed in both hospitals (Figure 2). 
The introduction of CPOE/CDSS led to an immediate decrease in level (�2) and 
trend (�3) for all types of MEs, except for therapeutic errors (Figure 3). The introduc­
tion of CPOE/CDSS had the largest impact on the number of administrative and 
procedural errors (a significant immediate change of -30% (95% Cl: -35%; -25%)). 
The immediate change in dosing and transcribing errors was about the same (-1 3% 
respectively -1 5%). With the introduction of CPOE/CDSS, the incidence of transcrib­
ing errors was not reduced to zero as in the University Medical Center Groningen 
transcribing errors still occurred in the post-intervention period, for example, labels 
fixed in the wrong place or on the wrong chart, or MOs still prescribed by hand 
instead of by CPOE/CDSS. 
In contrast to the medication errors, the introduction of CPOE/CDSS did not lead 
to a significant change in level and trend of pADEs (Figure 4). The observed under­
lying negative trend at baseline -4.0% pADEs per admission per month (95% Cl: 
-7.70%; -0.38%) negated the obvious reduction in pADEs that was observed in the 
descriptive analysis (Figure l ). 
No autocorrelation was detected for any of the outcome parameters presented. 




Y 0 (95% Cl) � 1 (95% Cl) 1\ (95% Cl) 
(mean (baseline (immediate 
percentage at trend) change) 
time=0; intercept) 
Total** 47.87* 0.63 - 40.30 (44.58; 5 1 . 1 6) (0.35; 0.9 1 )  ( - 45. 1 3; - 35.48) 
Tweest eden 49. 1 0  1 .25 - 45. 19 
hospital (44.87; 53.34) (0.89; 1 .6 1 )  ( - 51 .41 ; - 38.98) 
UMCG 42.85 0.42 - 41 .74 (39.40; 46.3 1 )  (0. 1 3; 0.72) (- 46.8 1 ;  - 36.67) 
*Significant values are in bold type face 
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Figure 2: Impact of CPOE/CDSS on percentage of medication orders with one or more 
medication errors (total study population) 
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Figure 3: Impact of CPOE/CDSS on percentage of medication orders with one or more 
subtypes of medication errors. Panels: administrative errors, dosing errors, transcribing 
errors, therapeutic errors. 79 
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Segmented Y 0 (95% Cl) 131 (95% Cl) 132 (95% Cl) 
regression (mean (baseline (immediate 
analysis for percentage at trend) change) 
pADEs per time=0) 
month 
28.42* - 4.04 - 0.42 
( 16.27; 40.57) (-7.70; - 0.38) (-1 5.52; 1 4.68) 
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Figure 4: Impact of CPOE/CDSS on percentage of admitted patients with one or more 
preventable Adverse Drug Events (pADEs). 
Discussion 
In our study, the introduction of CPOE/CDSS led to a large reduction In the incidence 
of medication errors in line with findings in earlier studies.3·9 All types of errors were 
reduced with the exception of therapeutic errors. However, this substantial reduction 
in errors was not followed by a significant reduction in the incidence of pADEs. 
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The lack of effect on pADEs may be explained by the lack of effect on therapeutic 
errors due to the fact that, as we have demonstrated earlier, this is the very type 
of medication error most strongly associated with an increased risk of pADEs. 19 
Another reason for not finding an effect may be that the CDSS in both hospitals was 
basic: only in case of overdosing, drug-drug interactions and allergies were alerts 
generated. To prevent other types of therapeutic errors, more advanced decision­
making support would be needed such as, for example, adaptive dose support for 
patients with clinical chemical parameters that are outside the normal range (e.g., 
renally excreted medication in patients with renal failure), support when drugs are 
contraindicated (e.g., in case of the frail elderly) or support for drug choice by 
linking the system to formularies and disease guidelines that could lead to more 
optimal pharmacotherapy. A further reason could lie in the inappropriateness of 
the CDSS in respect to the clinical setting, since the CDSS is based on a national 
drug database for community pharmacies and not for hospital pharmacies. The 
standard drug safety alerts that are generated may not always be relevant for the 
particular hospital setting, for example, an alert for the combination of an ACE­
inhibitor and a diuretic that gives rise to a risk of orthostatic hypotension or an 
alert for a high dose of Furosemide, both very commonly found in the hospital. This 
may lead to an overload of irrelevant alerts and may cause alert fatigue.20 One 
undesirable effect is that physicians not only override irrelevant alerts but also rel­
evant ones. It is possible that other measurements of decision-making support are 
needed such as clinical pharmacists attending physicians meetings21 at the medi­
cal ward or more intensive education in prescribing skills for junior physicians.22· 23 
On average, fewer patients experienced a pADE in the post-intervention period 
than in the baseline period (a reduction approximately by half). However, because 
of the underlying negative trend at baseline, this decrease cannot be attributed 
to the introduction of CPOE/CDSS. In four recent reviews of the effect of CPOE/ 
CDSS on medication safety, only a few studies evaluated the impact on pADEs or 
ADEs; this is possibly due to the labor-intensive way the data needed to determine 
(p )AD Es must be collected and assessed. 3· 7· 8 The evidence from these studies was 
inconclusive due to the fact that only half of the studies showed any significant 
effect on (p)ADEs and those studies that did show an impact primarily used a pre/ 
post analysis .9• 24•26 Our ITS study design with segmented linear regression analysis 
was more robust because it evaluated the longitudinal effect of an intervention 
and controlled for trends appearing in the outcome. 12 Thus, differences in the find­
ings between our study and other studies may be explained by the study design 
chosen and by the data analysis . Although there was no effect on the incidence of 
pADEs and therapeutic errors, it should be emphasized that the decrease in medi­
cation errors in the post-intervention period is likely to contribute to a decreased 
risk of preventable harm, because medication errors can be considered as proc-
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ess measurements, while pADEs are patient outcome measurements . 
With respect to the other types of errors, the largest impact was seen on the rate 
of administrative and procedural errors due to an improvement in readability 
and due to the fact that key characteristics of a prescription had to be filled in 
(required fields), which led to more complete medication orders. Although these 
types of errors do not frequently lead to patient harm, 19 we would argue that it is 
worthwhile preventing them; when nurses and pharmacy technicians must cor­
rect these errors, a substantial amount of valuable time is wasted, which could be 
better spent on primary patient care. In hospitals with paper-based systems that 
do not include nurse transcription - a potential source of MEs - the introduction of 
CPOE/CDSS might lead to a less impressive reduction in MEs. The same may be the 
case for hospitals that do include pharmacy review in their paper-based systems, 
which might lead to a lower number of MEs in the baseline than hospitals that have 
no pharmacy review. In our study the TweeSteden hospital made use of pharmacy 
review. The similar reduction in MEs found in both hospitals would indicate that 
pharmacy review in itself does not explain the observed reduction. In the baseline, 
probably other factors might be as or more important than the presence of this 
kind of pharmacy review, such as the illegibility and incompleteness of MOs. 
The significant upward trend observed in MOs with one or more MEs in the baseline 
period is surprising. This might well be an artifact stemming from a learning effect 
for both observers in terms of detecting medication errors. When they were assess­
Ing data, the observers were not blinded, neither before nor after the introduc­
tion of CPOE/CDSS. It was not feasible, in view of the time constraints, to begin to 
classify errors only after all data (pre- and post-CPOE/CDSS) had been collected. 
and therefore we could not blind our data. This is thus one limitation of our study. 
At the start of the study, the observers individually assessed ten pilot patients and 
then discussed differences in classification. Despite this pilot period and the use of 
a strict classification scheme, Interpretation of medication errors Is subjective and 
a learning curve cannot be excluded. Another explanation could be that, due to 
the limited number of data points, the baseline was unstable. Although we have 
adequately fulfilled the Cochrane criteria of 3 data points before and after the 
intervention, 18 longer time periods and more data points may well result in a more 
stable and reliable baseline. One-year data collection before and after CPOE 
implementation would facilitate a correction for seasonality. However, there is no 
evidence that pADEs are subject to seasonal influences. Longer data collection 
was not feasible in our case because of the labor-intensive assessment of pADEs, 
along with financial constraints. 
The delay in Implementation on the gastroenterology /rheumatology ward was 
due to management issues and strategic interests. The eventual implementation 
process on this ward took as long as on the other ward in the University Medi-
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cal Center Groningen (seventeen weeks). As on the other wards, data collection 
started eight weeks after finishing the implementation process. In another study, we 
concluded that physicians and nurses were positive about the way CPOE/CDSS 
was introduced as well as about the system itself.27 In addition, the CPOE/CDSS 
users on the gastroenterology /rheumatology ward were also satisfied and did not 
show any resistance to the system. These findings suggest that the delay would not 
have had any effect on the results of CPOE/CDSS on MEs and pADEs. 
One strength of our study is that we evaluated the impact of CPOE/CDSS in two 
different types of hospitals with one home-grown and one commercial package. 
Although these circumstances are considered potential sources of bias, similar 
effects for medication errors were demonstrated even despite different baseline 
rates. This emphasises the robustness of our study findings and implies that our 
results could be applicable to a wider range of settings than those of studies simply 
evaluating one type of CPOE system in a single hospital. 
Our study was performed in adult-based general medical wards, and findings 
should not be extrapolated to special-care settings such as intensive care wards. 
Future research may clarify the effect of CPOE/CDSS in these settings. Since investi­
gating the effect of CPOE/CDSS on the readmission rate would have been interest­
ing, future research is also needed into this effect. 
Conclusion 
Based on our findings it can be concluded that CPOE with basic CDSS decreased 
medication errors and thus possibly might contribute to a decreased risk of pre­
ventable harm. However, we were not able to confirm any effect on actual patient 
harm. Implementing a CPOE with basic CDSS is simply not enough to prevent 
pADEs in a general internal medicine/geriatric setting. More effort is needed, such 
as more advanced CDSS or other forms of clinical decision support. 
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With the introduction of Computerised Physician Order Entry (CPOE) in routine hos­
pital care much effort is put in refining Clinical Decision Support Systems (CDSS) to 
identify patients at risk of preventable medication related harm. 
Objectives: 
To identify to what extent patients at risk for medication related harm as Identified 
by basic CDSS and clinical rules (advanced CDSS) actually need a change in 
medication as indicated by medication review. 
Methods: 
In this cross-sectional study a change needed in medication was indicated by 
dosing and therapeutic errors which were identified through manual medication 
review of 3 13 patients admitted during 5 months to an internal medicine ward 
by a trained pharmacist. In a test setting the medication orders (MOs) of these 
patients were entered Into a CPOE with basic CDSS and generated safety alerts 
were collected. Secondly a set of 1 6  clinical rules was applied to the patient and 
prescribing data in MS Access 2003. Overlap between CDSS and clinical rules was 
determined. 
Results: 
Medication review identified 2 1 71 medication errors of which 57 were classified as 
an overdose and 1 43 as therapeutic errors (e.g. drug-drug interactions or contra­
indication). CDSS identified 297 overdoses. with sensitivity 0.32. specificity 0.92 and 
positive predictive value (PPV) 0.06; and 365 drug-drug interactions, with sensitivity 
0.96, specificity 0.91 and PPV 0. 1 2. The clinical rules identified 78 (39%) of the 200 
overdoses and therapeutic errors at which they were targeted. In 72 (23 %) of 
3 1 3  alerts generated a change of medication was actually indicated. When com­
bined CDSS and rules identified 1 3 1  (66%) of the 200 errors. 
Conclusions: 
Clinical rules combined with basic CDSS hold promise for routine use to identify 
patients at risk of preventable harm. but still need fine tuning since for a consider­
able number of alerts no subsequent change in medication is needed. 
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Introduction 
A substantial part of the hospitalised patients experience medication related 
harm that is preventable, for example due to incorrect dosing, contra-indicated 
drug choice or drug-drug interactions. 1 •4 To improve the situation, much effort is put 
in different strategies to prevent such problems. One strategy is structured review­
ing of patients' medication (medication review) by physicians or pharmacists to 
identify patients with medication errors (MEs) that may lead to harm. A limitation of 
this system is the retrospective character which implies a late intervention. Moreo­
ver this approach is very labour intensive since all medication of all patients has to 
be systematically reviewed. The advantage is that the complete clinical situation 
of the patient is taken into account when identifying problems, and only those 
problems are identified where action, a change of medication, is actually needed. 
A less labour intensive strategy is the use of computerised trigger systems. These 
systems can identify patients at risk for medication related harm (adverse drug 
events, ADEs) using either data on the prescribed medication only or the combi­
nation of medication with certain patient characteristics or clinical laboratory val­
ues. s-9 An example of such systems is the Clinical Decision Support system (COSS) 
within Computerised Physician Order Entry (CPOE) systems. 10 In the Netherlands, 
the CDSS integrated in most types of CPOE systems is basic; only in case of drug 
overdoses and drug-drug interactions alerts are generated. For successful iden­
tification of high risk patients more is needed, such as identification of patients at 
risk of dosing problems in case of clinical deviating chemistry parameters or deter­
mined blood drug concentrations or of the need to change a specific medicine 
(the appropriate antibiotic) for a specific disease.1 1 • 12 Currently some hospitals in 
the Netherlands are developing in addition to the basic COSS more advanced 
support by creating defined clinical rules - basically computerised algorithms that 
look for specific medication orders, patient characteristics and/or laboratory values 
that identify patients at risk for suboptimal therapy but also for medication harm.13 
The advantage of such computerised systems is clearly that they limit labour input 
dramatically. Such systems should be sensitive enough to identify patients at risk, 
but also specific enough to generate clinically relevant alerts in order to prevent 
alert fatigue. 
In this study we compare two computerised systems (a basic COSS within a CPOE 
and the use of clinical rules) with medication review to answer the question to 
what extent patients at risk for medication related harm as identified by the two 
computerised systems actually have a medication error as identified by the medi­




This study Is conducted in the framework of a study on the effect of a computer­
ised Physician Order Entry system on Medication Safety (POEMS study). 
Setting and study population 
This study was performed in two general internal medicine wards and one gastro­
enterology /rheumatology ward in the UMCG. AII patients admitted for more than 
24 hours to these wards were included (31 3  patients). A waiver of the Medical Ethi­
cal Committee was obtained for this study, as the study fell within the boundaries 
of normal hospital routine of quality improvement. Patients received information 
about the study and they could object to inclusion. During the study period the 
system of medication ordering was the conventional paper based system; physi­
cians wrote their medication orders on paper charts and nurses transcribed these 
orders on administration charts. 
Study design and data collection 
Our study had a cross-sectional design. The following patient data were collected 
in daily ward visits: patients ' characteristics (sex, age, length, weight, duration of 
stay on ward), medical history, diseases (reasons for admission and diagnoses dur­
ing hospital stay), medication (medication orders (MOs) during hospital stay), labo­
ratory values and adverse events (any untoward medical occurrences during hos­
pital stay, which do not necessarily need to be related to medication use). Data 
were extracted from the hospital information system, medical charts, medication 
orders and administration charts. 
Methods to identify medication errors or patients at risk 
- Medication review method to identify medication errors 
In the framework of the POEMS study all MOs were reviewed by a trained research 
pharmacist (JvD) with regard to the presence of medication errors (MEs) accord­
ing to the classification scheme of the Netherlands Association of Hospital Phar­
macists 14 and considering the complete clinical situation of the patient. The MEs 
were classified regarding administrative and procedural errors (e.g. errors on 
readability or missing route of administration), dosing errors (e.g. drug overdoses 
or incorrect length of therapy), therapeutic errors (e.g. drug-drug interactions or 
contra-indications) and transcribing errors (MOs which are wrongly transcribed on 
the administration chart). 
In this study we included only dosing and therapeutic errors. These errors If not cor­
rected have a high probability to lead to medication related harm2• 1<>-1 8  and are 
therefore the prime target of clinical decision support systems. 
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- COSS within CPOE system 
All MOs were manually entered into a test environment of the CPOE/CDSS system, 
the commercially available Medicator® (iSOFT, Leiden. the Netherlands). The COSS 
system of Medicator® is basic; safety alerts are generated only in case of over­
doses or drug-drug interactions. 19 These safety alerts are shown to physicians dur­
ing the prescribing phase. This medication surveillance is based on a national drug 
database for community pharmacies (the 'G-standard', Z-index BV, The Hague, the 
Netherlands). 
After entering the MOs into the system, all generated safety alerts were collected 
and both MOs and alerts were registered in a SPSS database (version 1 4). Per MO 
a variable was included indicating the absence or presence and type of safety 
alert (overdose or drug-drug interaction). 
- Computer based clinical rules 
Leiden University Medical Center (LUMC) has developed a computerised alert sys­
tem that uses clinical rules to detect patients with a potential adverse drug event 
or are at risk for an adverse drug event. The system uses combined data from the 
CPOE. the hospital information system (e.g. laboratory values) and the national 
drug information database CG-Standard') to detect potential patients at risk. The 
detection is based on defined algorithms, the so called clinical rules. Currently, 
more than l 00 clinical rules are defined and agreed on by a multidisciplinary team. 
including a pharmacist, a hospital pharmacist. an internal medicine specialist and 
a clinical pharmacologist. The clinical rules and the computer system are tested 
and validated. A pilot study was performed in the LUMC to compare this new com­
puterised alert system with the conventional medication surveillance in the CPOE/ 
COSS to assess Its additional value. This prospective pilot study was conducted on a 
general internal medicine ward during 6 months. Twenty different clinical rules led 
to an alert in the small patient population admitted to this ward. 
In our current study comparing this computerised approach to the patients identi­
fied as having a medication error, we excluded the four rules that were not defined 
as a medication error in the medication review, resulting in a set of 1 6  rules (see 
table 4). For each clinical rule a query was designed in MS Access 2003. These que­
ries were applied to the patient data to assess how many patients were triggered 
by the clinical rules. 
Analysis 
Data were processed with MS Access 2003. SPSS version 1 4  was used for the analy­
sis. For the total number of MOs the safety alerts generated by COSS were com­
pared to the errors on overdoses or drug-drug interactions detected by the medi­
cation review method. The overlap between the COSS and the medication review 
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method was analysed by calculating the sensitivity, specificity and positive predic­
tive value (PPV) for both the support on overdoses and the support on drug-drug 
interactions. The overlap between the clinical rules and the medication review 
method was analysed for the patients identified by the cl inical rules as being at risk 
and limited to patients with an identical medication error. Therefore sensitivity and 
specificity were not calculated, since patients without an alert and with a related 
medication error were not included. The overlap was manually reviewed and sub­
sequently analysed by calculating the percentage of patients that were identified 
to be at risk In both systems. For the medication review method only those patients 
with an error that corresponded to the related clinical rule were identified. 
Results 
In the medication review method 622 dosing errors and 1 43 therapeutic errors 
were found. The d ifferent types of dosing and therapeutic errors are shown in table 
1 .  The subtypes 'overdose· and 'drug-drug Interaction' were detected 57 respec­
tively 46 times. 
Table l: Frequency of different types of errors - medication review method 





Dosing frequency 1 99 
Overdose 57 
No maximum for 'as needed' 99 
Underdose 35 
Duration of therapy 1 7  
Directions for use 10  
Total 622 
Indication 1 9  
Contraindication 1 9  
Drug-drug interaction 46 
Improper monotherapy 1 8  
(Pseudo)double medication 40 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  Therapeutic monitoring _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  1 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  . 
Total 1 43 
In total 297 safety alerts on overdoses were generated by the basic CDSS within 
the CPOE. The PPV of this type of support was low (0.06), i .e. few of the generated 
safety alerts were indeed indicated as actual overdoses by the medication review 
method. The sensitivity of the support was higher but stlll not optimal (0.32). (Table 2) 
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Overdose in medication 
review (reference) 
Yes No 








In total 365 safety alerts on drug-drug interaction were generated by the basic 
COSS within the CPOE. Although the PPV was low (0.1 2), the sensitivity of the sup­
port was high (0.96). (Table 3) Almost all drug-drug interactions provide an alert 
by the system but the majority of the problems are not considered as medication 
errors in the medication review method when other patient data are taken into 
account. 






Sensitivity 0. 96 
Specificity 0. 9 1  
PPV 0. 12 
Yes 
No 
Drug-drug interactions in Medication medication review orders (n) (reference) 
Yes No 
44 321 365 
2 3 193 3 195 
46 351 4  3560 
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The set of sixteen clinical rules triggered in total 3 1 3  patients. In 72 (23%) of these 
patients the medication review method also identified one or more related MEs 
(table 4). This were in total 78 MEs (data not shown). Thus 23% of the patients trig­
gered to be at risk therefore actually need a change in medication or other kind 
of action to prevent an ME. For two rules the percentage of patients actually 
requiring a change in medication could not be determined because no patients 
were triggered and for seven clinical rules this percentage was zero. For the other 
clinical rules this percentage varies between l O and 58 (table 4). The percentage 
was highest for the rule 'use of an opioid and no prescription for a laxative' (58%). 
The main focus of the rest of the set clinical rules is to prevent potential therapeutic 
errors and potential overdoses in relation to declined renal function. In the medi­
cation review method 1 43 therapeutic errors and 57 overdoses were found (table 
l ). The set of sixteen clinical rules identified 78 MEs 39% of these 1 43 therapeutic 
errors and 57 overdoses found in the medication review method. Together CDSS 
and the clinical rules detect 1 8  overdoses + 44 drug-drug interactions + 69 clinical 
rule alerts (excluding rule 1 4  that signalled patients that were already detected In 
basic CDSS) = 1 3 1 (66%) of the 200 overdose and prescribing errors found in the 
medication review method. 
In box l some examples are given why patients triggered to be at risk of medica­
tion harm with the basic CDSS within the CPOE or the clinical rules were not consid­
ered to have medication errors according to the medication review method. 
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l .  Clearance < 50 ml/min or serum creatinine > 1 29 
1 50 µmol/L 
2. Serum creatinine Increase of > 50 µmol/L or of 37 
> 50% 
3. Use of Cefuroxime and clearance < 50 ml/min 7 
4. Use of Ceftazidime and clearance of < l 00 ml/ 2 
min 
5. Use of Ciprofloxacin and clearance of < 25 ml/ 1 1  
min 
6. Use of Ranitidine and clearance of < 50 ml/min 5 
7. Use of Cetirlzine and clearance of < l 0 ml/min 0 
8. Use of Sulphonamides urea derivate and 0 
clearance of < l 0 ml/min 
9. Gabapentine of pregabaline and clearance of 
< 50 ml/min 
10. Use of Digoxin > 0.0625 mg and 1 4  
• age > 7 0  yrs or 
• clearance < 50 ml/min or 
• low level of K or 
• unknown level of K 
1 1  . A serum level of aminoglycoside or 3 
Vancomycin 
1 2. Use of opioid and no prescription for laxative 45 
1 3 . Use of Ciprofloxacin or Norfloxacin and use of 2 
antiepileptic 
14 .  Use of Bisphosphonate and drug which has an 29 
effect on the absorption 
1 5. Use of Iron and a drug which forms a complex 1 1  
with Iron 
1 6. Use of Azathioprine (check dose) 1 7  
TOTAL 3 13  
Number of 





23 (1 8) 
1 1 (30) 
0 (0) 
0 (0) 















Box 1 Signal with CPOE/CDSS or clinical rule but no medication error in medication review 
Signal Reasoning 
CPOE/CDSS overdose e.g . :  
Furosemide IV 40 mg OD All these doses are well accepted in a clinical 
Amoxicillin IV l g QID setting in a more severely ill patient population 
Omeprazole IV 40 mg BID and deviate from the maximum recommended 
doses in a community setting for which the 
medication control database has been 
developed. 
CPOE/CDSS drug-drug 
interaction, e.g . :  
NSAIDs and prednisolone Due to the increased risk of gastro-intestlnal 
irritation this combination should be avoided 
or gastric protection should be given. In case 
that a proton pump inhibitor was administered 
simultaneously this Interaction was not 
considered an ME as the appropriate action 
had been taken. 
Clinical rules e.g. number: 
1 2. Use of opioid and no 1 2. Patient receives only single dose of opiate 
prescription for laxative (e.g. morphine IV stat), or has diarrhea when 
the signal is generated 
l 0. Digoxin rule (table 4) l 0. e.g. patient has low potassium levels but 
gets potassium suppletion 
l . to l 0. impaired renal l . to l 0. Dose has been adapted in line 
function and potential for with recommendations of the level of renal 
drug overdose impairment 
Discussion 
In a considerable number of patients at risk for medication related harm identified 
by both computerised systems, the basic COSS within a CPOE and the clinical rules, 
no medication error was found by the medication review method. Nevertheless, 
sensitivity and specificity of the basic CDSS to signal drug-drug interactions were 
good despite the low PPV. This study also shows that with a small set of clinical 
rules a fair proportion (39%) of medication errors detected with the medication 
review can be prevented and when the two systems are combined this increases 
to 66%. 
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CPOE/CDSS 
In their review on medication related clinical decision support in CPOE systems 
Kuperman et al.20 showed that CDSS can be divided into two stages, i.e. basic 
support -which covers the basic principles of support such as drug-drug interac­
tion checking and basic dosing guidance- and more advanced support - which 
covers in addition more complex support such as dosing support for suscepti­
ble patients or guidance for medication-related laboratory testing. The CDSS in 
Medicator® can be considered as basic and the set of clinical rules as a form of 
advanced decision support that can be used on top of CDSS. Because both CDSS 
and the set of clinical rules focus only on part of medication related problems, 
they should be further developed in the future to cover more potential problems. 
However, first it is important to guarantee that the current support is optimised. To 
our knowledge our study is the first that looks into the capability of CDSS in CPOE 
systems to identify patients truly in need of a change of medication to prevent 
potential harm, i.e. the sensitivity and PPV to identify medication errors. 
Our findings show that CPOE/CDSS generates many less relevant signals (PPV s 
0. 1 2) where the reported overdose or drug-drug interaction does not need a sub­
sequent change in medication. Nevertheless CPOE/CDSS misses a considerable 
number of overdoses (sensitivity = 0.32) identified through medication review. One 
reason for this low sensitivity may be the lack of dosing support for susceptible 
patients (patients with renal failure, geriatric patients or children), one of the fea­
tures of more advanced support systems such as the clinical rules. The reason for a 
low PPV might be that the alerts are based on a database for community pharma­
cies (the 'G-standard') instead of for hospital pharmacies. This leads to a number 
of irrelevant alerts for the hospital setting, such as alerts for an overdose that is 
perfectly acceptable in hospital but not in ambulatory care. To increase the PPV, 
this database should be further adapted to the hospital setting to prevent alert 
fatigue among hospital physicians.21 
Despite the high sensitivity and specificity of the drug-drug interaction alerts, many 
signals were generated that did not need a subsequent change in medication 
(low PPV). The challenge is thus to strike an optimal balance between the number 
of alerts that do not need follow up and the sensitivity to find serious drug-drug inter­
actions or overdoses. The most relevant determinant for including an alert should 
be the severity of the consequences of the overdose or drug-drug interaction. For 
example, in case of the drug-drug interactions with clozapine or methotrexate 
that could lead to myelosuppression and agranulocytosis, a high sensitivity is in this 
case more important than a high PPV. Obviously when there are less severe con­
sequences, such as the combination of calciumcarbonate and bisphosphonate 
that may lead to a decrease in the absorption of bisphosphonate, the need for a 
high PPV becomes more important. To improve the PPV in the latter case, the alert 
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could be refined by including the time of administering In order to generate only 
alerts when both drugs are administered at the same time. In short. it is important 
to assess the different alerts on clinical relevance and fine tune them to create an 
optimal number of signals. 22 These considerations have led to the development 
of the clinical rules discussed below and various approaches are currently under­
taken in developing better clinical decision support systems to be used in addition 
to the basic CDSS. 
Clinical rules 
In this study we tested a small set of clinical rules. Overall the clinical rules mean an 
improvement In identifying patients at risk in need of an actual change in medi­
cation. Whereas only up to 1 2% of the alerts generated by CPOE/CDSS needed 
a subsequent change in medication this was 23% of the alerts generated by the 
clinical rules. When the two are combined two-thirds of the medication errors are 
identified. 
Like the basic CDSS. the clinical rules generated signals that did not need a subse­
quent change In medication. Also with clinical rules the challenge is thus to strike 
an optimal balance between the number of alerts that need action or warning 
for potential risk full situations and alerts that do not need follow up. For example 
the rules 1 -9 regarding the use of medication and a declined renal function (table 
4) can be made more efficient by Incorporating a cut off dose below which no 
action and thus no alert is needed. Other rules, for example 'the use of an opioid 
receptor agonist and no prescription of a laxative·, are already quite efficient 
in selecting risk situations but can be made more efficient in adding a exclusion 
regarding the single dose. 
Other trigger tools have been developed with the same intention.s-s- 23•25 Some of 
these studies compared their tools to other methods to Identify medication errors 
and adverse drug events such as manual review or voluntary reports .5• 7 Others only 
verified the generated signals on the presence of medication errors or adverse 
drug events.6· 8• 25 Although these studies are positive in their conclusions, they all 
showed that additional information usually has to be collected about the indi­
vidual patient to know whether medication actually has to be changed. 
The advantage of these computerised COSS and trigger tools when combined is 
clearly that they are much less labour-intensive. Their effectiveness in daily practice 
will also be affected by the efficiency in trigger ing patients at risk that are actually 
in need of change of medication. If not they run the risk of alert fatigue, i .e. gener­
ating alerts that need no clinical or medication action. 
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Our study was limited by the fact that the medication review method was per­
formed by only one investigator. However a strict classification scheme was used to 
identify medication errors. This scheme distinguishes precisely different subtypes of 
medication errors and did not allow much room for difference In interpretation. The 
investigator was extensively trained in using this classification scheme. Another limi­
tation of this study was that the set of clinical rules studied was small (only sixteen 
rules). The majority of these rules focused on support for patients with renal failure 
and covered thus a small therapeutic area. In other studies often more diverse 
rules were assessed which gives further information about the effect of computer­
ised rules in the field of different therapeutic areas.7· 25· 26 
Conclusions 
We may conclude that our basic CDSS within a CPOE and the clinical rules are 
useful early strategies to prevent medication related harm. They can be the first 
step to more advanced decision support. These computerised systems will be even 
more useful in daily practice when they are further fine tuned to decrease the 
number of alerts that need no clinical action. 
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To explore physicians' and nurses' expectations before and experiences after the 
implementation of a Computerised Physician Order Entry (CPOE) system in order 
to give suggestions for future optimisation of the system as well as the implementa­
tion process. 
Method 
On four internal medicine wards of two Dutch hospitals 1 8  physicians and 42 nurses 
were interviewed to measure expectations and experiences with the CPOE sys­
tem. Using semi-structured questionnaires expectations and experiences of physi­
cians and nurses with the CPOE system were measured with statements on a five­
point Likert scale (1 = completely disagree, 5 = completely agree). The percentage 
respondents agreeing (score of 4 or 5) was calculated. Chi-square tests were used 
to compare the expectations versus experiences of physicians and nurses and to 
assess the differences between physicians and nurses. 
Results 
In general. both physicians and nurses were positive about CPOE before and after 
the implementation of this system. Physicians and nurses did not differ in their views 
towards CPOE except for the overview of patients' medication use that was not 
clear according to the nurses. Both professions were satisfied with the implemen­
tation process. CPOE could be improved especially with respect to technical 
aspects (Including the medication overview) and decision support on drug-drug 
interactions. 
Conclusion 
Overall we conclude that physicians and nurses are positive about CPOE and the 
process of its implementation and do accept these systems. However, these sys­
tems should be further improved to fit into clinical practice. 
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Introduction 
With the introduction of Computerised Physician Order Entry systems (CPOE) in 
an increasing number of hospitals the electronic way of medication ordering is 
becoming more common. The shift from a paper-based to a computerised sys­
tem affects clinical practice. 1 Mainly based on experiences in the USA we know 
that CPOE has benefits in comparison to a paper-based system; more structured 
and legible medication orders2 and clinical decision support during the prescrib­
ing phase. These benefits have been shown to contribute to a reduction in the 
number of medication errors identified in studies that evaluated the impact of 
CPOE on medication safety.3·5 
However disadvantages are also known such as rigidity of the system6, negative 
effect on the collaboration between physicians and nurses7· 8 and new types of 
medication errors introduced by the system.9 Most studies, however, show that 
these disadvantages are outweighed by the advantages, leading to increased 
medication safety. In order to achieve such a positive effect, the system should be 
successfully implemented taking into account the views, needs and acceptance 
of the users, i.e. the physicians and nurses.1• 10 Evaluation of the impact of the system 
enables improvements and adaptations, 1. io. 1 1  
The aim of this study was to explore physicians' and nurses' expectations before 
and experiences after the implementation of CPOE in order to give suggestions for 





Setting and design 
This survey study was conducted in two medical wards of the 1 300-bed University 
Medical Center Gronlngen (UMCG) (a general internal medicine and a gastroen­
terology/rheumatology ward) and in two medical wards of the 600-bed teaching 
hospital 'TweeSteden' in Tilburg and WaalwiJk (TSh) (a geriatric and a general internal 
medicine ward), the Netherlands . Health care professionals were surveyed at two 
time points. In both hospitals, the first survey was conducted towards the end of 2005 
prior to implementation of CPOE. The second survey was conducted after CPOE was 
implemented; for TSh in the summer of 2006 and for UMCC towards the end of 2006 
(internal medicine) and in April/May of 2008 (gastroenterology/rheumatology). 
Paper-based system versus CPOE 
Before the implementation of CPOE on the four medical wards the medication 
ordering system was paper-based. Physicians wrote prescriptions on forms and 
nurses transcribed these prescriptions on special administration charts which they 
used during the process of dispensing and administering. 
Following the introduction of CPOE the medication ordering process Is computer­
ised. Physicians prescribe the medication in a standardised way. They have to select 
drugs from menus and are required to fill in various prescription characteristics. Fur­
thermore during the prescribing phase drug safety alerts are generated in case of 
overdoses and drug-drug interactions. In the two hospitals different CPOE systems 
are used. The UMCG uses the commercially sold system Medicator® (ISOFT, Leiden, 
the Netherlands) in contrast to the TSh where the partly homegrown system Theriak® 
(Theriak evf, Tilburg, the Netherlands) is used. In the Medicator® system only the pre­
scribing phase is computerised (the registration for the dispensing and administra­
tion purposes is still paper-based) in contrast to the Theriak® system in which also the 
patient identification and administration phase is automated. 
Implementation of CPOE 
The boards of directors of both hospitals enforced their medical wards to Implement 
CPOE. Both hospitals had a systematic approach for the implementation of CPOE. 
The implementation process was performed by an implementation team consist­
ing of Information and Communication Technology and hospital pharmacy staff. 
In the UMCG the process took 1 7  weeks per medical ward. In the TSh it took l 0 
weeks. Before the implementation the current situation (organisational aspects of 
the medical ward. procedures and processes) was assessed, technical adjustments 
were made and physicians and nurses were introduced to and trained in the use 
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of the system. This introduction was different in both hospitals: demonstrations in the 
UMCG (passive learning) versus real practicing in prescribing (active learning) in the 
TSh. During the actual implementation, the implementation team was available to 
answer questions and solve problems. Finally, the implementation team evaluated 
the implementation process in a session at each ward with physicians and nurses. 
Study population and procedure 
The study population consisted of physicians and nurses working on the four study 
wards. The population was a convenience sample of residents and fellows in internal 
medicine, specialists, head nurses, coordinating nurses and regular nurses. Per ward 
at least one supervising specialist and one resident/fellow were approached for the 
study as well as the head nurse, one coordinating nurse and one regular nurse. The 
head nurse was asked who of the other nurses had time to participate in the study. 
Most residents and fellows worked temporarily on a ward and could only be con­
tacted either in the pre- or post-intervention period. The group of respondents in the 
baseline-period was not the same as in the post-intervention period except for the 
head nurses. The participants were surveyed in a face-to-face interview by one of 
three researchers (K\/, RZ, JvD). 
Questionnaire / interview instrument 
Two semi-structured questionnaires were developed targeting physicians and nurses 
respectively. These surveys were constructed to measure expectations and (com­
posed in a slightly different format) to measure experiences with CPOE. 
The overall attitude towards the handwritten and CPOE system was measured by 
the question "What is your overall opinion about the paper-based system respec­
tively CPOE system?" Respondents could answer 'fine/moderate/neutral/has con­
straints/completely outdated' for the paper-based system and 'fine (no need for 
changes)/moderate (there are still some bugs)/neutral/has constraints/does not 
meet the requirements' for CPOE. 
Expectations and experiences with CPOE were measured with statements using a 
five-point Likert scale, ranging from 7 = completely disagree through 5 = completely 
agree. In an open-ended question respondents were asked to mention advantages 
as well as disadvantages of the system. 
The respondents were asked in structured questions about the preparation, quality 
and duration of the support from the implementation team. For these questions, also 
a five-point Likert scale was used. 
Data analysis 
For the statements the percentage respondents agreeing (score of 4 or 5 on the 
Likert scale) was calculated. Chi-square tests were used to compare expectations 
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versus experiences of physicians and nurses and to assess differences between 
physicians and nurses. 
The overall positive view towards CPOE was assessed as a sumscore of eight state­
ments before as well as after the Implementation of CPOE: negative statements 
were recoded into positive statements and the mean number of positive scores 
over all respondents was calculated. Only the statements were included that were 
asked both before and after the introduction of CPOE and to both physicians 
and nurses. A t-test was used for assessing differences in the overall positive view 
towards CPOE between the two periods. All analyses were performed using SPSS 
version 1 4  (SPSS Inc., Chicago, I llinois). 
Results 
A total of 1 8  physicians (7 supervising specialists and l l residents/fellows) and 
42 nurses were interviewed (Table l ) . The size of the groups before and after the 
implementation of CPOE was approximately the same for both the physicians and 
nurses. In the TSh more physicians were surveyed than in the UMCG (1 2 versus 6), 
whereas in the UMCG more nurses were Included (23 in the UMCG versus 1 9  in the 
TSh). 
Table l: characteristics of respondents 
Paper-based CPOE 
system 
Physicians n (total = 1 8) 1 0  8 
Sex Female/male 5/5 3/5 
Profession Resident l 2 
Fellow 5 3 
Specialist 4 3 
TSh 6 6 
UMCG 4 2 
Nurses n (total = 42 ) 23 1 9  
Sex Female/male 1 7  /6 1 8/ l  
Profession Head nurse 5 4 
Coordinating nurse 8 7 
Nurse 1 0  8 
TSh 9 1 0  
UMCG 1 4  9 
The overall attitude of most physicians and nurses towards the paper-based sys­
tem was negative (Figure 1 ). The system was considered to have constraints and 
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to be completely outdated. In contrast most physicians and nurses experienced 
CPOE more positively, although they considered it not to be optimal yet because 
of some technical bugs (Figure 2). 
Figure l :  Overall attitude of physicians/nurses towards paper-based system 
Attitude of physicians/nurses towards paper-based system 
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Figure 2: Overall attitude of physicians/nurses towards CPOE 
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Physicians had positive expectations of CPOE being able to reduce prescribing 
errors and to give an improved overview of patients' medication use which was in 
line with their experience with CPOE once they had started working with it (Table 
2). This was in contrast to the physicians' expectations and experiences with the 
time it would take to prescribe medication orders by use of CPOE. It turned out 
to take less time than they had expected. They were neutral before as well as 
after the implementation of CPOE on the speed with which medication orders 
were communicated to the nurses and about how well their fellow physicians han­
dled the system. The way nurses used the system exceeded physicians' expecta­
tions although the difference with their expectations was not significant. Physicians 
expected CPOE to give good clinical support on drug-drug interactions but their 
experiences were less positive (again the difference was not significant). Physicians 
sticked to their opinion that CPOE still has some technical glitches . 
Nurses 
Nurses experienced CPOE to Improve the clarity of the prescriptions just as they 
had expected (Table 2) . They were positive about the way their fellow nurses cope 
with the system. Also they were rather positive about CPOE reducing errors in pre­
scribing. Their experiences with the support of CPOE in preventing drug-drug inter­
actions as well as how they experienced that physicians used the system turned 
out to be significantly worse than their expectations before. A minority of the nurses 
was positive about the speed with which they were informed about the medica­
tion orders. This was found both before (expectations) and after (experiences) the 
implementation of CPOE. Less technical glitches were experienced than expected, 
although these glitches are still considered to be a problem. 
Physicians and nurses 
No significant differences between the views of physicians and nurses were identi­
fied except for the overview they had of patients' medication use in CPOE which 
nurses experienced as not good in contrast to the physicians who experienced it 
as good. 
No significant differences were identified in the sum score of positive views towards 
CPOE (mean of the number positive answered items) before and after the imple­
mentation for physicians (mean before = 4.80, mean after = 5.25, p = 0.46) and for 
nurses (mean before = 4.74, mean after = 4.53, p = 0.63). There were also no differ­
ences between professions in their overall positive expectations (mean physicians 
= 4.80, mean nurses = 4.74. p = 0.9 1 )  nor in their overall positive experiences (mean 
physicians = 5 .25, mean nurses 4.53. p = 0.20) 
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By the Introduction of CPOE . . .  Physicians 
Nurses p 
Positive Statements: 
Fewer errors in prescribing 
A new medication order is sooner known 
to the nurses 
A better overview of patients' medication 
use 
A good support for preventing of drug-
drug interactions 
More clear which medication/dosage 
the patient should get 
The system is user-friendly enough to 
prescribe in an efficient way 
Negative statements: 
Many (colleague) physicians do not 
handle the system well, which causes 
problems 
Many (colleague) nurses do not handle 
the system well, which causes problems 
Prescribing takes a lot of time 
There are still many technical glitches 
* Expressed as percentage agreeing 
Expectations* 
(n = 10) 










Experiences* valuet Expectations* 
(n = 8) (n = 23) 
75% 0.09 83% 
50% 0.67 26% 
88% 0.87 6 1% 
50% 0.18 96% 
-** - 87% 
88% - -** 
50% 0.39 44% 
1 3% 0.09 48% 
1 3% 0.02 -** 
63% 0.41 87% 
(positive is defined as scores 4 and 5 on a 5 point Llkert scale (1 = strongly disagree and 5 = strongly agree)) 
t p values refer to chi-square tests for nominal variables 
** Not asked 
Experiences* 





































































The respondents in both hospitals were satisfied with the implementation process, 
despite the different approaches used (Table 3) . Most of the physicians and nurses 
reported to be sufficiently prepared to start working with the system . Most profes­
sionals present during the implementation process were satisfied with the availabil­
ity and the available support of the implementation team. 
In box l the most frequently mentioned advantages and disadvantages of  CPOE 
are listed. According to the respondents the system improved the efficiency of the 
medication process and improved the readability of the prescriptions. However, 
there were still many technical glitches. 
Table 3: Experiences with the implementation process 
Physicians 
(n = 8) 
Nurses 
(n= 19) 
You were sufficiently prepared to work with the system? 75%" 90%" 
Only for persons who were working at the ward during the 
implementation: (n = 4) 
100%" 
(n= 1 8) 
94%" There was enough support from the implementation team during the Implementation phase. 
The implementation team was sufficiently available to give 
support. 1 00%" 94%" 
• Expressed as percentage agreeing (positive is defined as scores 4 and 5 on a 5 point Llkert scale 
(1 =strongly disagree and 5 = strongly agree)) 
Box l :  Most listed advantages and disadvantages of CPOE 
Advantages Disadvantages 
"System gives a good overview of used 
medication" ( 1 3 times) 
"System is efficient" ( 1 3  times) 
"Readability is improved" (l l times) 
" Fewer medication errors than before" 
(9 times) 
I 
" Introduction of CPOE results in better 
logistics" (only UMCG) 
(7 times) 
"Clinical decision support is incorporated" 
(6 times) 
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"Still many technical glitches" 
(9 times) 
"Dependence on physicians" 
(only nurses) (6 times) 
"System does not give a good 
overview of used medication" 
(6 times) 
"Too many irrelevant drug-drug 
interactions" (3 times) 
" It is a slow system" (3 times) 
" Logistics got worse" (only TSh) 
(2 times) 
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Discussion 
Physicians and nurses were more positive about CPOE than the paper-based 
medication ordering system. They were also satisfied with the way the system was 
implemented. In general, their ideas about CPOE before implementation were 
comparable to their experiences. Even before implementation, a high degree of 
acceptance of CPOE existed on the work floor which undoubtedly facilitated the 
actual implementation and adoption. Coupled with the view of professionals that 
the paper-based system was outdated, this provides good conditions for change. 1 2 
At the same time we have to bear in mind that the use of CPOE was decided at 
the top of the organisation and once implemented there was no choice at the 
work floor whether to use CPOE or not. 
The most surprising difference between expectations and experiences is with 
respect to the time investment of prescribing. Prescribing by use of CPOE took less 
time than the physicians thought it would take. This is in contrast to earlier studies 
showing that physicians were annoyed with the additional time required for com­
puterised prescribing in comparison to the handwritten way of prescribing. 13 14 Our 
more positive findings may be explained by the more user-friendly interfaces that 
are being used nowadays in comparison with the systems in the nineties described 
in earlier studies. 
In contrast to physicians, nurses were negative about the overview they had of 
patients' medication use in CPOE. According to them these overviews were not 
clear. This is certainly a point of interest, because it affects the work process of 
nurses in a negative way and it can lead to medication errors. Furthermore, the 
nurses were negative about the way physicians handled CPOE. This may be caused 
by a change in the way nurses and physicians collaborate since the introduction 
of CPOE as has been described elsewhere.8· 15 It is known that in paper-based 
systems nurses and physicians interact more easily and efficiently with respect to 
patient's condition and medication.8 In the CPOE system such interaction is less 
easy because it separates the work of physicians from that of nurses; the prescrib­
ing phase takes place behind a computer with less feedback or information from 
nurses. Nurses become more dependent on the way physicians prescribe and 
they have less opportunity to correct physicians' actions. 
This study showed that the decision support on drug-drug interactions in CPOE 
needs more attention. Because in the paper-based system there was limited deci­
sion support during the prescribing phase, nurses and physicians' expectations 
about decision support were high. However these expectations were not met. The 
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main reason Is the generation of too many safety alerts which are not appropri­
ate for the hospital setting. Improvement is needed before 'alert fatigue' occurs, 
which can lead to ignorance of important alerts besides the unimportant ones.16 
Future research should investigate what the best approach is, as turning off alerts 
hospital-wide can be problematic because of differences in clinical relevance for 
the various medical specialties and differences in knowledge. 1 7 
Despite the difference in strategies for implementing CPOE between both hospi­
tals, physicians and nurses from both hospitals were satisfied with the duration and 
quantity of the support given by the implementation team. This suggests that both 
strategies were adequate approaches to implement CPOE, at least well fitted in 
their context. 
The main limitation of this study is the difference in study sample before and after 
the implementation of CPOE, i.e. few respondents were Interviewed twice.Another 
limitation is the use of a convenience sample instead of a randomised sample. It 
is possible that our respondents were more willing to participate than other users 
because they had a clear view towards CPOE, whether positive or negative. A 
strength of our study is the setting of two hospitals (a university and a teaching 
hospital) with two different CPOE systems. This enhances the generalisability of our 
results. 
Despite the positive experiences with CPOE, the system does not function opti­
mally yet. Based on the results of this study a number of recommendations can be 
made on how to optimise the system. First technical glitches should be fixed with a 
special Interest for improving the display of medication overviews for nurses. These 
glitches are still one of the most frequently mentioned disadvantages of CPOE. 
Furthermore, the decision support on drug-drug interactions should be improved 
in the sense that an assessment should be made on which safety alerts are really 
relevant for the hospital setting and which safety alerts should be turned off for 
each medical specialty separately. Finally, physicians and nurses should be aware 
that CPOE has an impact on their collaboration and that during the prescribing 
process nurses are more dependent on physicians than before. In this situation it is 
important to guarantee good communication between both professions. Hospitals 
aiming to start implementing CPOE must take into account these recommenda­
tions to guarantee an optimal use of their CPOE system. 
Overall we may conclude that physicians and nurses are positive about CPOE and 
the process of its implementation and do accept these systems. However. these 
systems should be further improved in order to fit into clinical practice. 
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Pharmacotherapy, prescribing medication. is an important aspect of almost all in­
hospital treatment regimes. Besides their obviously beneficial effects, medicines 
can also cause adverse drug events (ADE), which increase morbidity, mortality 
and health care costs. A part of these ADEs arise from medication errors, e.g. at the 
ordering stage. ADEs caused by medication errors are preventable ADEs. 
Until now, medication ordering was primarily a paper-based process and was thus 
error prone. Computerised Physician Order Entry, combined with basic Clinical 
Decision Support System (CPOE/CDSS) is considered to be a useful alternative to 
enhance patient safety. Limited information Is available on the balance between 
the health gains and the costs that need to be invested in order to achieve these 
effects. 
Objectives: 
To study the balance between the effects and costs of CPOE/CDSS compared 
to the traditional paper-based medication ordering system in a general teaching 
hospital and a University Medical Centre. 
Methodology: 
The economic evaluation was performed alongside a clinical study on the effec­
tiveness of CPOE/CDSS. It consisted of a cost minimisation and a cost-effectiveness 
analysis of CPOE/CDSS compared to the standard paper-based system. All costs 
of both medication ordering procedures were estimated based on resources 
used and time invested. Time spent by the health care professionals was calcu­
lated based on Interviews, questionnaires and actual time registration. Costs of ICT 
experts were based on the number of full-time equivalents assigned to the CPOE 
projects in both hospitals . The analyses were performed from a hospital perspec­
tive. Since the time horizon did not exceed l year, no discounting was applied. 
Prices were expressed in euros (level 2006). 
Outcome measures were medication errors (MEs) and preventable ADEs (pADEs), 
Results are presented in ratios of incremental costs to incremental effects ( ICER). 
Sensitivity analyses were performed. 
Results: 
In total l ,  1 95 patients were included; 592 admitted during the paper-based pre­
scribing period, and 603 during the CPOE/CDSS period. 
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The clinical study showed a decrease in the percentage of medication orders 
(MOs) containing at least one medication error from 55% with the paper-based 
system to 1 7% with CPOE/CDSS, and a decrease in the percentage of patients 
experiencing at least one pADE from 1 5.5% to 7 .3%. 
Total costs of the paper-based system and CPOE/CDSS amounted to € 1 1 .80 and 
€ 1 4.20 per patient/day respectively. The ICER for errors was 3 .38 and for pADEs 
307. 72, indicating the extra amount ( €) that has to be invested in order to prevent 
one ME or one pADE. Sensitivity analyses on costs and effects showed that the 
results were quite robust. 
Conclusions: 
This study showed that CPOE with basic CDSS contributes to a decreased risk of 
preventable harm. Overall, the extra costs of CPOE/CDSS needed to prevent one 
ME or one pADE seem to be acceptable, especially in relation to the costs of one 
ADE or additional admission days. 
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Introduction 
In the Netherlands, every year l ,  l 00 out of 1 0,000 citizens are admitted to a hospi­
tal. 1 Prescription of one or more drugs is an important aspect of almost all hospital 
treatment regimens. Medication ordering thus can be considered as a regular 
activity affecting a substantial part of the population. During this process, errors 
can be made. Studies examining medication errors (MEs), report that 2.9- 1 6.6% of 
all in-patients experience adverse events serious enough to prolong hospitalisa­
tion, cause significant morbidity or even mortallty.2•4 These ADEs caused by medi­
cation errors are considered to be preventable ADEs (pADEs). Medication errors 
in general and the associated awareness of potential harm are a threat to the 
(subjective) experienced safety of hospitalised patients. 
Thus, every possible improvement in the medication ordering process appears 
to be desirable with regard to health gains, patient wellbeing and experienced 
safety. However, with regard to a rational spending of the available healthcare 
budget, it is essential to also study the balance between units of health gained, 
and the costs that need to be invested in order to achieve these effects. 
In most Dutch hospitals, paper-based medication ordering systems are in use, which 
rely on hand written prescribing and transcribing activities of various health care 
professionals . Computerised Physician Order Entry (CPOE) systems are considered 
to be a useful alternative to enhance patient safety. These systems are becoming 
more common in the Netherlands and a growing body of knowledge on its clini­
cal effectiveness is presented in (inter)national journals. Recently, two systematic 
reviews were carried out on the effects of CPOE and CPOE with a Clinical Decision 
Support System (COSS). The most recent study5 analysed both MEs and pADEs and 
concluded that it seems that electronic prescribing can reduce the risk of MEs and 
pADEs. Wolfstadt et al.6 looked at the effects of CPOE/CDSS on the rate of pADEs. 
Results showed that 50% of the included studies reported a significant decrease in 
pADEs, 40% reported a non-significant reduction In pADEs, and 1 0% demonstrated 
no change in pADE rates. 
Besides their potential effectiveness, CPOE/CDSS systems are costly.2·3·7 8  On the 
other hand, MEs are costly as well. MEs may contribute for an important part to the 
total number of pADEs. Previous studies estimated that each pADE adds $2, 1 62 to 
$2,595 (USD) to the costs of hospitalisation and that annual attributable costs for 
preventable ADEs for a 700 bed teaching hospital are $2.8 million.2 3.1.a 
At present, limited information is available on the costs and cost-effectiveness of 
CPOE/CDSS. The few available studies generally show high costs and high cost­
effectiveness ratios, which means that the additional costs that have to be invested 
to gain one unit of additional effect (e .g. reduction in MEs or pADEs) are high. 
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Kuperman et al9 reports implementation costs of CPOE for a 500-bed hospital at 
almost $ 8,000,000 with ongoing annual maintenance costs of $ 350,000. Wu et al2 
performed a cost effectiveness analysis, and found incremental cost-effectiveness 
ratio of $ 1 2,700 per ADE averted. 
Study design, measures of effect, setting and health care system, however, limit the 
generalisability of these results. In addition for the European situation we know of 
no previous cost effectiveness studies on this subject. 
Therefore, the aim of the present study was to evaluate the balance between 
the effects and costs of CPOE compared to a traditional paper-based ordering 
system. 
Methods 
Design, population and setting 
The economic evaluation was performed alongside an interrupted time series 
study on the effects of a Computerised Physician Order Entry system , including 
a basic Clinical Decision Support System (CPOE/CDSS). The effectiveness study 
was performed in two Dutch hospitals, a University Medical Center (l ,300-beds), 
and a general teaching hospital (500-beds). All patients that were admitted for a 
duration of at least 24 hours to either the general internal medicine ward, or the 
gastroenterology ward in the University Medical Center or to the general internal 
or the geriatric ward of the general teaching hospital were suitable for inclusion. 
The study was designed as an interrupted time series with two periods of measure­
ment: a pre implementation measurement, in which the paper-based medica­
tion ordering system was evaluated, and a post implementation measurement, in 
which the CPOE/CDS system was evaluated. Data were prospectively collected for 
592 patients admitted during twenty weeks before and for 603 patients admitted 
during twenty weeks after introduction of CPOE/CDSS. Primary outcome measures 
were the percentage of medication orders with one or more ME and the percent­
age of patients with one or more pADE. 
A waiver of the Medical Ethical Committee was obtained for this study, as the study 
fell within the boundaries of normal hospital routine of quality improvement. All 
patients received information about the study and had the opportunity to object 
to inclusion. 
Standard method of prescribing and intervention 
The standard (pre intervention) way of prescribing medication was a paper-based 
system. Physicians wrote prescriptions on forms and nurses transcribed these pre­
scriptions on special administration charts, which they used during the process of 
dispensing and administering. In the general teaching hospital, MO's were also 
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entered into the pharmacies computer system for the purpose of medication sur­
veillance. 
The intervention, CPOE/CDSS, was a computer-based system by which physicians 
prescribe medication in an electronically, standardised way. Medicines can be 
selected from menus in which medication from the local stock or from the phar­
macy drug database are shown. In both hospitals different types of CPOE/CDSS 
systems were used. The University Medical Center used a commercially available 
system (Medicator® ,iSOFT, Leiden, the Netherlands). The general teaching hospital 
used a partly home-grown system (Theriak® , Theriak evf, Tilburg, the Netherlands), 
The CDDS system in both Medicator® and Theriak® was basic, meaning that only 
dosage and drug-drug interaction alerts were generated. 
Economic evaluation cost types and cost categories 
The economic evaluation consisted of a cost minimisation and a cost-effective­
ness analysis of CPOE/CDSS compared to the traditional paper-based medication 
order system. 
Assessing the costs of medication ordering before and after implementing the 
CPOE/CDSS was an important element of the economic evaluation. Since the 
economic evaluation was performed from a hospital perspective, all relevant costs 
related to medication ordering made in the hospital were calculated and taken 
into account in the cost-effectiveness analysis for all prescriptions of alt included 
patients. 
Resource quantities and unit prices 
Costs of both medication ordering procedures were assessed. Costs were calcu­
lated based on true resources used and time invested, according to the Dutch 
guidelines for cost-studies. 10 Time spent by various health care professionals was 
calculated based on interviews (expert opinions), standardised questionnaires, 
and actual time registration by the researchers. Costs of time spent by ICT experts 
for maintenance etc. of the computer system and software were calculated 
based on the number of full-time equivalents assigned to the implementation and 
maintenance of CPOE/CDSS in both hospitals. 
Unit prices for these resources were assessed at the University Medical Center and 
at the general teaching hospital. The price level used is that of 2006. Prices have 
been assessed in Euros. Table 1 shows the various cost categories and types of 
costs that have been assessed as well as the method that was used to calculate 
the costs. 
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Table 1 .  Unit prices of included cost categories 1 
Cost category Method 
Medication ordering related activities Resources used; time investment 
doctor 
Medication ordering related activities Resources used; time investment 
nurse 
Medication ordering related activities Resources used; time investment 
pharmacy staff 
Computer system used for medication Interest and debits 5 years 
ordering 
ICT support and software licence Resources used; time investment 
Implementation process Resources used; time investment 
Housing and overhead 45% of subtotal 
1 Price level 2006. 
Results are presented in ratios of incremental costs to incremental effects. 
ICERerr = 
Additional costs of CPOE/CDSS (compared to paper-based system) 
MEs averted with CPOE/CDSS (compared to paper-based system) 
ICER = 
Additional costs of CPOE/CDSS (compared to paper-based system) 
pADE 
pADEs averted with CPOE/CDSS (compared to paper-based system) 
The economic evaluation was performed from a hospital perspective. All relevant 
costs made inside the hospital were taken into account. The time horizon used was 
the same as that for the clinical study, which means that costs were calculated 
during the same period the clinical outcomes were measured. That is, from the 
moment the patient was admitted until discharge. 
Since the measurement period did not exceed one year, according to the Dutch 
guidelines for cost-studies 10 no discounting rate was used in the present study. 
Data analysis 
Descriptive statistics of the various cost components were performed. In addition 
univariate and multivariate sensitivity analyses were performed to explore to what 
extent the cost-effectiveness ratios were influenced by variations in the major cost 





Previous research of our group showed that during the baseline (paper based) 
period, the mean percentage of MOs containing at least one ME was 55% whereas 
in the post-intervention period this was 1 7%. Introduction of CPOE/CDSS led to a 
significant immediate absolute reduction of 40.3% (95%Cl:-45. l 3;-35.48) of MOs 
with one or more MEs and a change in trend of -0.92% (95%CI: - l .3 1 ;  -0.52) per 
week. 
In the baseline period, the mean percentage of admitted patients experiencing 
at least one pADE was 1 5.5% in contrast to 7 .3% in the post-intervention period. 
However, since the change is not significant (-0.42, 95% Cl:- 1 5.52; 1 4.68) because 
of an underlying negative trend at baseline of -4.04% (95% Cl: -7.70; -0.38), this 
decrease could not be attributed to the introduction of CPOE/CDSS. 
Costs of the different prescription systems 
Cost results for the handwritten, paper-based medication ordering system and the 
CPOE/CDSS are displayed in table 2. Mean costs of the paper based medication 
ordering system amounted to € l l .80 per patient per admission day. Mean costs 
for CPOE/CDSS were € 1 4.22.The higher costs for CPOE/CDSS were mainly caused 
by the extra costs for the system (equipment, software and ICT support) and the 
implementation. Regarding personnel, costs of time investment by the doctor and 
the pharmacy technician decreased dramatically after the implementation of 
CPOE/CDSS, whereas the time investment costs of the nurse and to a lesser extent 
the hospital pharmacist increased. 
In separate analyses, differences between hospitals were analysed (results not 
shown). Differences appeared to be minimal, except for the time Investment costs 
of the pharmacy technician during the paper based medication ordering sys­
tem. These costs amounted to € 0 . 16  and € 4. 1 0  per patient per day in the uni­
versity medical centre and the general teaching hospital respectively. This can 
be explained by differences in procedures between both hospitals; in the gen­
eral teaching hospital, central order entry by the hospital pharmacy was in use 
before electronic medication ordering started, which was time consuming for the 
pharmacy technicians. Furthermore, pharmacy technicians played a role during 
patient admission, which was not the case in the university medical centre. 
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Table 2. Costs of the medication ordering systems per patient/day in Euro (€) 
Cost category Paper-based CPOE/CDSS 
Personnel 
Time investment doctor 3. 1 9  0.81 
Time investment nurse 2.37 3.80 
Time investment pharmacy technician 2.1 3 0.77 
Time investment hospital pharmacist 0.45 0,93 




ICT support and software licence 1 .32 
Implementation 1 .74 
Housing and overhead 3.66 4.41 
Total 1 1 .80 14.22 
Cost minimisation and cost effectiveness analysis 
Based on the overall average of both hospitals, the cost difference (€ 1 4.22- €1 1 .80) 
was € 2.42, meaning the computer based prescribing system did cost an extra 
€ 2.42 per patient per day. 
Incremental cost-effectiveness ratios (ICER) for both MEs prevented (5724-1 355) 





Thus, in order to prevent one extra ME with the electronic medication ordering 
system, an additional € 3.38 have to be invested compared to the paper based 
ordering system. 
Overall, in order to prevent one extra pADE with the electronic medication order­
ing system an extra € 307. 72 have to be invested compared to the traditional 
ordering system (see ratio below). 
� 1 4,770, -
48 




In order to study the effects of changes in important cost components on total costs 
and on cost effectiveness ratios different types of sensitivity analyses were performed. 
First. cost categories were unlvariately increased ( +20%) or decreased (-20%). or in 
case of overhead and housing and implementation costs. excluded (-1 00%). 
Effects of varying the different cost categories on the differences in costs between 
the two methods were minimal. The cost difference between both ordering sys­
tems ranged between € 0. 1 0  (paper-based more expensive compared to CPOE/ 
COSS) and € 2.95 (CPOE more expensive compared to paper-based (original 
value € 2.42 CPOE/CDSS more expensive compared to paper-based). Excluding 
the implementation costs (which were only made for CPOE/CDSS) had the big­
gest influence on the cost difference between the two systems. In this scenario 
the costs of CPOE/CDSS were lower than those of the paper based system (table 
3). As expected, excluding the costs of implementation or overhead and hous­
ing had the biggest effect on the ICERs for MEs and pADEs. Excluding the costs 
of implementation caused the ICERs to become negative. This implies that both 
MEs/pADEs. and total costs were reduced after the implementation of CPOE/CDSS 
compared to the paper based system. 
Table 3. Univariate sensitivity analysis: effect of varying major cost categories on total costs 
in Euro (€) and Incremental Cost Effectiveness Ratios (tCER). 
Cost category Variation Total costs (€) per patient/day ICER 
Paper-based 
CPOE/CDSS Difference ICERen ICERpADE system 
Original value None 1 1 .80 14.20 2.42 3.38 307.72 
Personnel 
+20% 14. 1 6  1 6.05 l .89 2. 14 1 94.57 
-20% 9.44 1 2.39 2.95 4.62 41 9.96 
Equipment. +20% 1 1 .80 1 4.73 2.93 3.49 31 7.93 
software, ICT -20% 1 1 .80 1 3.7 1  1 .9 1 3.27 297.51 
lmplemen- +20% 1 1 .80 1 4.73 2.93 4.34 395.05 
tation - 20% 1 1 .80 1 3 .72 1 .92 2.43 221 .23 
- 100% 1 1 .80 1 1 .70 -0. 1 0  -1 .57 - 142.54 
Housing & +20% 1 2.53 1 5. 1 1  2.58 3.61 328.71 
Overhead - 20% 1 1 .07 1 3 .34 2.27 3.00 290. 1 8  
- 1 00% 8. 1 4  9.81 1 .67 1 .33 1 2 1 .23 
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To create a more extreme scenario compared to the univariate analysis, in a mul­
tivariate sensitivity analysis all cost categories in one of both prescribing systems 
were decreased with 20%, and increased with 20% in the other system. Results of 
this analysis are displayed in table 4. As expected, the difference in costs between 
the paper based and the CPOE system increased with the multivariate sensitivity 
analysis.A negative difference (cost savings) was present after increasing the costs 
of the paper based system with 20%, while at the same time decreasing the costs 
of CPOE/CDSS with 20%. 
Table 4. Multivariate sensitivity analysis: effect of varying major cost categories on total 
costs in Euro (€) and Incremental Cost Effectiveness Ratios (ICER). 
Variation method Total costs (€) per patient/day ICER 
Original value 
All cost categories in 
paper-based system 
- 20% and in CPOE 
system + 20% 
All cost categories in 
paper-based system 
+ 20% and in CPOE 
system - 20% 
Paper-based CPOE/CDSS Difference ICER.. ICER
pAOE 
system 
1 1 .80 14.20 
8.86 1 8. 1 3  




3.38 307. 72 
1 6.62 1 51 2.33 
-9.80 -891 .87 
The effects of the multivariate sensitivity analysis on the ICERs are displayed in Table 
4 and in figures l and 2 (Scenario l ). 
Increasing the costs of CPOE/CDSS with 20% while at the same time decreasing 
the costs of the paper based system, caused a major augmentation of the ICERs, 
especially the ICER for pADEs. Increasing the costs of the paper based system and 
decreasing the costs of CPOE/CDSS caused all lCERs to become negative, reflect­
ing both a reduction of MEs/pADEs, and costs with CPOE/CDSS (compared to the 
paper based system). 
In Figures l and 2 results of 4 alternative scenarios of varying the numbers of MEs 
and pADEs are presented. 
In scenario 2 the total numbers of MEs and pADEs were decreased with 20% for 
both the paper based and CPOE/CDSS and in scenario 3 the total numbers of MEs 
and pADEs were increased with 20% for both systems. Scenario 4 represents the 
results of increasing the numbers of MEs and pADEs in the paper based system with 
20% and decreasing this number with 20% in CPOE/CDSS and finally, in scenario 5 
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the numbers of MEs and pADEs in the paper based system were decreased with 
20% and in CPOE/CDSS increased with 20%. As expected. scenario 5, in which the 
number of MEs/pADEs averted with CPOE/CDSS, compared to the paper based 
system was minimised, had the most dramatic effect. This effect was maximised 
when hen it was combined with the multivariate sensitivity analyses on costs. 
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Figure l .  Effect of sensitivity analyses on the ICER (MEs) 
Scenario 1 :  original number of MEs 
6 
• original value costs 
pers+20% 
pars+ 20% 
x equlp +20% 
X equlp· 20'% 
• lrrp +20 % 
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• mJtlvar paper -20% E V S  +20% 
x mJtlvar paper +20% EVS -20% 
Scenario 2: 20% decreased In number of MEs for paper-based and CPOE system 
Scenario 3: 20% Increased In number of MEs for paper-based and CPOE system 
Scenario 4: number of MEs 20% Increased in for paper-based and 20% decreased for CPOE system 
Scenario 5: number of MEs 20% decreased in for paper-based and 20% Increased for CPOE system 
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Effect of sensitivity analyses in ICER (pADEs) 
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Figure 2. Effect of sensitivity analyses on the ICER (pADEs) 
Scenario 1 :  original number of pADEs 
Scenario 2: 20% decreased In number of pADEs for paper-based and CPOE system 
Scenario 3: 20% Increased In number of pADEs for paper-based and CPOE system 
Scenario 4: number of pADEs 20% Increased In for paper-based and 20% decreased for CPOE system 
Scenario 5: number of pADEs 20% decreased In for paper-based and 20% Increased for CPOE system 
Discussion 
The present study is one of the first that measured and compared both costs and 
effects on MEs and pADEs of a paper-based medication ordering system and 
CPOE in different settings. Results showed that overall costs per patient per admis­
sion day were € 2.42 higher with the CPOE/CDSS system compared to the paper­
based prescribing system. Relative to the total costs of one admission day, which 
amount to € 495 for a university hospital and € 351 for a general hospital 1° the 
additional costs appear to be minimal. Still, when considering implementing a new 
system in medical practice, not only information on costs, but particularly informa­
tion on the balance between effects (health gains/safety) and costs is essential for 
the decision. In the present study, the balance between extra costs invested and 
MEs averted was € 3.38. Extra costs that had to be invested to prevent one extra 
pADE amounted to € 308,-.To put these figures into perspective, in 2007, Wu et al.2 
found an incremental cost effectiveness ratio of $ 1 2, 700 per pADE averted. The 
most important cost components is this study were implementation and training 
costs, whereas in our study personnel costs of prescribing were the most important. 
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However, due to the different setting and methodology used In that study, these 
results are difficult to compare with ours. Data on effectiveness were extracted 
from a heterogeneous collection of studies looking at ADE rate and effectiveness 
of CPOE/CDSS. Since developments in computer based systems are quite rapid, 
present-day systems are difficult to compare to the older ones. The effectiveness 
studies used in Wu's paper were mostly performed in the nineties. Furthermore, cost 
effectiveness was estimated over a l O year horizon. 
In our sensitivity analysis it appeared that varying the different cost components 
had a minor effect on the cost differences between the paper-based and the 
CPOE system and consequently on the ICERs. Univariate sensitivity analysis on the 
additional costs of CPOE compared to the paper-based system, showed an upper 
limit of € 2.95, and a lower limit of 
- € 0. 1 0, while the originally calculated value was € 2.42 per patient, per day. 
This scenario, in which the costs of Implementation were excluded, also had a 
positive effect on the ICER for MEs (- 1 .57) and pADEs (-1 42. 54), meaning saving 
money while at the same time MEs/pADEs were prevented. Overall, different types 
of sensitivity analyses showed that extra costs that have to be invested with CPOE/ 
CDSS in order to prevent one extra error compared to the paper-based prescrib­
ing system, stayed below € 25,-. in all scenarios. For pADEs this value didn't  exceed 
€ 2,000,-. except for the most extreme scenario, in which both costs and pADEs 
where decreased by 20% for paper-based, and increased with 20% for CPOE/CDSS. 
From literature it is known that the additional costs of one pADE are estimated to 
vary between $21 62 and $2595 (USD).2.3.1.s Relative to those costs, the investments 
needed to prevent one pADE seem reasonable. 
An Important difference between the paper-based prescribing system and CPOE 
is the time investment of the nurse. With CPOE In both hospitals the time Investment 
of the nurse increased, while the time investment of the doctor decreased. This was 
contrary to the increased time investment doctors expected before the imple­
mentation of the system. This can probably be explained by the fact that the doc­
tor has to spend less time answering questions concerning Illegible handwriting, 
continuation of certain medication etc. On the other hand, the extra time spend 
by the nurses mainly has to do with increased time for checking the medication 
administration charts during the night shift. This takes more time compared to the 
paper-based system, due to the illogical order of drugs in the medication admin­
istration charts (University Medical Centre). From the clinical analysis, it was con­
cluded that there was no significant effect of CPOE/CDSS on the rate of pADEs. 
This finding may question the relevance of calculating an ICER. However, based on 
the decline in the absolute proportion of pADEs after implementing CPOE/CDSS, its 
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clinical relevance and the fact that the cause of the negative trend in pADEs dur­
ing baseline was unknown. we decided this information was valuable and these 
ICERs should be presented after all. 
Although computer software. maintenance and equipment are an important part 
of the prescribing system, varying those costs had little effect on total costs and on 
incremental cost effectiveness ratios. This can be explained by the fact that these 
costs are a relatively small part of the total costs. Therefore. for policy makers not 
only the system but also the work processes and the possible changes in these 
processes should be considered when deciding whether or not to implement an 
electronic medication ordering system. 
In conclusion. the additional costs to prevent one ME are almost negligible, espe­
cially compared to the total costs of one admission day. Although in our study 
we didn't measure patient reported outcome, we feel these extra costs are 
compensated by the additional effects in terms of ME reduction and possibly 
increased experienced safety. The latter however, has to be confirmed in addi­
tional research. 
With regard to the extra costs to prevent one pADE; those are substantially higher 
compared to the ICER for MEs. However. relative to the additional costs of one 
pADE, the investments needed to prevent one pADE seem worthwhile. 
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A substantial part of the hospitalised patients suffers from harm due to errors 
occurring in the prescribing process of medication. 1 •3 The optimisation of this 
process will contribute to an increase in medication safety. One approach to 
this optimisation is the introduction of a Computerised Physician Order Entry sys­
tem with Clinical Decision Support (CPOE/CDSS) that offers a computerised and 
standardised way of prescribing with incorporated decision support. Although 
studies from the USA showed positive effects of these systems in reducing medi­
cation errors and adverse drug events, it is important to confirm these effects for 
the Dutch hospital setting in a study with a robust design. Furthermore, the bal­
ance between costs and effects of CPOE/CDSS should be explored because lit­
tle knowledge exists about the cost-effectiveness of these systems in comparison 
to the traditional paper-based system. This information is valuable, because pres­
ently many hospitals are considering the purchasing of CPOE/CDSS. However, 
studying the effects of these systems is a challenge because the assessment of 
medication errors and related patient harm is complex. Various definitions, meth­
odologies and causality assessments exists and the agreement is often not very 
high between assessors.4-6 This results in a lack of clarity as to what types of errors 
are the most relevant from a clinical perspective and what the determinants of 
errors and adverse drug events are, although these are the main targets for inter­
ventions that aim to improve medication safety, such as CPOE/CDSS. Therefore 
the main objectives of this thesis were: 
PART 1 : Medication errors and preventable adverse drug events 
• to explore methodological aspects of identifying medication errors and 
adverse drug events and to assess the clinical relevance of medication errors 
and the determinants of medication errors with and without patient harm 
PART 2: CPOE/CDSS in relation to medication safety 
• to evaluate what the effect of CPOE/CDSS is on the incidence of medica­
tion errors and preventable adverse drug events in two Dutch hospitals 
• to explore in depth important features of CPOE/CDSS, namely the effect of 
clinical decision support (COSS) on medication safety, the cost-effective­
ness of CPOE/CDSS in comparison to the paper-based system and expec­
tations and experiences of health care professionals with CPOE/CDSS. 
In this discussion the main findings of the studies will be summarised and presented 
and the implications for clinical practice and future research will be discussed. 
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In PART l of this thesis we focused on the one hand on the methodological aspects 
of identifying medication errors and adverse drug events, and on the other hand 
on the determinants of drug related problems and the clinical relevance of medi­
cation errors. We assessed the reliability of the assessment of preventable adverse 
drug events in daily practice and we explored the impact of the assessors' profes­
sion (physician or pharmacist) on reliability (chapter 2). We showed that assessing 
preventable adverse drug events is difficult, because the agreement between indi­
vidual raters is fair (kappa is 0.36) and the agreement between different professions 
is moderate (kappa is 0.47). The best approach for assessing preventable adverse 
drug events is a consensus method, including both physicians and pharmacists as 
raters. We used a consensus approach in which five pharmacists assessed adverse 
drug events that were potentially related to errors in the medication ordering pro­
cess in chapter 3. The association between different types of prescribing (adminis­
trative, dosing and therapeutic) and transcribing errors and preventable adverse 
drug events was studied. The results of this study showed that transcribing errors (OR 
adjusted 1 . 1 2; 95% Cl 1 .0 1  to 1 .25) and therapeutic errors (OR adjusted 1 .98; 95% Cl 1 .53 
to 2.56) were significantly associated with pADEs. The association of therapeutic 
errors was the strongest and from a clinical point of view this type of errors is most 
relevant. In order to prevent these errors it is important to know their determinants. 
In chapter 4 we studied the determinants of medication errors with and without 
patient harm. A number of determinants were shown to be the same for the two 
types of medication errors, namely hospital, ward, age of the patient and the ther­
apeutic classes of anti-infectives and neurological medication, although for some 
of these determinants this was only shown as a non-significant trend. This is prob­
ably due to the fact that the number of medication errors leading to patient harm 
was relatively low, thus resulting in insufficient power of our study. Future studies with 
larger sample sizes of medication errors leading to harm are needed. 
In PART 2 of this thesis we focused more on CPOE/CDSS in relation to medication 
safety. We evaluated the effect of CPOE with basic clinical decision support (COSS) 
on the incidence of medication errors and preventable adverse drug events in two 
Dutch hospitals. Results are discussed in chapter 5. Introduction of CPOE/CDSS led 
to a significant immediate absolute reduction of 40.3% (95%Cl:-45 . 1 3% to 35.48%) 
of medication orders with one or more errors. In the pre-CPOE/CDSS period, the 
mean percentage of admitted patients experiencing at least one pADE was 1 5.5% 
in contrast to 7.3% In the CPOE/CDSS period. However, this decrease could not be 
attributed to the introduction of CPOE/CDSS itself. The immediate change was not 
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significant (-0.42%, 95% Cl:-1 5.52% to 1 4.68%) because of the observed underly­
ing negative trend during the pre-CPOE/CDSS period of -4.04% (95% Cl: -7.70% to 
-0.38%) per month. More advanced clinical decision support may be needed to 
reduce the number of preventable adverse drug events. In chapter 6 we identi­
fied to what extent patients at risk for medication related harm as identified by 
basic CDSS and a set of clinical rules (advanced CDSS) actually need a change 
in medication. The actual change in medication was determined by medication 
review. For this study we used a part of the study population as described in chap­
ter 5. Medication review Identified 57 overdoses and 1 43 therapeutic errors in these 
patients. CDSS identified 297 overdoses, with sensitivity 0.32, specificity 0.92 and 
positive predictive value (PPV) 0.06; and 365 drug-drug interactions, with sensitivity 
0.96, specificity 0.91 and PPV 0. 1 2. The clinical rules identified 78 (39%) of the 200 
overdoses and therapeutic errors . In 72 (23 %) of 3 1 3  alerts generated a change 
of medication was actually indicated. When combined CDSS and rules identified 
1 3 1 (66%) of the 200 errors. The combination of basic CDSS and clinical rules are 
promising strategies to prevent medication related harm. They will be more useful 
when they are fine tuned in order to decrease the number of alerts that need no 
action. 
In chapter 7 we described expectations and experiences with CPOE/CDSS of 
physicians and nurses. In general they were positive about the system before as 
well as after the implementation of CPOE/CDSS. However they think that CPOE/ 
CDS systems can be further optimised, especially regarding technical function­
ing and incorporated decision support on drug-drug interactions. Finally we stud­
ied the balance between the effects and costs of CPOE/CDSS compared to the 
paper-based medication ordering system in chapter 8. Total costs of the paper­
based system and CPOE/CDSS amounted to € l l  .80 and € 1 4.20 per patient/ 
day respectively. The ratio of incremental costs to incremental effects (ICER) for 
medication errors was € 3.38 and for preventable adverse drug events € 307 .72, 
indicating the extra amount of money that has to be invested in order to prevent 
one medication error or one preventable adverse drug event. Extra costs of CPOE/ 
CDSS needed to prevent one medication error or one preventable adverse drug 
event seem to be acceptable, especially in relation to the costs of one adverse 
drug event or additional admission day. 
Part 1 - Conclusions and future perspectives on medication errors 
and preventable adverse drug events 
Several studies have been performed in order to assess the incidence of medica­
tion errors and (preventable) adverse drug events in different settings.3· 1-10 There 
is high variability among the findings of these studies due to the different study 
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populations and settings but also due to the different methods used to assess 
medication errors and adverse drug events. The assessment of the relationship 
between medication errors and patient harm is complex because patient harm 
can be caused by other factors than medication use, e.g. disease related factors. 
This assessment will always leave room for subjective interpretation of the rater, 
leading to lack of agreement between individual raters (this thesis). Therefore the 
results of medication safety studies based on the assessments of one individual 
rater may be not reliable. It is necessary to perform this kind of assessments by a 
panel of raters (at least more than two) and preferably by pharmacists and physi­
cians to combine the more drug oriented view of the pharmacists with the more 
clinical view of physicians. The fact that only pharmacists were participants in the 
consensus method of the studies described in the chapters 3 and 5 of this thesis is 
a limitation. However, in chapter 5 (the effect of CPOE/CDSS on medication safety) 
we were more interested In the effect of the intervention itself than in the exact 
incidence of medication errors and preventable adverse drug events. In that situ­
ation the most relevant condition is that the same methodology is used before and 
after the intervention to determine a reliable effect. In our study we assured that 
the same raters assessed cases In the same systematic way in the pre- as well as in 
the post-intervention phase. 
We may conclude that there still is no method described for the identification of 
medication error related patient harm that excludes the element of individual 
judgement, leaving a grey zone around incidence rates . To increase the rellabil­
ity of these identification methods and to be able to compare Incidence rates 
between different settings (ambulatory care, care institutions, hospitals and differ­
ent departments in hospitals), standardisation is needed. Both scientists and pro­
fessionals working in daily practice should reach consensus on what is the best 
approach for assessing drug related problems. After this has been established, the 
method should be used in future medication safety studies to draw reliable con­
clusions about the incidence rates in the different settings. 
In this thesis we explored the determinants of medication errors with as well as with­
out patient harm and we studied what subtypes of these errors are mostly associ­
ated with patient harm. Due to insufficient power (low number of patients with 
preventable adverse drug events), only a few determinants of errors with patient 
harm were found and future research is needed with larger sample sizes of these 
events. Based on our findings that organisational determinants (e.g. hospital and 
ward) were significantly associated with both medication errors with and without 
harm, we may conclude that for these determinants medication errors without 
harm could be an acceptable interim measure for preventable adverse drug 
events. For more patient- or medication related determinants these conclusions 
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can not be drawn and therefore we still have to be careful with using medication 
errors as interim measures for adverse drug events in studies looking into determi­
nants of drug related problems. When looking at the potential mechanisms associ­
ated with medication errors and preventable adverse drug events, the association 
of medication errors (whether leading to patient harm or not) with organisational 
characteristics seems plausible and this was indeed confirmed in our study. Further­
more, it seems likely that for medication errors to actually cause patient harm both 
patient related characteristics (e.g. age, comorbidities) and medication related 
characteristics (e.g. intrinsic toxicity of the medication) are necessary. Therefore. 
we can speculate that patient- and medication related determinants would dif­
fer for medication errors leading to patient harm, when compared to medication 
errors not leading to patient harm. However, as said before we could not prove this 
hypothesis in our study because the sample size was too small. 
Despite the low power our study did throw light on the most relevant errors in the 
medication ordering process in terms of preventing harm to the patient. Therapeu­
tic errors (drug-drug interactions, contra-indications, double medication, improper 
mono therapy) seemed to be most strongly associated with patient harm. It implies 
that this type of errors should be the main target for interventions that focus on the 
reduction of errors in the prescribing process. From both a clinical and scientific point 
of view these particular interventions might be interesting because they can possi­
bly lead to a significant reduction in preventable adverse drug events. Nevertheless 
in clinical practice the prevention of other types of prescribing errors can not be left 
out of consideration because these errors contribute to the potential risk of patient 
harm. Future research is needed to assess also the clinical relevance of types of 
errors in other routes of the medication process, such as the administering process or 
the interface between different settings (hospital and ambulatory care). 
Based on the findings in part l of this thesis we can conclude the following . 
There is need for the standardization of methods for identifying drug related prob­
lems, especially the identification of the relationship between medication errors 
and adverse drug events. The use of one standard method would enable the 
comparison between incidence rates and determinants of drug related problems 
in different settings. To assess the current Dutch situation in the future a multi-center 
study (including different settings as hospital -, ambulatory care and care institu­
tions) should be performed studying the rates and the determinants of drug related 
problems using the same standard method in all participating centers and should 
give more understanding in the determinants of adverse drug events because of 
potential larger sample sizes. 
It seems that from a clinical perspective, therapeutic errors are relevant drug 
related problems. Minimising these errors will lead to the reduction of preventable 
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patient harm. Therefore strategies aiming at the prevention of therapeutic errors 
in the prescribing process should be developed and evaluated. Next to the exist­
ing computerised clinical decision (see below, part 2) other strategies should for 
example be the involvement of pharmacists as consultants on hospital wards or in 
care institutions, the review of patients' medication by physicians and pharmacists 
together and education of physicians in pharmacotherapy and prescribing of 
medication. For the evaluation of these interventions, the same systematic method 
to assess the incidence of preventable patient harm should be used before as 
well as after the intervention. These kinds of evaluations and studies should not only 
focus on preventable patient harm but also on patient outcome in general. 
Part 2 - Conclusions and future perspectives on CPOE/CDSS in 
relation to medication safety 
In the nearby future, computer technology will be increasingly adopted in efforts 
to improve the quality and safety of patient care . Computerising the medication 
process Is useful to increase the efficiency in the workftow and may also contribute 
to improve patient safety, patient outcome and reducing health care costs. 1 1  In 
this thesis we focussed on the effects on medication safety and the cost-effec­
tiveness of this technology in comparison to the traditional way of prescribing . In 
our study into the effect on medication safety we used a more robust design and 
analysis than the pre/post analyses mainly used in other CPOE/CDSS studies. Our 
interrupted times series design with segmented linear regression analysis evaluated 
the longitudinal effect and controlled for trends in the outcomes. 1 2  We have shown 
that CPOE/CDSS has a positive effect on medication safety and Is cost-effective in 
comparison to the paper based system. The effect on medication safety is compa­
rable to the findings of other studies: CPOE/CDSS reduces the incidence of medi­
cation errors but a decrease in preventable adverse drug events can not always 
be demonstrated. 13 16 Nevertheless we may conclude that these systems attribute 
to a decreased risk of preventable harm first because they reduce the number of 
medication errors of which a significant part could harm patients and secondly 
because they decrease time spent on correcting errors which could otherwise be 
spent on primary patient care. However, we have to bear in mind that the imple­
mentation of CPOE/CDSS is only the beginning towards high quality prescribing . 
There is still room for improvement. 
Most Dutch CPOE/CDSS systems have a basic form of clinical decision support. In 
this thesis we have shown that this basic form is not enough to prevent therapeu­
tic errors, the most relevant medication errors in terms of preventing harm to the 
patient. To achieve a significant effect on preventable adverse drug events, the 
current clinical decision support must be further developed to fit better Into clinical 
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practice. First of all, there is need for a better balance between warnings of severe 
and less severe drug related problems. At present all drug-drug interactions and 
overdoses are shown to all physicians which results in over-alerting and will finally 
cause alert fatigue. 1 7  To prevent over-alerting, alerts should be patient-specific and 
adjusted to the different medical specialties . In the future, consensus should be 
built among health care professionals on which alerts should be adjusted or turned 
off. Besides pharmacists also physicians should be participating in this decision­
making to increase the acceptability in the field of clinicians. Warnings that are not 
valued by clinicians will not be effective. 
One of the other areas that need to be studied and further developed is what is 
the best way to present alerts. 18 How to differentiate high-risk situation alerts from 
low-risk situation alerts? How to present a clear informative description of the drug 
related problem without leaving room for different Interpretations? How to give 
clear information about what the actions in response to the warning should be? 
These are all aspects that are important to assess in order to lead to effective deci­
sion support. 
A next step to increase the impact of clinical decision support on medication 
safety is to develop and introduce more advanced decision support on top of the 
already existing decision support such as support on dosing for patients with renal 
or liver failure, support on therapy for patients with specific risk factors, support on 
rational drug choice for a certain indication but also reminders when medica­
tion monitoring should take place. For most Dutch hospitals the use of this kind of 
clinical decision support still lies in the future . Some hospital pharmacies are mak­
ing the first preparations for the implementation of this type of support. Clearly 
computerised support is a major step forward as a tool in preventing medication 
related harm in routine practice. The combination of both basic COSS and clini­
cal rules identified two thirds of the therapeutic medication errors determined in 
medication review. However, as we have shown in this thesis such efforts should also 
pay attention to finetuning this support in order to decrease the number of alerts 
that need no clinical action. For an optimal use and effect of this support, such 
finetuning should be validated in an expert group of pharmacists and physicians. 
Only thereafter advanced decision support can be adequately implemented at 
a large scale in daily clinical practice. Regarding this aspect it is also necessary to 
pay attention to the possibility to make use of a clinical decision support system 
in a different way and adapted to the different professionals (e.g. physicians and 
pharmacists) with their own responsibility. 
Technical issues, such as improving the current decision support and developing 
advanced support, is one aspect needed to be addressed in the implementa­
tion of CPOE/CDSS. The other is the organisational embedding of CPOE/CDSS . The 
introduction of any computer technology should be one of guiding organisational 
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change by a process of experimentation and mutual learning rather than one of 
planning, command, and control. 19 Organisations such as hospitals are simultane­
ously social ( e ,g. consisting of people, values, norms and culture) and technical ( e.g. 
technology, equipment, procedures). Social and technical elements are deeply 
interrelated.20 The implementation of CPOE/CDSS will affect existing processes and 
workftows and therefore its implementation is not only a change in technology but 
also in organisation. In  this thesis we have shown that physicians and nurses were 
positive about CPOE/CDSS and the implementation process of this system, but we 
paid tittle attention to the organisational aspects. In one of the two hospitals in our 
study. the implementation process of CPOE/CDSS was seriously delayed because 
of lack of support of several heads of medical departments. Strategic aspects 
played an important role in this situation. Another reason was that these physicians 
believed the system was not yet fitted to their particular situation, i.e. useful when 
prescribing complex medication protocols for cancer patients. This demonstrates 
first that it is important that physicians and nurses trust CPOE/CDSS and have a 
shared vision together with the rest of the organisation towards It. Otherwise this 
could potentially lead to failure of the implementation. Secondly, it ls important to 
know what the reasons are why physicians consider the system as inappropriate 
to be able to adapt to physicians' views and feelings. In our example, CPOE/CDSS 
is still not implemented on the oncology wards. At present, efforts are made to 
develop a better model of CPOE/CDSS by which complex medication protocols 
could be prescribed in an efficient and safe way and that is supported by the 
clinicians. 
In this thesis we evaluated the cost-effectiveness of CPOE/CDSS in comparison to 
the traditional paper based way of prescribing, an Important issue for the man­
agement and policy makers of healthcare organisations. Only a few other studies 
performed such a cost-effectiveness analysis and to our knowledge we are the 
first in the Netherlands. It is clear that more future research is needed into the costs 
and effects of these systems, especially because presently more and more hospi­
tals are considering implementing CPOE/CDSS. Because there is variation in costs 
and effects between various hospital settings, data from several other hospitals are 
needed to come to more robust findings. As we have shown in our sensitivity analy­
ses, differences in costs of CPOE/CDS systems. implementation projects and main­
tenance processes can lead to different cost-effectiveness ratios. Also differences 
in incidence rates of medication errors and preventable adverse drug events 
show variation in results; in settings where medication errors frequently occur (set­
tings with vulnerable and elderly patients) the balance between costs and effects 
might be more favourable than in settings with lower error rates. Based on our 
findings we might conclude that for many hospital settings it will be cost-effective 
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to introduce CPOE/CDSS, certainly if we compare the maximum costs to prevent 
one medication error and one preventable adverse drug event to the additional 
costs of one preventable adverse drug event according to other studies.21-24 Fur­
thermore based on the findings of a recent study in community-based medical 
practices25, electronic prescribing might reduce the medication costs when a for­
mulary decision support is incorporated that encourage physicians to prescribe 
generic or lower-cost alternative medication. This is another way by which CPOE/ 
COSS offers the opportunity to reduce health care costs. In this situation consider­
ing the views of physicians towards using CPOE/CDSS for this purpose is especially 
important, because physicians may be reluctant to use a system that focuses too 
clearly on costs in stead of patient care. Furthermore, the case-mix of their patient 
populations determines to what extent they are capable to prescribe according 
to the formulary decision support, so the system may prove to be poorly adapted 
to the physicians' patients. 
In our study we have focussed only on the cost-effectiveness of CPOE/CDSS. Future 
research is needed into the cost-benefit of these systems to take into account the 
consequences of reduction in medication errors and adverse drug events, namely 
less treatment, fewer medications administered or shortening of hospital stay. Such 
a cost-benefit analysis will give a better estimate of the balance between costs 
and effects than a cost-effectiveness analysis does. However, our study is the first 
into the aspect of costs of CPOE/CDSS in the Netherlands and will hopefully be a 
stimulus for more future studies. 
Conclusions 
In summary, we may conclude that much effort is put into optimising medication 
safety. CPOE/CDSS is a useful and cost effective tool to support medication safety 
in hospitals. However, there is still some way to go to improve such systems and 
other approaches to make the use of medication in hospitals as safe as can be. 
This provides opportunities for further research into the effects and costs of CPOE, 
its clinical decision support and advanced support such as the clinical rules. This 
research should be performed in a reliable way with special interest in the meth­
ods of measuring medication safety because identifying medication errors and 
adverse drug events continues to be a challenge. 
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methodologische aspecten en 
preventie door een elektronisch 
voorschrijfsysteem. 
Een aanzienlijk deel van de In ziekenhuizen opgenomen patienten ondervindt 
geneesmiddelschade veroorzaakt door voorschrijffouten. Daarom zal het optlmali­
seren van het voorschrijfproces bijdragen aan het verbeteren van medicatieveillg­
heid. Een mogelijkheid tot optimalisatie is het implementeren van een Elektronisch 
Voorschrijfsysteem met klinische beslissingsondersteuning (EVS). Met dit systeem 
wordt er geautomatiseerd en gestandaardiseerd voorgeschreven en vindt er 
medicatiebewaking plaats. Hoewel Amerikaanse onderzoeken een positief effect 
van dit systeem hebben aangetoond op de reductie van het aantal medicatie­
fouten en geneesmiddelschade, is het belangrijk dot we dit oak onderzoeken voor 
de Nederlandse situatie door middel van een onderzoek met een robuust onder­
zoeksdesign. Daarnaast moet er uitgezocht warden wot de batons tussen kosten 
en effecten van het EVS is omdat er weinig bekend is over de kosten-effectiviteit 
van het EVS ten opzichte van het handgeschreven systeem. Dlt is belangrijke infor­
matie aangezien veel ziekenhulzen in Nederland bezig zijn met de aanschat van 
een EVS. 
Het is een uitdaging om de effecten van dit systeem In kaart te brengen omdat 
de beoordeling van medicatle tauten en geneesmiddelschade zeer complex is 
mede door de verschillende definities, methodes en causiliteitsbepalingen die 
gebruikt warden. Bovendlen is vaak oak de overeenstemming in uitkomsten tus­
sen de verschillende beoordelaars niet erg hoog. Dit leidt tot onduidelijkheid welk 
type tauten het meest klinisch relevant zijn en wot de determinanten voor het 
ontstaan voor medicatiefouten en geneesmiddelschade zijn. loch zijn dit meestal 
de aspecten waar interventies die verbetering van medicatieveiligheid beogen 
(zoals onder andere het EVS) zich op richten. Daarom zijn de belangrijkste onder­
zoeksvragen van dit proetschrift: 
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Medicaliefouten en geneesmiddelschade bij opgenomen potienfen: methodologische ospecten en preventie door 
een elektronisch voorschrijfsysteem. 
Deel 1 : Medicatiefouten en voorkombare geneesmiddelschade 
• Het onderzoeken van methodologische aspecten random het identificeren 
van medicatiefouten en geneesmiddelschade. Het beoordelen van de kli­
nische relevantie van medicatiefouten en het beoordelen van de determi­
nanten van medicatiefouten zowel met als zonder geneesmiddelschade. 
Deel 2: Het EVS in relatie tot medicatieveiligheid 
• Het evalueren van het effect van het EVS op de incidentie van medica­
tiefouten en voorkombare geneesmiddelschade in twee Nederlandse zie­
kenhuizen 
• Het nader evalueren van bepaalde kenmerken van het EVS, namelijk het 
effect van medicatiebewaking /beslissingsondersteuning op medicatievei­
ligheid en de kosten-effectiviteit van het EVS in vergelijking met het hand­
geschreven systeem. Het in kaart brengen van de verwachtingen en erva­
ringen met het EVS van professionals in de gezondheidszorg. 
In dit deel zullen de belangrijkste resultaten van het proefschrift warden beschre­
ven en komen de implicaties voor de klinische praktijk en eventuele aanbevelin­
gen voor volgende onderzoeken aan bod. 
Resultaten 
In het eerste deel van het proefschrift richtten we ons ten eerste op de methodo­
logische aspecten random het identificeren van medicatiefouten en geneesmid­
delschade en ten tweede op de determinanten van geneesmiddel gerelateerde 
problemen en de klinische relevantie van medicatiefouten. We beoordeelden de 
betrouwbaarheid van de beoordeling van voorkombare geneesmiddelschade in 
de dagelijkse klinische praktijk. Daarnaast bepaalden we de invloed van de pro­
fessionele achtergrond van de beoordelaars (arts of apotheker) op de betrouw­
baarheid (hoofdstuk 2) . We hebben aangetoond dot het beoordelen van voor­
kombare geneesmiddelschade moeilijk is, omdat de overeenstemming tussen 
individuele beoordelaars matig (kappa is 0.36) en de overeenstemming tussen 
de verschillende professies redelijk is (kappa is 0.47). De beste oplossing voor het 
beoordelen van voorkombare geneesmiddelschade is een consensus methode 
waarbij zowel artsen als apothekers beoordelaars zijn. Hoewel deze gemengde 
samenstelling van het beoordelingspanel het meest optimaal zou zijn, gebruikten 
we in hoofdstuk 3 een consensus methode waarbij vijf apothekers beoordeelden 
of patientschade potentieel veroorzaakt was door fouten in het voorschrijf proces. 
We onderzochten de associatie tussen aan de ene kant de verschillende typen 
voorschrijffouten (administratieve fouten, doseerfouten en therapeutische fouten) 
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en overschrijffouten en aan de andere kant voorkombare geneesmlddelschade. 
Uit de resultaten van dit onderzoek bleek dot de associaties tussen zowel over­
schrijffouten (OR
geco
,rlQeerd l ,  1 2; 95% betrouwbaarheidsinterval: 1 ,0 1  tot 1 ,25) en voor­
kombare geneesmiddelschade als therapeutische fouten (OR
gscor
,1geerd 1 ,98; 95% 
Bl: 1 ,53 tot 2,56) en voorkombare geneesmiddelschade significant waren. De laat­
ste associatie (therapeutische fouten) was het sterkste en vanuit klinisch oogpunt is 
dit type medicatiefout het meest relevant. Om te onderzoeken of de determinan­
ten van fouten met voorkombare geneesmiddelschade dezelfde zljn als die van 
fouten zonder voorkombare geneesmiddelschade bestudeerden we In hoofdstuk 
4 de determinanten van beide soorten medicatiefouten. Een aantal determi­
nanten bleken hetzelfde te zijn voor medicatiefouten met en zonder geneesmid­
delschade: het ziekenhuis, de afdeling, leeftijd van de patient, de geneesmid­
delgroep antlbiotica en middelen blj neurologische aandoeningen. Echter, voor 
sommige van deze determinanten resulteerde dit alleen in een nlet slgnificante 
trend. Dit werd waarschijnlijk veroorzaakt door het loge aantal medicatiefouten 
met geneesmiddelschade en dus een te loge power van ons onderzoek. Daarom 
is het belangrijk dot toekomstige onderzoeken grotere studiepopulatles (= medi­
catiefouten met geneesmiddelschade) gebruiken. 
In het tweede deel van dit proefschrift richtten we ons meer op het EVS in relatie 
tot medlcatieveiligheid. We evalueerden het effect van het EVS op de inciden­
tie van medlcatiefouten en voorkombare geneesmiddelschade in twee Neder­
landse ziekenhuizen. De resultaten zijn besproken in hoofdstuk 5. De implementatie 
van het EVS veroorzaakte een significante onmiddellijke reductie van 40,3% medi­
catieopdrachten met een of meer fouten (95% Bl :-45, 1 3% tot -35,48%). In de base­
line periode was het gemiddelde percentage van opgenomen patienten dot 
voorkombare geneesmiddelschade ondervond 1 5,5% in tegenstelling tot 7,3% in 
de post interventie periode. Deze afname kon echter niet worden toegeschreven 
aan de daadwerkelijke implementatie van het EVS: de onmiddellijke afname was 
niet significant (-0.42%; 95% Bl:-15,52% tot l 4,68%) vanwege een onderliggende 
negatieve trend gedurende de baseline periode van -4,04% per maand (95% 
Bl: -7, 70% tot -0,38%). Waarschijnlijk is er behoefte aan een meer geavanceerde 
medicatiebewakingsmodule in het EVS en meer beslissingsondersteuning om 
voorkombare geneesmiddelschade te reduceren. In hoofdstuk 6 onderzochten 
we hoeveel van de patlenten die volgens de medlcatiebewakingsmodule van 
het EVS en een kleine set van klinische beslisregels risico liepen op geneesmid­
delschade ook daadwerkelijk een aanpassing in hun medicatie nodig hadden. 
Dit laatste werd bepaald aan de hand van een medicatie review methode. In 
dit onderzoek maakten we gebruik van een deel van de onderzoekspopulatie 
beschreven in hoofdstuk 5. Met behulp van de medlcatie review methode werden 
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57 overdoseringen en 1 43 therapeutische fouten ge'identificeerd in de medicatie 
van deze patienten. De medicatiebewakingsmodule identificeerde 297 overdo­
seringen (met een sensitiviteit van 0,32, een specificiteit van 0,92 en een positief 
voorspellende waarde van 0,06) en 365 geneesmiddelinteracties (met een sensiti­
viteit van 0,96, een specificiteit van 0,91 en een positief voorspellende waarde van 
0, 1 2). De set klinische beslisregels identificeerde 78 (39%) van de in totaal 200 over­
doseringen en therapeutische fouten. In 72 (23%) gevallen van de 3 1 3  gegene­
reerde signalen was er oak daadwerkelijk een aanpassing in de medicatie nodig. 
De combinatie van de medicatiebewakingsmodule en de set klinische beslisre­
gels identificeerde 1 3 1  (66%) van de 200 medicatiefouten. Deze combinatie van 
verschillende vormen van voorschrijfondersteuning biedt toekomstperspectief in 
het voorkomen van geneesmiddelschade, zeker wanneer er aandacht besteed 
wordt aan het reduceren van overbodige signalen. 
In hoofdstuk 7 beschreven we de verwachtingen en ervaringen met het EVS van 
artsen en verpleegkundigen. Beide groepen waren in het algemeen positief over 
het systeem, zowel voor als na de implementatie. Wei gaven ze aan dat het sys­
teem verder geoptimaliseerd moet warden met name op het gebied van de 
medicatiebewaking van geneesmiddelinteracties en het technisch functioneren 
van het systeem. 
Als laatste onderzochten we in hoofdstuk 8 de balans tussen de effecten en kosten 
van het EVS in vergelijking met het handgeschreven systeem. De totale kosten van 
het handgeschreven systeem en het EVS waren € 1 1 ,80 respectievelijk € 1 4,20 per 
patient per dag. De ratio van incrementele kosten tot incrementele effecten was 
€ 3,38 voor medicatiefouten en € 307, 72 voor voorkombare geneesmiddelschade. 
Deze ratio geeft de extra hoeveelheid geld weer die moet warden ge'investeerd 
om een medicatiefout of een voorkombare bijwerking te voorkomen. De extra 
kosten lijken acceptabel, zeker in vergelijking met de kosten die gepaard gaan 
met geneesmiddelschade of een ziekenhuisopnamedag. 
Deel l - Conclusies en toekomstperspectief op het gebied van 
medicatiefouten en voorkombare geneesmiddelschade 
Verscheidene onderzoeken zijn uitgevoerd om de incidentie van medicatiefou­
ten en (voorkombare) geneesmiddelschade te bepalen in verschillende settings. 
Door de verschillende onderzoekspopulaties, settings en gebruikte methoden is 
de variatie in de resultaten groat. Daarnaast is de beoordeling van de relatie tus­
sen medicatiefouten en patientschade complex omdat patientschade oak door 
andere factoren dan geneesmiddelgebruik veroorzaakt kunnen warden, bijvoor­
beeld ziekte gerelateerde factoren. Daarom laat deze beoordeling altijd ruimte 
open voor een subjectieve interpretatie van de beoordelaar, wat soms leidt tot een 
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loge overeenstemmlng tussen individuele beoardelaars (dit proefschrift). Daarom 
zijn resultaten van medicatieveiligheidsonderzoeken gebaseerd op de beoarde­
ling van een beoordelaar mogelijk niet betrouwbaar. Het is belangrijk om deze 
beoardelingen door een panel van meerdere beoordelaars (meer don twee) uit 
te voeren. Bovendien goat de voorkeur ernaar uit om zowel artsen als apothekers 
in het panel te betrekken om zowel de klinische blik van de artsen met de meer 
geneesmiddel gearienteerde blik van de apothekers te combineren. Het feit dot 
alleen apothekers betrokken waren bij de consensus methode in de onderzoe­
ken beschreven in de hoofdstukken 3 en 5 is een beperking van dit proefschrif t. 
Echter, in hoofdstuk 5 (het effect van het EVS op medicatieveiligheid) waren we 
meer ge'interesseerd in het effect van de interventie zelf (EVS) don de daadwer­
kelijke incidentie van medicatiefouten en voorkombare geneesmiddelschade. In 
een dergelijke situatie is het belangrijk dot dezelfde methode zowel voor als no 
de interventie gebruikt wordt. In ons onderzoek hebben we zorg gedragen dot de 
data op dezelfde systematische wijze werden beoardeeld in zowel de baseline 
periode als de post interventie periode. 
We kunnen concluderen dot er nog steeds geen methode voar het identificeren 
van medicatiefouten gerelateerde geneesmiddel schade bestaat die de indivi­
duele (subjectieve) beoordeling uitsluit. Het ontbreken van deze methode leidt 
nog altijd tot een grijs gebied random incidentie cijfers. Om aan de ene kant de 
betrouwbaarheid van de bestaande methodes te verbeteren en aan de andere 
kant de incidentie cijfers in verschillende settings (eerste lijn, verpleeghuizen, zie­
kenhuizen en verschillende afdelingen van ziekenhulzen) met elkaar te kunnen 
vergelijken, is standaardisatie van methodes nodig. Zowel wetenschappers als pro­
fessionals in de gezondheidszorg moeten consensus berelken over wot de beste 
benadering is om geneesmiddel gerelateerde problemen te beoardelen. Hierna 
kan deze methode gebruikt warden in toekomstige medlcatieveiligheidsonder­
zoeken zodat er betrouwbaardere conclusies kunnen warden getrokken over de 
incidentie cijfers van geneesmiddel gerelateerde problemen in de verschillende 
settings. 
In dit proefschrlft onderzochten we de determinanten van medlcatiefouten met 
en zonder geneesmiddelschade en we bestudeerden welke subtypen medica­
tiefouten het meest geassocieerd waren met geneesmiddelschade. Vanwege 
onvoldoende power van ons onderzoek (een te laag aantal patienten met voor­
kombare geneesmiddelschade) konden we weinig determlnanten voor medica­
tiefouten met geneesmiddelschade aantonen . In de toekomst moeten er onder­
zoeken warden uitgevoerd met grotere studiepopulaties . Uit onze resultaten bleek 
dot determinanten op het vlak van arganisatie (bljvoarbeeld het ziekenhuis en 
de afdeling) significant geassocieerd waren met medicatiefouten met en zonder 
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geneesmiddelschade. We kunnen concluderen dot betreft deze determinanten 
medicatiefouten zonder geneesmiddelschade als interim uitkomstmaat kunnen 
fungeren voor voorkombare geneesmiddelschade. Echter, voor de determinan­
ten op het vlak van de patient en medicatie kunnen deze conclusies niet worden 
getrokken en daarom moeten we nog steeds terughoudend zijn met het gebruik 
van medicatiefouten zonder geneesmiddelschade als interim uitkomstmaat. Wan­
neer we de potentiele achterliggende mechanismen van het ontstaan van medi­
catiefouten en voorkombare geneesmiddelschade in ogenschouw nemen, don 
lijkt de associatie tussen medicatiefouten (zowel met als zonder schade) en orga­
nisatiekenmerken logisch. Verder lijkt het waarschijnlijk dot bepaalde patientken­
merken (zoals leeftijd en co-morbiditeit) en bepaalde geneesmiddelkenmerken 
(zoals de intrinsieke toxiciteit van het geneesmiddel) een voorwaarde zijn voor het 
totstandkomen van geneesmiddelschade. Dit zou een mogelijke oorzaak kunnen 
zijn voor het feit dot patient en geneesmiddel gerelateerde determinanten voor 
medicatiefouten zonder schade niet dezelfde zijn als voor medicatiefouten met 
schade. We hebben deze hypothese echter niet kunnen bevestigen vanwege 
een te kleine onderzoekspopulatie. 
Desondanks hebben we kunnen aantonen welk type medicatiefout in het voor­
schrijfproces het meest relevant is in het kader van voorkomen van patientschade. 
Dit bleken therapeutische tauten (geneesmiddelinteracties, gecontra'indiceerde 
medicatie, dubbelmedicatie, onterechte mono therapie) te zijn. Dit betekent dot 
dit type tout de belangrijkste focus voor interventies gericht op het verminderen 
van fouten in het voorschrijfproces moet zijn. Vanuit klinisch en wetenschappelijk 
oogpunt zijn deze interventies belangrijk omdat ze mogelijk voorkombare genees­
middelschade significant kunnen verminderen. Niettemin moet er ook aandacht 
besteed worden aan interventies gericht op andere typen voorschrijffouten 
omdat deze in potentie ook geneesmiddelschade kunnen veroorzaken. Toekom­
stig onderzoek moet zich richten op de klinische relevantie van tauten in andere 
fasen van het medicatie proces, zoals het toedienen van geneesmiddelen en de 
overdracht van medicatiegegevens tussen de eerste en tweede lijn. 
We kunnen het volgende concluderen op basis van de resultaten uit het eerste 
gedeelte van dit proefschrift: 
Er is behoefte aan de standaardisatie van methoden voor het identificeren van 
geneesmiddel gerelateerde problemen. Dit betreft zeker de methoden voor het 
bepalen van de relatie tussen medicatiefouten en geneesmiddelschade. Door 
het gebruik van een standaardmethode zijn incidentie cijfers en determinanten 
voor geneesmiddel gerelateerde problemen beter te vergelijken tussen verschil­
lende settings. Daarom is er vraag naar een multi center onderzoek met een grate 
populatie waarbij deze aspecten door middel van een standaardmethode in 
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de verschillende settings (in de eerste lijn, tweede lijn en verpleeghuizen) in kaart 
wordt gebracht voor de Nederlandse situatie. 
Vanuit klinische oogpunt blijken therapeutische fouten relevant te zijn. Het minima­
liseren van deze fouten zal leiden tot het verminderen van voorkombore genees­
middelschade. lnterventies gericht op dlt type fout moeten verder ontwikkeld 
en geevalueerd warden. Hierbij moet gedacht warden aan geautomatiseerde 
medicatiebewaking (zie verder, deel 2), moor ook aan de rol van (ziekenhuis)apo­
thekers als consulenten op verpleegafdelingen, het gezamenlijk beoordelen van 
medicatieoverzichten door artsen en apothekers en verbetering van het onderwljs 
aan artsen In het voorschrijven van medicatie. Onderzoeken die deze interventies 
evalueren moeten ervoor zorgen dot zowel voor als no de interventie dezelfde 
systematische methode om geneesmiddel gerelateerde problemen in kaart te 
brengen, wordt gebruikt. Deze onderzoeken moeten naast voorkombore genees­
middelschade ook meer algemeen patient gerelateerde uitkomstmaten meene­
men, zoals lengte van ziekenhuisopname, heropnames, morbiditeit en mortalltelt. 
Deel 2- Conclusies en toekomstperspectief op het gebied van het 
EVS in relatie tot medicatieveiligheid 
Computer technologie zal in de toekomst steeds meer zljn intrede nemen in de 
gezondheidszorg om de kwaliteit en veiligheid van deze zorg te verbeteren. De 
automatisering van het medicatie proces zal leiden tot een efficlenter verloop van 
werkprocessen, verbetering van patientveillgheid en een afname van de gezond­
heidskosten. In dit proefschrift hebben we gekeken naor het effect van deze com­
puter technologie op medicatieveiligheid en de kosten-effectiviteit van deze tech­
nologie ten opzichte van het handgeschreven systeem. In ons onderzoek naor het 
effect op medicatieveiligheid gebruikten we een meer robuust onderzoeksdesign 
en een robuustere analyse in vergelijking met de designs en pre - post analyses 
die de meeste andere EVS onderzoeken hebben toegepast. Het 'interrupted time 
series' onderzoeksdesign met de gesegmenteerde regressie analyse stelden ons in 
stoat om het lange termijn effect van het EVS te evatueren en om te corrigeren voor 
eventuele trends In de uitkomsfmaten. We hebben aangetoond dot het EVS een 
positief effect heeft op medicatievei!igheid en dot het systeem kosten-effectief is 
ten opzlchte van het handgeschreven systeem. Het effect op medicatieveiligheld 
is vergelijkbaor met de resultaten van andere onderzoeken: de lmplementatle van 
een EVS leidt weliswaor tot de reductie van medicatiefouten moor een effect op 
voorkombore geneesmiddelschade is niet altijd aantoonbaar. Toch kunnen we con­
cluderen dot deze systemen bijdragen aan een afname van het risico op voorkom­
bore geneesmiddelschade, enerzijds omdat ze het aantal medicatiefouten vermin­
deren waorvan een deel potentleel tot schade kan leiden, anderzijds omdat ze 
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meer tijd creeren voor patientenzorg omdat er minder medicatiefouten hoeven te 
warden gecarrigeerd. Wei moeten we ons beseffen dot de implementatie van het 
EVS pas een van de eerste stappen is richting hoogwaardig voarschrijven, aange­
zien er nog steeds ruimte blijft voar verbetering. 
De meeste Nederlandse elektronisch voarschrijfsystemen hebben een basis vorm 
van medicatiebewaking (alleen controle op overdoseringen, geneesmiddelinter­
acties en dubbelmedicatie). We hebben in dit proefschrift aangetoond dot deze 
basis vorm niet voldoende is om therapeutische fouten, vanuit klinische oogpunt 
de meest relevante voorschrijffouten, te voorkomen. Om een effect te bereiken zal 
de huidige vorm van medicatiebewaking verder ontwikkeld moeten warden om 
beter te kunnen functioneren in de klinische praktijk. 
Ten eerste is er behoefte aan een betere balans tussen signalen die een ernstig en 
minder ernstig geneesmiddel gerelateerd probleem aan de orde stellen. Momen­
teel zijn alle geneesmiddelinteracties en overdoseringen zichtbaar voor alle art­
sen, wot leidt tot een overmaat aan signalen. Uiteindelijk draagt dit bij aan 'signaal 
vermoeidheid'. Om deze vermoeidheid tegen te goon is het belangrijk dot de 
signalen meer toegespitst warden op individuele patienten en dot ze aangepast 
warden aan de verschillende medische specialismen. Het is don oak belangrijk 
dot er consensus wardt bereikt onder de verschillende professionals welke sig­
nalen aangepast moeten warden en welke eventueel uitgezet kunnen warden. 
Naast apothekers moeten ook artsen betrokken zijn bij deze beslissingen. Signalen 
waar voarschrijvers geen waarde aan hechten zullen niet effectief zijn en zullen 
leiden tot weinig draagvlak in de kliniek. 
Ten tweede moet er meer aandacht besteed warden aan de manier waarop de 
verschillende signalen aan de voorschrijver warden gepresenteerd. Hoe kunnen 
we goed onderscheid maken tussen signalen met een hoog risico op schade en 
signalen met een laag risico? Hoe kunnen we goede, duidelijke infarmatie geven 
over het risico zonder het gevaar op verschillende manieren van interpretatie? 
Hoe moeten we duidelijk aangeven wot de actie op het signaal moet zijn? Dit 
zijn allemaal zaken die aan de orde moeten komen om een effectieve vorm van 
medicatiebewaking/beslissingsondersteuning te bewerkstelligen. 
Een volgende stop om het effect van de medicatiebewakingsmodule/beslissings­
ondersteuning te vergroten is het ontwikkelen en introduceren van meer geavan­
ceerde beslissingsondersteuning bovenop de al bestaande varm. We moeten 
hierbij bijvoarbeeld denken aan doseringsondersteuning bij patienten met nier- en 
leverfunctiestoornissen, ondersteuning bij therapie voor patienten met bepaalde 
risicofactoren, ondersteuning bij geneesmiddelkeuze bij bepaalde indicaties 
en ook signalen wanneer geneesmiddelspiegels bepaald moeten warden. Het 
gebruik van deze meer geavanceerde ondersteuning is voar de meeste Neder-
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landse ziekenhuizen nag steeds toekomstmuziek. Sommige ziekenhuisapotheken 
zi jn echter al bezig met de eerste stappen rlchting gebruik van deze ondersteu­
ning. 
Het is duldelijk dot geautomatlseerde ondersteuning zal bijdragen aan het voar­
komen van geneesmiddelschade in de klinische praktijk. In dit proefschrift heb­
ben we aangetoond dot de basis vorm van medicatiebewaking samen met een 
kleine set van klinische beslisregels 2/3 van het aantal therapeutlsche fouten en 
overdoseringen (geidentificeerd mbv medicatle review) signaleerde. Toch moet er 
aandacht besteed warden aan het verfijnen van deze varm van beslissingsonder­
steuning, zeker op het vlak van de hoeveelheid signalen waorbij geen actie nodig 
is. Het verder ontwikkelen en aanpassen moet plaats vinden in een expert groep 
van artsen en apothekers. Alleen onder die voorwaorde kan warden begonnen 
met het grootschalig toepassen van dit soort systemen in de hele kliniek. 
Tot nu toe hebben we het alleen nag moor gehad over de technlsche aspec­
ten van het EVS zoals het optimaliseren van de medicatlebewaklng/beslissings­
ondersteuning. Een ander belangrijk aspect is de lnbedding van dergelijke syste­
men in de organisatie. De implementatie van computer technologie bestaat uit 
de begeleldlng van een organisatieveranderlng. Bij voorkeur zou deze begeleiding 
gepaord moeten goon met een proces van experimenteren en wederzijds leren 
en niet met een proces van plannen, uitvoeren en controleren. Organisaties zoals 
ziekenhuizen hebben aan de ene kant sociale elementen (bestaan uit personen, 
hebben eigen waorden en narmen en een elgen cultuur) en aan de andere kant 
technische elementen (hebben technologie, apporatuur en procedures). Belde 
soorten elementen zijn nauw met elkaar verbonden. De implementatie van een 
EVS zal van invloed zijn op bestaande procedures en werkprocessen en zal daorom 
niet alleen een verandering teweeg brengen in de technologie moor oak in de 
hele organisatie. Alhoewel we in dit proefschrift hebben aangetoond dot artsen en 
verpleegkundigen positief woren over het EVS en de lmplementatie van het EVS, 
hebben we weinlg aandacht besteed aan de organisatieverandering. In een van 
de ziekenhuizen, betrokken blj ans onderzoek. liep de implementatie van het EVS 
vertraging op vanwege te weinig draagvlak blj de hoofden van een aantal medi­
sche verpleegafdelingen. Een van de redenen dot er weinig draagvlak was onder 
de afdelingshoofden was dot ze het EVS niet geschikt achtten voor het voorschrij­
ven van lngewikkelde cytostatica kuren aan oncologie patienten. Dit loot ten eerste 
zien dot het belangrijk is dot de gebruikers van het EVS vertrouwen hebben in het 
systeem en dezelfde !deeen hebben over het systeem als de rest van de organi­
satie. Is dit niet het geval, don leidt dit mogelijk tot het falen van het implementatie 
proces. Ten tweede Is het belangrijk om aandacht te besteden aan de redenen 
waorom EVS-gebruikers bezworen zien tegen het gebruik van het systeem. In het 
betreffende ziekenhuis uit ans onderzoek wordt er nag steeds niet elektronisch voar-
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geschreven op de oncologie afdelingen. Momenteel is men bezig om een speciale 
module voor het EVS te ontwikkelen waarmee complexe cytostatica kuren op een 
efficiente en veilige manier kunnen warden voorgeschreven en die gedragen wordt 
door de voorschrijvers. 
We hebben in dit proefschrift de kosten-effectiviteit van het EVS geevalueerd ten 
opzichte van het handgeschreven systeem. Deze evaluatie biedt belangrijke infor­
matie voor zowel het management als beleidsmedewerkers van gezondheidszorg 
organisaties . Er zijn moor weinig onderzoeken die een dergelijke kosten-effectiveits­
analyse hebben uitgevoerd en voor zover wij weten is ons onderzoek de enige in 
Nederland. In de toekomst is er zeker plaats voor meer onderzoeken naar de kos­
ten en effecten van deze systemen aangezien steeds meer ziekenhuizen overwe­
gen om elektronisch voor te goon schrijven. Vanwege de grate variatie in kosten 
en effecten tussen verschillende ziekenhuizen is het belangrijk om gegevens te ver­
zamelen uit verschillende settings om tot meer robuuste resultaten te komen. Zoals 
we hebben aangetoond in onze sensitiviteitsanalyses kunnen verschillen in kosten 
van het systeem, het implementatie proces en het onderhoudsproces resulteren in 
verschillende kosten-effectiviteitratio's. Ook de verschillen in incidentie cijfers van 
medicatiefouten en voorkombare geneesmiddelschade leiden tot variatie in resul­
taten; in ziekenhuizen waar medicatiefouten frequent voorkomen (kwetsbare en 
oudere patienten) zal de balans tussen kosten en effecten positiever uitvallen don 
in ziekenhuizen waar minder medicatiefouten plaats vinden. Op basis van onze 
resultaten kunnen we concluderen dot het voor veel ziekenhuizen kosten-effectief 
zal zijn om het EVS te implementeren. Zeker wanneer we de investeringskosten om 
een medicatiefout en een voorkombare bijwerking te voorkomen vergelijken met 
de extra kosten die gepaard goon met voorkombare geneesmiddelschade uit 
de literatuur. Een recent onderzoek, uitgevoerd in de eerste lijn, toonde aan dot 
een elektronisch voorschrijfsysteem met een ingebouwd formularium medicatie­
kosten kan reduceren door artsen aan te moedigen generieke en goedkopere 
geneesmiddelen voor te schrijven. Dit is een andere manier waarop het EVS een 
bijdrage kan leveren aan de reductie van gezondheidszorgkosten. Toch is het ook 
in deze situatie belangrijk om aandacht te schenken aan de mening van de voor­
schrijvers; artsen kunnen mogelijk een negatief oordeel hebben over een systeem 
dot meer gericht is op reductie van kosten don verbetering van patientenzorg. 
Bovendien bepaalt de heterogeniteit van de patientenpopulatie in welke mate 
voorschrijvers in stoat zijn om volgens het formularium voor te schrijven. 
In dit proefschrift hebben we alleen gekeken naar de kosten-effectiviteit van 
het EVS ten opzichte van het handgeschreven systeem. In de toekomst zal ook 
de balans tussen kosten en baten van het systeem verder onderzocht moeten 
1 53 
worden. Niet alleen de effecten moor oak de gevolgen van de effecten (minder 
behandeling, minder gebruik van geneesmiddelen, afname van de lengte van 
ziekenhuisopname) moeten don worden meegenomen. Een dergelijke kosten­
baten analyse geeft een betere weerspiegeling van de balans tussen kosten en 
effecten don alleen een kosten-effectiviteitsanalyse doet. Ons onderzoek is het 
eerste Nederlandse onderzoek op het gebied van de kosten random een EVS en 
is hopelijk een stimulus voor verdere toekomstige kosten onderzoeken. 
Conclusies 
We kunnen concluderen dot er momenteel wereldwijd veel gedaan wordt aan 
het verbeteren van medicatieveiligheid. Het EVS is een (kosten) effectief middel 
om vooruitgang op het gebied van medicatieveiligheid te bewerkstelligen. Toch 
moeten deze voorschrijfsystemen nag verder geoptlmaliseerd warden om het 
voorschrijven en toedienen van medicatie in ziekenhuizen zo veifig mogelijk te 
maken. Dit biedt mogelijkheden voor verder wetenschappelijk onderzoek op het 
gebied van de kosten en effecten van het EVS, de medicatiebewaklngsmodules 
in het EVS en geavanceerde beslissingsondersteuning zoals klinische beslisregels. 
Het is noodzakelijk dot dergelijk onderzoek op een betrouwbare wijze wordt ultge­
voerd met speciale aandacht voor de methode van het identificeren van medi­
catiefouten en voorkombare geneesmiddelschade. Dit blijft immers nag steeds 





In dit dankwoord richt ik me alleen tot de mensen die me de afgelopen jaren 
op 'zakelijk' gebied hebben bijgestaan: begeleiders, mede-onderzoekers en 
collega's. Op deze plek dus geen persoonlijke dankbetuiging richting familie en 
vrienden ondanks dot ze bijzonder belangrijk voor mij zijn geweest gedurende 
de afgelopen 4 jaren. Ze hebben voor mij een omgeving gecreeerd waarin ik dit 
proefschrift heb kunnen voltooien. Als vanzelfsprekend heb ik hen zeer lief. Dot kan 
ik niet in woorden uitdrukken! 
Wei een aantal persoonlijke woorden tot de personen met wie ik in het promotie­
onderzoek nauw heb samengewerkt. Mijn onderzoek - de POEMS studie - werd 
begeleid door een stuurgroep. Deze groep functioneerde als een top brein en kan 
trots zijn op de daaruit voortgekomen resultaten. Graag wil ik de leden van "het 
brein" persoonlijk bedanken: 
Allereerst mijn promotor Prof. dr. F.M.  Haaijer-Ruskamp. Beste Floor, in het begin was 
het voor beide partijen wot aftasten. Gelukkig hebben we samen de juiste weg 
gevonden en dot heeft mooie resultaten opgeleverd waarvoor dank. Floor, suc­
ces met al het toekomstige onderzoekswerk en ik wens je samen met Geerd nog 
veel gezonde jaren toe. 
Dan mijn copromotores Dr. P.G.M. Mo/, Dr. J .G.W. Kosterink en Dr. P.M.L.A van den 
Bernt. 
Beste Peter, mijn eerste werkdag bracht ik bij jou aan het bureau door, waar je met 
groot enthousiasme je eerste promovendus over de toekomstige ideeen betreft 
ons onderzoek vertelde. Na afloop tuitten mijn oren en heb ik 's avonds als een 
zombie (met pizza) op de bank gezeten. lk ben gelukkig gewend geraakt aan je 
gedachtegangen. Peter, ik waardeer je enthousiasme. Wanneer ik bij je aanklopte, 
maakte je altijd tijd vrij. lk wens je veel succes zowel bij het CBG als in de weten­
schap en ik weet zeker dot tussen al je ideeen gouden creaties zitten !  
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Beste Jos, je wist altijd als echte voorzitter structuur te houden tiJdens onze bijeen­
komsten. Ondanks je drukke agenda, maakte je tijd vrij voor de POEMS studie. 
Denk alleen al aan onze tripjes naar Utrecht in verband met 'beoordellngsdagen' 
waar oak nag eens veel 'huiswerk' aan vooraf ging. Dank dot je veel mogelijk hebt 
gemaakt, tot een nachtelijke taxirit van Utrecht naar Groningen in gure weersom­
standigheden aan toe. 
Beste Patricia, we hebben elkaar de afgelopen jaren niet veel in levende lijve 
gezien: onze contacten liepen vaak via de email of telefonisch. Dit heeft geluk­
kig geen inbreuk gedaan op onze goede samenwerking. lk heb altijd met veel 
plezier je snetle en inhoudelijke reacties ontvangen. Je wist me soms op de juiste 
momenten een steun in de rug te geven. Op naar nag meer medicatieveitigheids­
studies en misschien kunnen we in de toekomst nag een keer samen een haarf6hn 
kopen! 
Dan de andere stuurgroepleden: Prof. dr. A.C.G. Egberts, Drs. R.J. Zaal, Dr. K.M. Ver­
meulen en Drs. A.W. Lenderink. 
Beste Taine, alhoewel je vanaf een afstand blj onze studie betrokken was, bete­
kent dot niet dot je minder waardevol was. Dit uit zlch alleen al in het feit dot jij de 
bedenker was van ans mooie acronym 'POEMS' . Je voorzag alle stukken op snelle 
wijze van doordacht commentaar. Ondanks de afstand ben ik blij dot je een lid 
van ans POEMS 'brein' was. Dank hiervoor. 
Beste Rianne, jij was mijn 'partner in crime' in de moeilijke drukke periode van de 
dataverzameling. lk heb veel waardering voor je nauwkeurigheid en ik weet zeker 
dot we uiteindelijk mede door jouw kritische blik de juiste data op de juiste wijze 
hebben verzameld. Misschien begin Jij oak aan een promotieonderzoek in de toe­
komst? lk weet zeker dot je naast een goede ziekenhuisapotheker oak een goede 
onderzoeker zult zijn. 
Beste Karin, het uitvoeren van het kosten-deel van onze studie was een zware kluif. 
Zeker omdat je als buitenstaander bij onze studie betrokken was. Je hebt je er dap­
per door heen geslagen en het heeft een mooi artikel opgeleverd. Dank hiervoor 
en oak dank voor je lulsterend oar. 
Beste Berti!, we hebben zelf weinig contact met elkaar gehad. In Tilburg heb je met 
name Rianne begeleid bij het managen van de tijd die ze moest verdelen over de 
POEMS studie en hoar opleiding tot ziekenhuisapotheker. Deze begeleiding heeft 
ze als zeer plezier ig ervaren. Dank voor die steun. 
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Naast de stuurgroep wil ik de leden van de beoordelingscommissie, Prof. dr. J .R.B .J .  
Brouwers. Prof. dr. P.A. de Graeff en Prof.cir. H.J. Guchelaar bedanken voor het lezen 
en beoordelen van mijn proefschrift. 
Ook wil ik de mensen van de vakgroep Klinische Farmacologie van de medische 
faculteit bedanken. Frank. Amany, Petra, Jaco, Ellen. Dirk, Daniela, Arna, Sigrid. 
Liana, Liana en Ruth. ik heb het meest met jullie te maken gehad tijdens onze 
gang-overleggen en dRUGs meetings. Alhoewel ik me niet op jullie 'gang· bevond. 
heb ik jullie als echte collega's ervaren. Dank voor alle ideeen en suggesties en 
ook voor alle gezelligheid. 
Hierbij wil ik Roy Stewart van de afdeling Gezondheidswetenschappen bedanken 
voor het herstructureren van onze database. Roy,jammer genoeg waren het moor 
een paar bezoekjes maar gelukkig wel hele gezellige. 
Vier studenten hebben me de afgelopen jaren tijdens verschillende periodes bijge­
staan. Janneke en Volkan. bedankt voor het verzamelen van de patientgegevens uit 
de medische dossiers. Dit was een moeilijke en arbeidsintensieve klus. Petje of! Froukje 
en Annemieke. beiden zijn jullie een paar weken bezig geweest met het verwerken 
en analyseren van vragenlijsten. Jullie hebben een prima stuk werk geleverd! 
Naast deze vier mensen heb ik in de laatste periode van mijn onderzoek veel steun 
gehad van Aileen. Aileen. het was een hele uitdaging om al die Nederlandse dos­
siers te moeten lezen. Toch heeft je dot er niet van weerhouden om ontzettend 
goed werk af te leveren! 
lk wil ook mijn collega Eli Dijkers bedanken voor het ontwerpen van de cover. Beste 
Eli. enorm bedankt! Je hebt veel tijd in het ontwerp gestoken en ik ben uitermate 
tevreden. Vanaf volgend jaar op naar die zilveren camera! Houd je ogen open 
voor eventuele mooie foto·s (en zo nu en don ook je oren . . . . .  ). 
En don als laatste de andere collega's in het UMCG: Donald. Marian. Marjolijn. 
Marieke, Barbara. Prashant, Hendrikus. Reinout, Jan-Willem, Jan. Marina. Esther. Helen. 
Mathieu, Annemiek. Wianda, Jessica. lemke. Hilma, Hermien (het sprookjesboek is 
voltooid!), Els, Kim en alle andere collega's uit de ziekenhuisapotheek van het 
UMCG. lk was de afgelopen vier jaren als enige full-time onderzoeker een beetje 
een vreemde eend in de bijt in de ziekenhuisapotheek. Toch toonden velen van jul­
lie interesse in het reilen en zeilen rondom het onderzoek. Dot heeft ervoor gezorgd 
dot ik me nooit eenzaam heb gevoeld. Bedankt hiervoor. En voor de anderen die 
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